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Zusammenfassung 
Die Alzheimer Demenz (AD) und der Morbus-Parkinson (MP) sind die beiden 
meistbekannten, langsam fortschreitenden neurodegenerativen Erkrankungen. 
Kennzeichnend für beide Krankheiten sind proteinhaltige Ablagerungen, welche post mortem 
in den betroffenen Hirngeweben gefunden werden. Charakteristisch für die AD sind die 
beiden Proteine Amyloid-β (Aβ) und Tau, wohingegen für den MP Ablagerungen von α-
Synuclein (ASN) in den Neuronen der substantia nigra pars compacta pathologisch 
kennzeichnend sind. Die Herstellung hirngängiger Substanzen in der AD, welche spezifisch 
an Aβ-Plaques und an den neurofibrillären Bündeln (NFTs) binden, sind nicht nur ein 
diagnostischer Ansatz, sondern auch ein erster Schritt in Richtung der 
Medikamentenentwicklung. Die derzeitige in vivo Diagnose der AD wird durch unzureichende 
Sensitivität und Spezifität der diagnostischen Methoden beeinträchtigt, weshalb eine neue 
nicht-invasive Bildgebung zur Früherkennung der AD benötigt wird. Derzeit gibt es 
unterschiedliche Verbindungsklassen für die Detektion der Aβ-Plaques, jedoch ist nur eine 
geringe Anzahl an Substanzen für den pathologischen Nachweis der NFTs bekannt. In 
dieser Arbeit wurden erfolgreich fluoreszierende Liganden unterschiedliche Substanzklassen 
der Thiazole, der Bisstyrole, der Spiropyrane, der Trimethincyanine oder auch der Indolyle 
für die Detektion der Aβ-Plaques und der NFTs in Hirngeweben von AD Patienten 
synthetisiert. Die Visualisierung der selektiv gebundenen Substanzen an Aβ-Plaques oder 
NFTs im Hippocampus eines AD-Gehirns erfolgte mittels eines Fluoreszenzmikroskops. Zur 
Bestimmung der Bindungsaffinität wurde ein neuer kompetitiver Thiazin Red R Assay 
eingesetzt. Des Weiteren wurden potentielle Verbindungen in vitro in einem hepatozellulären 
Karzinom-Assay (HepG2) sowie in einem Zebrafisch-Embryo Toxizitäts-Assay untersucht. 
Hierbei zeigten die Substanzen keine oder geringfügige Zytotoxizität bei entsprechender 
Konzentration auf, wodurch die Evaluation in einem in vivo Maus-Modell gegeben ist. 
Darüber hinaus ist die Detektion nasaler Tauablagerungen mittels dieser fluoreszenter 
Liganden in der Nasenschleimhaut möglich. Nach entsprechender Präparation erzeugen 
diese eine entsprechende Fluoreszenzmarkierung der entsprechenden Pathogene, wodurch 
eine Frühdiagnose ermöglicht wird. Gleichzeitig wurden ausgewählte Substanzen als 
potentielle Liganden für die Bindung an ASN in MP untersucht. Durch PET- bzw. SPECT-
Bildgebung können weitere radioaktiv markierte Analoga als Sonden für Aβ, Tau und ASN 
dienen. 
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1.  Introduction 
 
1.1. Alzheimer’s disease 
In 1906, Dr. Alois Alzheimer, a German pathologist, discovered lesions in the brain of a 
woman who died with dementia at age 56.  Alzheimer's disease (AD) was first described by 
Dr. Alzheimer and named after him. Today, one hundred years later, AD is becoming the 
most common form of dementia affecting millions of elderly people, which can be caused by 
a lot of progressive disorders that affect memory, thinking, behavior, the ability to perform the 
everyday activities and eventually by disturbances in reasoning, planning, language and 
perception.1-3 
One major risk factor of AD progression is age, and most individuals with the disease are 
age 65 or older. After age 65, the possibility of developing dementia roughly doubles every 
five years. It was estimated that 36 million people were living with AD and other dementias 
all over the world in 2011, this number will rise up to 66 million by 2030 and 115 million by 
2050.4 It is noteworthy that almost 60% of the patients live in low and middle income 
countries currently, and the number will increase to 70% by 2050. According to the World 
Alzheimer Report 2010, it was proposed that the worldwide costs of dementia were more 
than 600 billion US dollars in 2010, which amounts to more than 1% of global GDP in that 
year.5 The average social costs are 33 thousands per person with dementia every year, 
which is even higher than the annual income in Germany. 
Figure 1.1 The amyloid cascade hypothesis of Alzheimer’s disease 
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Amyloid deposition 
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The risk factors for AD include age and genetics regarding the etiology of AD. Other possible 
environmental factors are level of education, sex, head injury, exposure to heavy metals and 
toxins.6 Even positive family heredity will affect and cause dementia (Figure 1.1).1,7 
Post-mortem analysis of human brains provided the mechanisms of disease and potential 
interventions. A century ago, Dr. Alzheimer started to describe the disease by two kinds of 
abnormal proteins in patients' brains: senile plaques (SPs) and neurofibrillary tangles (NFTs) 
(Figure 1.2).7-9 Currently, scientists generally agree that SPs and NFTs are major hallmarks 
of AD.10,11 SPs are composed of the β-amyloid (Aβ) peptide, a fragment of the amyloid 
precursor protein (APP), whereas the NFTs are comprised of the hyperphosphorylated form 
of the microtubule-associated protein tau. 
 
Figure 1.2 Immunohistochemical staining with antibodies against Aβ plaques (left) and NFTs 
(right) 
A deeper understanding of different cellular functions of hallmarks will help us to study the 
diagnostic and therapeutic methods for AD. 
1.1.1. Overview of amyloid precursor protein processing enzymes and 
products 
The pathology of AD has been studied intensely in the last two decades. Although the real 
mechanisms to cause AD are not fully understood, according to the amyloid cascade 
hypothesis, it is widely believed that the uncontrolled clumping of Aβ plaques is one of the 
cardinal factors to cause AD.12,13 The deposition of Aβ is related to an imbalance between its 
production and clearance. The excess Aβ is believed to be a main contributor to the 
dysfunction and degeneration of neurons that occurs in AD.14 Aβ plaque formation is a 
neuropathological hallmark which is found in the brain of patients with AD. 
APP is a type-1 membrane protein with a large extracellular portion, which is expressed in 
various mammalian cells. The biochemical studies of APP and the presenilins (PS) have 
greatly enhanced the understanding of the molecular pathways leading to Aβ generation.15,16 
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The major component of Aβ plaques are small 38- to 42-amino-acid-long β-amyloid peptides. 
They are generated by the stepwise cleavage of APP, which is a transmembrane 
glycoprotein of undetermined function.8 APP can be processed by α-, β- and γ-secretases. 
Aβ protein is generated by the successive action of β-secretase and γ-secretase. These two 
secretases serve to release various isoforms of the Aβ peptide. Aβ is prone to aggregation, 
giving rise to toxic species, including dimers, oligomers and fibrils. The most aggregation-
prone Aβ42 isoform aggregates faster to form toxic oligomers and deposits as Aβ plaques. 
 
Figure 1.3 The APP processing and cleavage products. Aβ fragments oligomerize and fibrillize 
leading to AD pathology (left and upper panel). APP: amyloid precursor protein; CTF: carboxy-terminal 
fragments; AICD: APP intracellular domain; Ex: extracellular; PM: plasma membrane; Cyt: cytosol. 
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A simplified APP processing is depicted in Figure 1.3.3,7,17-22 The non-amyloidogenic APP 
processing pathway (right) involves cleavages by α- and γ-secretases resulting in the 
generation of a long secreted form of APP (sAPPα). The amyloidogenic APP processing 
pathway (left) involves cleavages by β- and γ-secretases resulting in the generation of a long 
secreted form of APP (sAPPβ). The carboxy-terminal fragments (CTF) generated by α- and 
β-secretase are called CTF83 and CTF99, respectively.23 γ-Secretase cleavage of CTF83 
and CTF99 in the membrane results in the generation of P3 and Aβ, respectively, as well as 
the amino-terminal (N-terminal) APP intracellular domain (AICD). 
β-secretase and β-cleavage 
β-Site APP cleaving enzyme 1 (BACE1), was first identified and characterized as β-
secretase in AD in 1999 by five research groups from industry and academia.24 It is a type I 
transmembrane aspartyl protease with its active site on the luminal side of the membrane. 
Certainly, BACE1 exhibited all the known characteristics of β-secretase. The 501 amino acid 
sequence of BACE1 bears the hallmark features of eukaryotic aspartic proteases of the 
pepsin family.25,26 β-Secretase cleaves APP in its extracellular domain and leaves a fragment 
called CTF99, which is further cleaved by the transmembrane γ-secretase complex that 
includes presenilin. It was also reported that BACE1 can also cleave APP at a more carboxy-
terminal (C-terminal) position to result in CTF89.17 
A related enzyme, BACE2, exerts β-secretase activity, but it is expressed at very low levels 
in the brain and is mostly restricted to glial cells.27,28  
γ-secretase and γ-cleavage 
γ-Secretase is a high-molecular-weight protein complex and the detailed structure is still 
unknown. It cleaves APP at multiple sites and in sequential steps to generate Aβ peptides of 
different lengths, as well as the N-terminal AICD (Figure 1.4). There are two major Aβ 
species that are being formed: the 40-amino-acid-long peptide (Aβ40) and the more 
aggregation-prone 42-amino-acid-long peptide (Aβ42). It has been shown that under 
physiological conditions, Aβ40 constitutes nearly 90% of the total amount of Aβ. Besides, the 
dominant γ-cleavage site at Aβ40 and Aβ42 residues, ζ-cleavage at 46 and ε-cleavage at 49 
residues are also thought to be mediated by γ–secretase.21,29-31 
The monomeric Aβ (molecular weight ~4 kDa) is produced mainly in neurons from APP 
(molecular weight ~120 kDa) via sequential scission by the enzymes β- and γ-secretase.14 
Great progress has been made in characterizing molecules involved in APP processing and 
functions of APP cleavage products. Nevertheless, Aβ remains the main suspect in AD 
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pathogenesis. Understanding of the process would help us to explore the diagnostic and 
therapeutic methods in the future. 
 
Figure 1.4 The role of β-secretase and γ-secretase in the proteolytic processing of APP. 
1.1.2. The role of tau in Alzheimer's disease 
NFTs are another major pathologic hallmark of AD. In normal cells tau regulates the 
assembly and maintenance of the structural stability of microtubules. However, tau becomes 
abnormally phosphorylated, aggregates into paired helical filaments (PHFs) and loses its 
ability to maintain the microtubule tracks in the diseased brain.32 Afterwards, the free tau 
molecules aggregate into PHFs to form NFTs.33  
Tau contains three major domains: an N-terminal projection domain, a C-terminal domain of 
microtubule binding repeats and a short tail sequence. In the adult human central nervous 
system (CNS), there are six tau isoforms, about 352- to 441-amino-acid-long residues 
(Figure 1.5). Tau isoforms are likely to have specific functions related to the absence or 
presence of regions encoded by the cassette exons 2, 3 and 10. The two 29-amino acid 
sequences encoded by exons 2 and 3 (E2 and E3) give rise to different lengths of the N-
terminal part of Tau proteins. These two additional inserts are highly acidic. They are 
followed by a basic proline-rich domain (PRD).13,34,35 Exon 10 encodes an additional 
microtubule binding repeat, resulting in isoforms with either three- (3R) or four- (4R) 
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microtubule binding internal repeats.36 Splicing generates two series of tau isoforms, each 
containing either 3R or 4R microtubule-binding repeats (M1-M4) with differential affinity for 
microtubules.13,19 The 3R or 4R is made of a highly conserved 18-amino acid repeat. It has 
been demonstrated that 3R tau isoforms also bind less tightly than 4R tau to microtubules.37 
In normal brain, the 3R/4R tau ratios for both mRNA and protein are almost equal. The role 
of altered 3R/4R tau ratio in AD remains controversial. Several findings suggested that 
increased 3R tau may contribute to AD, because 3R, but not 4R, tau contributes to the 
increased phosphorylated tau levels in brain.38 However, the tau transgenic mice available 
for the in vivo experiment are all based on the 4R tau repeat and deposit very little amounts 
of tau.39 The 3R tau isoforms are predominant in neonatal mouse whereas in adult mouse 
the 4R isoforms are predominant.40,41 This shortcoming may limit the use of mouse models 
for the in vivo evaluation of tau imaging agents. 
 
Figure 1.5 In the human CNS, the alternative splicing of exons 2, 3 and 10 generates six tau 
isoforms which ranges in size from 352- to 441-amino acids. Lack of E2 and E3 leads to 0N tau 
isoforms, whereas inclusion of E2 gives rise to 1N and inclusion of both E2 and E3 produce 2N tau 
isoforms. M1–M4 corresponding to the four imperfect-repeat microtubule binding domains in which M2 
is encoded by exon 10. Absence of M2 gives 3R tau and inclusion results in 4R tau isoforms. 
The microtubule-associated protein tau is the main component of NFTs. In the normal state, 
it is a hydrophilic, soluble protein that promotes microtubule assembly and stabilization. 
However, pathological forms of tau are abnormally phosphorylated at certain residues and 
significantly reduced affinity for microtubules. Currently, there is limited knowledge about the 
impact of phosphorylation on tau function. Generally, it negatively regulates the binding of 
tau to microtubules.9 It is known that tau is one of the microtubule-associated proteins (MAPs) 
that stabilize neuronal microtubules for their role in the development of cell processes, the 
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establishment of cell polarity and intracellular transport. In the healthy brain, only two or three 
residues on tau are phosphorylated. The degree of phosphorylated tau depends on the 
activities of protein kinases and phosphatases. But in AD and other tauopathies, the 
phosphorylation level of tau is much higher, with approximately nine phosphates in every 
molecule.18,42 The abnormal hyperphosphorylation of tau may result in the upregulation of tau 
kinases or downregulation of tau phosphatases in AD brains. Some of them may regulate its 
microtubule-binding properties. Several groups reported recently that tau has 84 putative 
phosphorylation sites including 45 serines (Ser), 35 threonines (Thr) and 4 tyrosines (Tyr).8 
Hyperphosphorylation of tau may occur at different putative Ser, Thr, and Tyr residues 
through a disruption of the equilibrium of tau kinases and tau phosphatases activity.33 
Especially, the phosphorylation of orthologous residues in the adjacent microtubule-binding 
repeats at Ser262 and Ser356 has been suggested to detach tau from microtubules.43 
Indeed, hyperphosphorylated tau accumulates in the somatodendritic compartment of 
neurons, aggregates and eventually forms NFTs.8 
Figure 1.6 Proposed model of tau leads to neurofibrillary tangle formation. 
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Tau phosphorylation has been demonstrated to cause decreased binding and destabilization 
of microtubules, and hyperphosphorylated tau from AD brains fails to bind microtubules. 
Hence, functions of tau that involve microtubules, such as microtubule stabilization and the 
regulation of axonal transport may be compromised, possibly contributing to disease. Indeed, 
the majority of studies suggest that hyperphosphorylation of tau is a major contributor to the 
pathologic progression that leads to tangle formation.13  
There are three kinds of NFT can be recognized morphologically: pretangles, intracellular 
tangles and extracellular (ghost) tangles. It is reported that intracellular tangles were 3R/4R 
tau-positive, however most pretangles were 4R tau-positive and ghost tangles were 3R tau-
positive. These evidences suggested that isoforms of tau aggregates may shift from a 4R 
tau-predominant formation to a 3R tau-predominant formation during the development of 
NFT.44 Phosphorylated Ser101 plays an important role in the formation of ghost tangles and 
pretangles. The ghost tangles appeared as loose bundles of fibers and located in the 
neuropil when intracellular tangles are exposed extracellularly. More and more evidences 
indicated that hyperphosphorylated tau is toxic to neurons and this toxicity is associated with 
the induction of cell death.44-46  
Different from the antibody against paired helical filaments, the antibodies against tau and 
phosphorylated neurofilaments do not stain ghost tangles. It suggested that the loss of 
specific epitopes during the progression of the disease may cause the inability to detect 
ghost tangles by immunohistochemistry.47 However, ghost tangles were clearly visualized 
with Thiazine Red R. The affinities of these probes to aggregated tau and Aβ40 were 
determined by displacement of the reference dye Thiazine Red R, hence IC50 data obtained 
in the competition assay are reported rather than Ki values. Thiazine Red R was selected as 
reference ligand for the displacement assay, because it was previously shown to be superior 
to Thioflavin S or immune histochemical detection of aggregated Tau and Aβ40.48,49 It was 
shown to be an accurate maker for β-pleated sheet structures and to reliably stain Aβ 
plaques and diffuse NFTs (Kd for aggregated Aβ40 = 49 nM and Kd for aggregated tau = 18 
nM). It was reported that the in vitro binding affinity (Ki) of Methoxy-X04 (Chapter 1.3.2) is 
26.8 nM.50 The same compound was measured in Thiazine Red R assay and IC50 values are 
shown in experiment sections.  
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1.2.  Therapeutic approaches to Alzheimer's disease 
1.2.1.  β-Secretase as a therapeutic target for Alzheimer’s disease 
Currently, the reduction of Aβ levels in the brain is an attractive clinical approach to treat AD. 
According to the amyloid cascade hypothesis, it is believed that β-secretase is the first 
protease that processes APP in the pathway leading to the production of Aβ.51 For this 
reason, β-secretase is an attractive therapeutic target for the development of inhibitor drugs. 
The development of β-secretase inhibitors has been pursued more than a decade.  
There are some factors that should be taken into consideration for the development of a 
viable β-secretase inhibitor. Generally, drugs for β-secretase should be small, potent and 
display low toxicity. They must exhibit favorable selective transition state analogues with 
good membrane penetration and pharmaceutical properties.26,52-54 Besides, the inhibitor 
should express sufficient lipophilicity to efficiently cross the blood–brain barrier (BBB) to 
achieve high concentrations in the brain.24 
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Figure 1.7 Hydroxyethylamine (HEA) and Hydroxyethylene (HE) BACE1 inhibitors 
Since the identification of β-secretase in 1999, a series of β-secretase inhibitors had been 
employed.55 So far, several promising inhibitors have entered early phase clinical trials 
(Figure 1.7). The overall progress in the field permits some optimism that this structure-
based design strategy will lead to better compounds. It seems that β-secretase inhibitors 
may be a valuable and important therapeutic target for the treatment of AD. 
1.2.2.  γ-Secretase as a therapeutic target for Alzheimer’s disease 
As previously discussed, γ-secretase is a rationale target for the treatment of AD because it 
regulates the final step of the Aβ formation. The main form of Aβ contains 40 amino acids, 
but the carboxy-terminal-extended species, made up of 42 residues, is also produced at the 
same time. The longer form is more prone to aggregate into fibrils and Aβ42 makes up the 
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major component of SPs. Selective lowering of Aβ42 levels with small molecule γ-secretase 
modulators (GSMs), such as some non-steroidal anti-inflammatory drugs (NSAIDs),56 a holds 
promise in the treatment of AD. 
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Figure 1.8 Structures of γ-Secretase inhibitors. 
In short, γ-secretase is a complicated and unusual proteolytic complex. However, several 
classes of potent inhibitors have been discovered and evaluated. Currently, at least six 
compounds have entered clinical development. In 2001, the first in vivo testing of a γ-
secretase inhibitor involved the dipeptidic compound DAPT (N-[N- (3,5-difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester) (3) was reported, which was developed by Elan and Eli 
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Lilly (Figure 1.8).  The benzodiazepine analog LY-411575 (4) and benzolactam 
semagacestat (LY-450139) (5), which were developed by Eli Lilly, are others potent, orally 
available and active γ-secretase inhibitors which have been tested extensively in vivo.57-59 
LY-411575 is one of the most potent γ-secretase inhibitors yet reported, with an IC50 value of 
119 pmol/L for the inhibition of Aβ production in APP overexpressing HEK293 cells. LY-
450139 is a functional γ-secretase inhibitor that has been tested in the human Phase II 
trial.60 Bristol-Myers Squibb (BMS) and the former SIBIA Neurosciences developed the 
sulfonamide inhibitor BMS-299897 (6) as the first γ-secretase inhibitor to reach clinical trials. 
This compound displays an IC50 = 7 nmol/L in the inhibition of Aβ production in APP-
overexpressing HEK293 cells. However, human testing of BMS-299897 started in 2001, but 
clinical data have never been fully reported. The long-lasting lack of data on its clinical 
development indicate that it has been abandoned.61 Besides, five other γ-secretase 
inhibitors, GSI-953 (7), MK-0752 (8), BMS-708163 (9), E-2012 (10) and PF-3084014 (11) 
already entered the clinical trials.62,63  
1.2.3.  Tau as a therapeutic target for Alzheimer’s disease 
NFTs are one of the pathological hallmarks of AD and primarily composed of aggregates of 
hyperphosphorylated forms of the MAPs tau. Tau phosphorylation is believed to initiate or 
facilitate dissociation from microtubules leading to microtubule destabilization, decay of 
cellular transport properties and cell death. 
The last decade has witnessed the rise of interest in inhibitors of tau aggregation as potential 
target of drugs for therapeutic purposes in AD. Numerous researches in tau therapeutics are 
in process. Some of the principal lines to investigate tau in neurodegenerative disease have 
been implemented.64 First, reduction or prevention of the abnormal tau hyperphosphorylation 
through inhibition of specific protein kinases, such as glycogen synthase kinase-3 (GSK-3), 
cyclin-dependent kinase-5 (CDK-5), casein kinase-1 (CK-1), cAMP dependent protein kinase 
(PKA), calcium-calmodulin-dependent kinase-II (CaMK-II), and microtubule affinity-regulating 
kinase family (MARK).19,33 Second, the prevention of disassembly of tau aggregates into 
PHFs. Furthermore, the development of tau immunotherapy and anti-inflammatory therapy 
as a means of controlling pathogenesis and preserving neuronal function in disease was 
suggested to be a valid strategy.  
1.2.3.1. Drug development targeting the kinase in Alzheimer’s disease 
GSK-3 
Glycogen synthase kinase 3 (GSK-3), a tau kinase with a plethora of other substrates, is 
able to phosphorylate both non-Ser/Thr-Pro sites and Ser/Thr-Pro sites. There are two 
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related isoforms of GSK-3 encoded by two independent genes, GSK-3α and GSK-3β, which 
share 98% homology in their catalytic domains and have similar biochemical properties.65,66 
GSK-3 is highly enriched in the human brain and recent research indicates that the GSK-3β 
isoform is a key kinase required for the abnormal hyperphosphorylation of tau.67 However, 
several investigations suggest GSK-3α as a potential target for the treatment of AD and other 
CNS diseases.68,69 
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Figure 1.9 Small-molecule inhibitors of GSK-3. 
Lithiumchloride was the first GSK-3 inhibitor to be discovered, but the mechanism of action is 
still not well understood. Indeed, during the last decade, various types of small organic 
molecules as GSK-3 inhibitors have been published (Figure 1.9). A wide range of molecules 
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that inhibit GSK-3 have been evaluated such as maleimide derivatives (12), staurosporine 
and organometallic inhibitors (13), indole derivatives (14), paullone derivatives (15), 
pyrazolamide derivatives (16), thiazole derivatives (17), oxadiazole derivatives (18), 
thiadiazolindiones (19) and furopyrimidine derivatives (20).70,71 Currently, some GSK-3 
inhibitors pass through preclinical or clinical trials with the therapeutic indication AD. 
CDK-5 
CDK-5 is a 33 kDa heavy proline-directed protein kinase (PDPK), which phosphorylates 
Ser/Thr residues immediately preceding a proline residue. It has also been associated with 
the development of neurofibrillary pathology because of its overexpression in a mouse model. 
Further results have shown to induce tau hyperphosphorylation and tangle formation. 
Additionally, due to the GSK-3 overactivity in the double transgenic mice and colocalized 
with both aggregated tau and CDK-5, it implied that CDK-5 may also act directly, indirectly or 
in concert with GSK-3.72 
Others kinases 
Altogether, it seems that numerous kinase interactions cause the abnormal tau 
hyperphosphorylation. It is believed that more than one kinase is involved in tau 
phosphorylation. The net effect of different kinases will be focus of research in the next 
decade. 
1.2.3.2. Small molecule inhibitors of tau aggregation  
Under normal conditions tau is a very soluble protein that does not readily aggregate into 
filaments. In AD, protein aggregation processes have been implicated in neuronal 
dysfunction and cytotoxicity. Tau aggregation is a potential mediator of neurodegeneration. 
Further development of small molecules to reduce tau aggregate formation and/or enhance 
their clearance will be an efficient pathway to treat AD. 
Interestingly, the first drug, which is currently evaluated in clinical trials and directly 
modulates tau, is methylene blue (MB) (21) (RemberTM). In 1996, MB was first found to 
inhibit tau-tau binding through the repeat domain. In 2008, Wischik’s team reported inhibitors 
of tau aggregation as potential therapy for AD.64    
In 2004, Jeff Kuret’s lab developed a cyanine dye named N744 (22), which was found to 
inhibit tau fibrillization and promote disaggregation of mature synthetic filaments in vitro.73 
They found that inhibitors, which include thiacarbocyanine dyes, can inhibit recombinant tau 
fibrillization in the presence of anionic surfactant aggregation inducers. In 2007, Kuret’s lab 
synthesized and characterized a cyclic bis-thiacarbocyanine molecule containing two 
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thiacarbocyanine moieties (23) to evaluate tau fibrillization inhibitory activity.74,75 The bis-
thiacarbocyanine was evaluated in the action of cyanine-mediated inhibition of tau 
aggregation, which inhibited the aggregation of full-length tau protein with >4-fold better 
potency than the monomer N744 (Figure 1.10). 
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Figure 1.10 Tau aggregation inhibitors. 
In brief, small molecule inhibitors of tau aggregation serve as important research tools and 
possibly as basis for potential new therapeutics. Searching in the National Institute of Health 
(NIH) clinical trial database demonstrates that more than 950 clinical trials have been 
conducted or are ongoing (search for “tauopathy” in the www.clinicaltrials.gov, in 
18.12.2012). Most of these studies are mainly directed to find new AD treatments or 
diagnostics. Fortunately, some new classes of drugs that have been previously tested in 
preclinical tau models are now being tested in different clinical trial phases at present. By 
pursuing these lines of study, a viable therapy for AD and related tauopathies may be 
achieved.  
 
1.3.  Molecular imaging in Alzheimer's disease 
Imaging biomarkers hold great promise for diagnosing disease, monitoring disease 
progression, tracking therapeutic effect, and improving our knowledge of pathophysiology.76 
Molecular imaging allows repetitive, non-invasive assessment in biological and biochemical 
processes in living subjects. Therefore, this technology could enhance the understanding of 
disease and identify drug activity during the preclinical and clinical stage of drug 
development (Figure 1.11). The parallel paths for the development of therapeutic drugs and 
diagnostic agents raise exciting opportunities to develop technology and to improve the 
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efficiency. It contributed to selected candidates which seem most likely to be successful or to 
halt the drug development which would eventually fail. It will significantly save time and cost 
to improve the overall drug development process.77-79 
 
Figure 1.11 Drug developments is a long process that generally spans about 10 to 15 years, but 
molecular imaging can help in many steps of the process. 
The key considerations for the imaging compounds include target validation, identification of 
suitable candidate compounds with high affinity and uptake at the target site, adequate 
clearance and low potential toxicity.80 Habitually, the exploration of imaging agents starts 
with the design and synthesis of novel and unique probes which can directly interact with 
specific molecular targets, such as a receptor, transporter or enzyme. With conception and 
creation, iterative modification of knowing structure is the main approach to obtain the new 
compounds as imaging agent which selectively bind to the target. Additionally, the bioactivity 
such as the sensitivity of detection and specificity of interaction, pharmacokinetics of 
delivery, and signal-to-noise ratio will be characterized by appropriate in vitro and in vivo 
assays which are important for the imaging agent performance.  
Imaging agents can be aimed at targets, such as Aβ, tau or α-synuclein (ASN), which play 
critical roles in neurodegenerative diseases. However, imaging agents do not modify the 
functional targets of the disease. This technology may also be used in the earlier stage of the 
disease to detect the hallmarks. It will provide valuable time for effective prevention, 
treatment and reduce or avoid the pain of the disease. Development of molecular imaging 
probes is essential for the application of multimodal molecular imaging techniques in the 
drug development processes. Currently, some probes are widely used in rodents or larger 
animals. Once the imaging agent has passed through preclinical testing, it would be 
ultimately used in clinical trials, such as positron emission tomography (PET), single-photon 
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emission computed tomography (SPECT), magnetic resonance imaging (MRI) and 
ultrasound.77   
With the advances in the development of imaging agents, molecular imaging is believed to 
play an important role in accelerating and improving drug development in the future. 
1.3.1.  Molecular imaging techniques in Alzheimer's disease 
Imaging techniques offer a non-invasive or minimally invasive method for visualizing, 
characterizing, and quantifying anatomical structures and physiological processes at cellular 
and subcellular levels. Early symptoms of the disease may be detected by imaging 
technologies. Generally, molecular imaging can provide early and clear identification of 
fundamental biological and biochemical processes such as the cause, location and extent of 
the disease. Over the past two decades, neuroimaging techniques such as computed 
tomography (CT), PET, SPECT, MRI and multiphoton microscopy (MPM) have increasingly 
been employed to detect AD, to clarify the neuropathology and to monitor disease 
progression in vivo. 
Structural imaging techniques such as CT and MRI are often done to exclude some causes 
of dementia, such as normal pressure hydrocephalus or some special lesions like tumors. At 
the same time, they can help to clarify the diagnosis by detecting areas with atrophy or 
vascular lesions in the early stage of disease. While CT provides good spatial resolution, the 
MRI provides comparable resolution with far better contrast. Because of greater accuracy, 
manipulability and precision, MRI has more recently surpassed CT in diagnosis of AD.31,81  
PET and SPECT have been extensively evaluated as diagnostic procedures for AD. They 
can image and detect the concentrations of neuroreceptors, transporters, and 
neurotransmitters in the picomolar range in vivo.82 As well it serves to define a patient’s 
pathological status when the neurological symptoms can not be explained by CT or MRI. 
PET and SPECT are often used as extremely sensitive noninvasive imaging techniques to 
label the molecules with positron emitting radionucleotides.83 The radioisotopes decay will 
result in the emission of detectable γ-rays. Afterwards, the tomographic reconstruction 
techniques are used to obtain three-dimensional (3D) images.84 γ-ray emitting isotopes such 
as [15O], [13N], [11C] and [18F] have widely been used in PET. However, these positron 
emitters have very short half-lives ([15O], t1/2 = 2.1 min; [13N], t1/2 = 10.0 min, [11C], t1/2 = 20.1 
min; [18F], t1/2 = 110 min). Among these, [11C] and [18F] are more frequently used to replace 
hydrogen or a hydroxyl group on substrates to target receptors.85 Meanwhile, compounds 
labeled with longer half-lives isotopes such as [99mTc] (t1/2 = 6h) or [125I] (t1/2 = 13h) are 
commonly used in SPECT imaging. In comparison to the PET, SPECT is more widespread 
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in clinical settings because there is no need for an on-site cyclotron. In addition, SPECT has 
lower costs compared with PET imaging. 
Table 1.1 Advantages and limitations of different imaging techniques. 
Imaging techniques Advantage Disadvantage 
Optical imaging 
• High-throughput screening 
• High sensitivity 
• Limited clinical translation 
• Low depth penetration 
PET  
• Clinical translation 
• High sensitivity 
• Noninvasive 
• Costs 
• Limited spatial resolution 
SPECT  
• Clinical translation 
• High sensitivity 
• Noninvasive 
• Limited spatial resolution 
MRI 
• Clinical translation 
• Relatively High resolution 
• Noninvasive 
• Costs  
• Imaging time 
• low sensitivity 
CT 
• High spatial resolution 
• Clinical translation 
• No target-specific imaging 
• Radiation 
• Poor soft-tissue contrast 
Ultrasound imaging 
• Clinical translation 
• High spatial and temporal 
resolution 
• Low costs 
• Operator dependency 
• Targeted imaging limited to 
vascular compartment 
MPM 
• High signal to noise ratio 
• Very high resolution 
• Invasive 
In general, each imaging technique has some advantages as well as limitations (Table 1.1). 
The combination of different imaging techniques provides great promise for the effective 
diagnosis of the disease. Actually, all imaging techniques are rather complementary than 
competitive. Currently, neuroimaging techniques have more and more been used to detect 
effects in the AD brains. There is still a demand for effective biomarkers in AD to improve the 
diagnosis and to detect disease progression, to monitor the therapeutic effects and to predict 
future dementia prior to onset of cognitive decline.31 
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1.3.2.  Imaging agents for the detection of Aβ plaques 
Excessive Aβ aggregation forms Aβ plaques in the brain and plays one of the most important 
roles in the early pathological stage of AD.86 In this case, with noninvasive technologies, Aβ 
plaques bear potential to be a useful biomarker for the early diagnosis of AD. For this reason, 
it may be used to evaluate the clinical efficacy of therapies. 
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Figure 1.12 Organic dyes widely used for the histological staining of Aβ plaques. 
In the past ten years, several research groups synthesized a large number of small molecule 
compounds as candidates for amyloid imaging agents (Figure 1.12).50,87-92 Some of these 
derivatives exhibit high binding affinities to Aβ plaques and display excellent brain 
pharmacokinetic profiles.93 Generally, the imaging agents should meet the following 
conditions: first, effectively image Aβ plaques; second, have good reproducibility in many 
subjects and clinical settings; third, widely appropriate for specific task; and fourth, easily 
cross the BBB with the property of rapid clearance from the brain. However, only a few 
agents were able to satisfy these requirements right now.94 
Several lead compounds have been studied, such as Congo red (CR) (24), benzothiazole 
derivatives (26), 6-dialkylamino-2-naphthylethylidenemalononitrile (DDNP) derivatives (31), 
styrylbenzene (SB) derivatives (32) and vinylbenzoxazole derivatives (33) (Figure 1.12 and 
Figure 1.13).90,95 The candidates differ in binding characteristics and in their brain uptake. 
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Some of the agents have recently led to promising in vivo imaging of Aβ plaques in patients 
with AD.96 
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Figure 1.13 PET and SPECT imaging probes for Aβ plaques. 
The most studied amyloid PET imaging probe [N-methyl-11C]2-(4’-methylaminophenyl)-6-
hydroxybenzothiazole, also called Pittsburgh Compound-B (11C-PIB) (30) had advanced 
research in AD.97-99 So far, at least four other amyloid PET ligands have been evaluated with 
PET in AD patients (Figure 1.13), such as [18F]-1,1-dicyano-2-[6-(dimethylamino)-2-
naphtalenyl] propene (18F-FDDNP) (31),100,101 [11C]4-N-methylamino-4´-hydroxystilbene (11C-
SB13) (32),102 [11C]2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxa-
zole (11C-BF-227) (33)103 and [18F]-Florbetaben (18F-BAY94-9172) (34).104 These derivatives 
show excellent binding affinities with Kd values of < 10 nM for aggregates of Aβ40.105 
Because of the long half-lives ([99mTc] and [125I]) of positron emitters and other advantages 
over PET, a series of Aβ specific imaging agents and their related derivatives were 
synthesized for SPECT. But to our knowledge, until now only [123I]-6-iodo-2-(4’-
dimethylamino)phenyl-imidazo[1,2-a]pyridine ([123I]IMPY) (35) have been tested in humans 
(Figure 1.13).106 It is regrettable that [123I]IMPY (35) ultimately failed in the clinical trials. At 
this point, it is urgent to develop novel Aβ specific imaging agents for SPECT. 
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1.3.3.  Imaging agents for the detection of neurofibrillary tangles 
While many imaging probes for Aβ plaques have been developed in the last decade, it is 
inconceivable that only few compounds for targeting NFTs have been reported. 
Neurofibrillary lesions appear at certain sites decades before the onset of dementia in AD. 
They are highly correlated with AD symptoms and proved as a potential surrogate marker for 
the detection of disease at very early stages. It is believed that NFTs detection should lead to 
the early diagnosis of AD and estimate the severity stage of disease. Besides, the relation of 
tau aggregates to neurodegeneration and cognitive decline in AD also provides a potential 
surrogate marker for the disease. In the view of these superiorities, in vivo imaging of NFTs 
is needed and should be a necessary complement to the imaging of Aβ plaques as useful 
tool for the early and accurate diagnosis of AD.107 
Requirements for the ideal tau imaging agent should meet the following principal criteria. 
First, they require sufficient permeability to the BBB after intravenous injection while 
simultaneously being subject to rapid clearance from normal brain tissue. Because the major 
PET radionuclides 11C and 18F have very short half-lives, it will contribute to detect the 
specific binding in vivo. Second, the imaging agent should express excellent affinity for NFTs 
and sensitivity to be detected. Last but not least, in order to make sure the neuritic lesion 
spatial distribution would not be covered up or confounded by other lesions in the brain, 
imaging agents must bind tau aggregates with sufficient selectivity or low nonspecific binding 
to other lesions.107,108 
Until now only few reports are published on the development of imaging probes which target 
NFTs (Figure 1.14). The first tau aggregate binding agent Thioflavin T (26) was recognized 
on the basis of direct fluorescence in tissues. However, the toxicity and inability to cross the 
BBB limited further tests in vivo. Afterwards, several papers have reported FSB (29), FDDNP 
(31), curcumin (36), neutral benzothiazole derivatives (30, 37 and 38), thiohydantoin (TH) 
(39), rhodanine (RH) (40), benzimidazole (41) derivatives, carbazole derivatives (42) and 
quinolines (43-45) as candidate probes for in vivo imaging of tau pathology in AD.   
Multitracer PET imaging use FDDNP (31) and neutral ThT derivatives such as PIB (30) to 
reveal some complex disease progression in AD. In spite of low specific binding, they could 
provide significant information about the differences in topographical distribution between 
FDDNP-PET and PIB-PET images and assist to understand the distributions of Aβ plaques 
and NFTs in both subjects with or without AD.109 
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Figure 1.14 Imaging probes for targeting NFTs. 
Okamura et al. introduced some novel compounds such as 4-[2-(2-benzoimidazolyl)ethenyl]-
N,N-diethylbenzenamine (BF-126) (41), 2-[(4-methylamino)phenyl]quinoline (BF-158) (43) 
and 2-(4-aminophenyl)quinoline (BF-170) (44) as candidate compounds for in vivo imaging 
of tau pathology in the AD brain. These agents are injected intravenously into normal mice 
and exhibit excellent brain uptake and fast clearance from normal brain tissue.108 Besides, 
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these probes display relatively higher binding affinity to tau fibril comparing with the binding 
affinity to Aβ fibrils. 
In the past few years, our group and Saji et al. developed several phenyldiazenyl 
benzothiazole derivatives, for example [125I]4-((6-iodobenzo[d]thiazol-2-yl)diazenyl)-N,N-
dimethylaniline (PDB) (37) and [18F]4-((6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-
benzo[d]thiazol-2-yl)diazenyl)-N,N-dimethylaniline (FPPDB) (38), also with a series of 
thiohydantoin (39) and rhodanine (40) derivatives as candidate probes targeting NFTs.110-112 
Several compounds displayed high uptake after 2 min post-injection and a relatively fast 
washout from mice brain. It was observed that these probes may be suitable for PET 
imaging of NFTs in the brain of AD patients.  
All of these compounds together with FSB (29) and curcumin (36) are not specific in binding 
to NFTs. They also bind to Aβ plaques in the brain.39,107 Currently, the preclinical tests of 
THK-523 (45) exhibited up to 10-fold higher binding affinity for NFTs over Aβ aggregates. 
The high affinity and selectivity for tau pathology, both in vitro and in vivo, indicate that radio-
labeled THK523 (45) may fulfill ligand criteria for human imaging trials.113  
At present, no PET/SPECT imaging agents have been used to evaluate the tau pathology in 
the brain of AD patients.112 Thus, PET/SPECT imaging agents with greater affinity and 
selectivity for NFTs are still required. In vivo imaging of tau pathology will provide new insight 
into tau aggregation in the human brain. 
1.3.4.  A general model for ligand binding to cross-β-sheet aggregates 
Amyloid aggregates are hallmarks of neurodegenerative diseases such as AD and 
Parkinson’s disease (PD). The formation of amyloid fibrils assembled from a wide variety of 
peptides and proteins such as Aβ peptides, tau proteins and ASN are adopt an in-register 
parallel cross-β-sheet conformation.114-117 It has been proven that β-strands are the 
predominant secondary structural elements, yet 3D topology of these arrangements results 
in different strains of Aβ aggregates. 
The intracellular filaments consist of PHFs and straight filaments (SFs). An early 
investigation by X-ray diffraction of bulk fibers made from preparations of PHFs showed 
evidence for a cross-β structure.116 The β-sheets in amyloid fibrils have a cross-β orientation, 
which means that the β-strand segments arrange approximately perpendicularly to the long 
axes of the fibrils. At the same time, the inter-strand hydrogen bonds should be directed 
approximately parallel to the long axes.118 According to current research, the side chains on 
each side of the β-sheet form neat rows, which are also called ‘binding channels’. They run 
along the fibril and perpendicular to the strands. 
 Page 23 
‘binding channels’ is the distance between every second residue and the average β-sheet is 
6.50-6.95 Å (Figure 1.15, b).119 
 
Figure 1.15 (a) Schematic representation of the x-, y-, and z-principal axes of the ThT. Molecular 
dimensions were obtained via ChemDraw and Chem3D software (b) Schematic representation of a 
cross-β-sheet and possible position of dye molecules (green cubes) in the ‘binding channel’. The 
molecule interacts with the fibril by binding mode A or B. The backbone atoms (N, C, and C0) and the 
side chain (R) for one residue are indicated. The hydrogen bonds are not listed and this scheme is 
valid for both parallel and anti-parallel sheets.  
Several models have been proposed for the interactions between imaging agents and 
amyloid fibrils.114 However, the exact mechanism and interaction are still unknown. On the 
basis of molecular dynamics simulations and direct binding studies, some reports focus on 
ThT and other cyanine dyes to elucidate the binding mode to Aβ, tau and ASN. Detection of 
these fibrils is usually achieved by measuring the significantly enhanced fluorescence after 
the specific fluorescent probes bind to fibrils. The results suggest that the probe binds to the 
fibrils with its long axes, parallel to the fibril axes, by embedding into the “binding channel” 
which runs along the filament surface.  
Krebs et al. proposed a general model to clarify binding of ThT to amyloid fibrils. Afterwards, 
Volkova et al. used this model to study ASN with cyanine dyes.114,119,120 Both of them 
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calculated the molecular dimensions as x-, y-, and z-principal axes lengths to estimate the 
correlation between the size as well as properties of imaging probe and its ability to interact 
selectively with fibrils. It was assumed that the imaging probe with favorable molecular 
dimensions may insert into the “binding channel” effectively. Generally, the molecular 
dimensions (y-, and/or z-axes) should not exceed 6.5 Å, the supposed width of “binding 
channel” (Figure 1.15, b). 
Quantum-chemical calculations of the ThT conformation indicated that it has a noticeable 
nonplanar conformation in the ground state S0 and the torsion angle φ between the 
benzothiazole and the dimethylaminobenzene rings is about 37°. In the excited singlet state 
S1, a twisted internal charge-transfer (TICT) process takes place which results in a transition 
from the fluorescent state to the nonfluorescent TICT state. Hereby the angle φ between the 
benzothiazole and the benzene rings changes from 37° to 90° (Figure 1.15, a).121 The 
dimensions value of ThT is in the ground state (x = 15.2 Å; y = 6.1 Å; z = 4.3 Å) suggested 
that the dye inserted itself into the binding channel with its shortest axes perpendicular to the 
fibril axes (Figure 1.15, b). As soon as the ThT located in the rather rigid microenvironment 
of amyloid fibrils, the interactions should lead to immobilization of the dye in the “binding 
channel” and further limit intramolecular dye rotation because of the steric hindrance. This 
result would prevent the excited state to be quenched and even enhance the fluorescence 
intensity.  
In conclusion, the hypothesis suggested that imaging probes with favorable molecular 
dimension values, approximately 3 Å along z-axes and up to 6.5 Å along y-axes, could 
preferentially insert into ‘binding channels’ with their x-axes parallel to the fibril axes, closely 
surrounded by the fibrils side chains (Figure 1.15, b).120 With knowledge of the structural 
constraints amyloid fibrils it will be possible to guide the design of novel imaging agents 
which bind to targets more specifically and which will give us insight into the aggregation 
process. 
 
1.4.  α-Synuclein and Parkinson's disease 
PD is the second most common neurodegenerative disorder after AD. It is estimated that PD 
affects about 1-2% of the population over the age of 65 years worldwide. The clinical 
symptoms of PD include tremor at rest, rigidity on passive movement, bradykinesia and 
hypokinesia.122,123 The typical pathological hallmarks of PD are characterized by the 
deficiency of dopaminergic neurons from the pars compacta of the substantia nigra, and the 
formation of fibrillar aggregates composed of ASN and other proteinaceous substances such 
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as Lewy bodies (LBs) and Lewy neurites (LNs) in the brainstem and cortical areas (Figure 
1.16).124,125 All of them contribute to the major clinical symptoms of PD.126 
 
Figure 1.16 Immunohistochemical staining with antibodies against Lewy bodies (left) and Lewy 
Neurites (right).  
So far, 13 genetic loci, PARK1-13, have been suggested for the rare forms of PD such as 
autosomal dominant and autosomal recessive PD. The identification of several single gene 
mutations linked to PD, such as ASN, ubiquitin C-terminal hydrolase like 1 (UCH-L1), parkin 
(PRKN), leucine-rich repeat kinase 2 (LRRK2), PTEN-induced protein kinase 1 (PINK 1), 
microtubule-associated protein tau (MAPT) and oncogene DJ-1 genes, contribute to 
understand the pathogenesis of the disease.127-130 The combination of genetic and 
environmental factors is likely to be implicated in producing abnormal protein aggregation 
within specific groups of neurons, leading to cell dysfunction and death.129 These will improve 
our understanding of the mechanisms leading to inherited and idiopathic forms of PD.130 
1.4.1.  Pathological role of α-synuclein in Parkinson's disease 
ASN is a small (14.5 kDa), abundant, highly soluble, intrinsically disordered and natively 
unfolded protein. It is mainly expressed in neurons of the central nervous system and 
localized at presynaptic terminals in close proximity to synaptic vesicles.131 Structurally ASN 
is composed of 140 amino acids and distributed in three different parts (Figure 1.17). First, 
the amphipathic N-terminal region (residues 1-60), shows imperfect KTKEGV repeats which 
are involved in lipid binding. Second, the highly hydrophobic self-aggregating sequence of 
residues 61-95 is supposed to be responsible for ASN aggregation and β-sheet formation. 
Third, the acidic C-terminal region (residues 96-140) which is rich in Pro, Asp and Glu 
residues plays a critical role to regulate fibril formation.132-134 
The human ASN protein plays an important role in the etiology of PD. While natively 
unfolded proteins may lack static conformers containing extended regions of α-helix and β-
sheet, the oligomeric conformation will gradually be converted to β-sheet-rich fibrillar 
structures.131 The fibrillar aggregates of ASN are formations of heavily insoluble polymers of 
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protein observed in LBs and LNs.135 In the most of the patients, these two synucleinopathies 
are easy to differentiate clinically by the predominance of extrapyramidal motor features in 
PD patients. They are believed to be the most cardinal hallmarks of PD.136 In fact, LBs 
contain many proteins, including neurofilaments and other cytoskeletal proteins, suggesting 
that there are co-precipitants, which might be important in aggregation. However, ASN is 
thought to be the most sensitive marker for LBs and necessary for their formation. 
 
Figure 1.17 Primary structure of ASN. The imperfect 11-mer repeats are emphasized. There are 
three different regions of the protein which are indicated in the ASN sequence (bottom). The N-
terminal amphipathic region (green) contains most of the repeats and the three point mutations linked 
to autosomal dominant early-onset PD. The central non-amyloid-β component (NAC) (red) 
encompasses the most hydrophobic residues and promotes aggregation. The C-terminal acidic region 
(blue) tends to decrease protein aggregation. 
Three ASN mutations (A53T, A30P and E46K) associated to autosomal dominant early-
onset PD have been published (Figure 1.17).127,131,137 In order to explore the differential 
neurotoxicity between the various forms of ASN, it is necessary to identify the mechanisms 
of toxicity and to understand the role of ASN in PD. Some researchers believe that LBs are 
neurotoxic while others have deemed that oligomers, not fibrils, are even more toxic. In vitro 
finding suggests that fibril formation is accelerated by the E46K and A53T mutation. In 
contrast, the A30P mutation increases the total rate of aggregation of ASN, while on the 
other hand, it slows the rate of formation of mature filaments. Presently, it has been debated 
that particular species of ASN are toxic.124,137-139 Apparently, ASN is a protein with a natural 
tendency to aggregate into oligomers. These oligomers can further aggregate into fibrils that 
are deposited as LBs and LNs. It is important in PD and help to clarify both genetic and 
nongenetic factors which increase this aggregation. 
N C 
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1 60 95 140 
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In brief, mutations variably produce either oligomers or fibrils. Such evidence may be used to 
design diagnostic tools and therapeutics aiming at the prevention or reduction of toxic ASN 
aggregates in the brain. Thus, the inhibition of ASN oligomerization and aggregation may 
produce a therapy for both sporadic and inherited PD.129,134 Furthermore, the identification of 
ASN deregulation in synucleinopathies may help the development of effective treatments. 
1.4.2.  Clinical diagnosis and treatment of Parkinson's disease 
PD is also characterized by a progressive loss of nigrostriatal dopaminergic neurons 
associated with intracellular Lewy inclusion bodies. LBs are hallmark lesions of PD that 
appear in dopaminergic neurons of the substantia nigra and other brain regions.140 Although 
the real cause of the degeneration is not known, in order to improve the clinical diagnosis of 
PD, some clinical criteria have been established, and most experts use the UK Parkinson’s 
Disease Society’s Brain Bank diagnostic criteria.122,129 The major clinical syndrome of PD 
pathology is the loss of the dopaminergic neurons in the substantia nigra pars compacta 
(SNc) which results in striatal dopamine deficiency, as well as dysfunction of non-
dopaminergic pathways, including serotonin, noradrenaline, and acetylcholine neuronal 
systems. For the past two decades, neuroimaging techniques such as PET, SPECT, MRI 
and transcranial sonography (TCS) have more and more been evolved to detect PD and to 
elucidate the neuropathological mechanisms, compensatory responses, fundamental 
symptoms, treatment associated complications, and monitor the disease progression in 
vivo.141-143 Functional imaging approaches such as PET and SPECT have been successfully 
employed to detect dopaminergic dysfunction in PD and monitor PD progression, which is 
reflected by changes of levodopa, glucose metabolism and dopamine transporter binding in 
the brain. Structural changes in the substantia nigra of PD patients can be detected with both 
TCS and diffusion tensor MRI.143  
For almost half a century, levodopa combined with a peripheral dopa decarboxylase inhibitor 
has been regarded as the gold standard and most effective therapy for the treatment of 
PD.141,144-146 As noted above, ASN is the major fibrillary component of LBs and LNs, which 
are the pathologic hallmarks of PD (Figure 1.18). It also makes ASN an excellent candidate 
to monitor prodromal PD. Therefore, several therapeutic strategies aim to inhibit filament 
formation and promote filament clearance.140,147,148 Several studies have described small 
organic molecules that inhibit the filament formation, for example catecholamines, porphyrin 
phthalocyanine, the polyphenol baicalein and the anti-tuberculosis drug rifampicin.149 
Currently, mutations in the LRRK2, DJ-1, PINK1 and Parkin gene are targets of drug 
development at major pharmaceutical companies.150 
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Figure 1.18 Imaging of ASN aggregates by cyanine dyes (Tissues: midbrain; Patient: male, 87 
years old, PD). 
 
1.5.  Zebrafish as a good model in neurodegeneration disease 
The mouse has become the pre-eminent model for human physiology and disease. However, 
several factors limit its use in large-scale genetic and therapeutic screening. National and 
international government agencies have called to reduce, refine or replace mammalian 
species in toxicological tests with alternative methods, even with non-mammalian models.151 
Currently, the zebrafish (Danio rerio) has been concerned as a classical tractable vertebrate 
and embryological model for human disease.152 There are a number of favorable features 
that make it an excellent alternative model for biomedical and behavioral genetics studies, 
including its small size, high fecundity, rapid external development, optical transparency 
during early embryogenesis, permeability to small molecules, amenability to high-throughput 
screening, and genetic similarity to humans.153,154 
1.5.1.  The husbandry of zebrafish (Danio rerio) 
Comprehensive understanding of the zebrafish in their native environment, such as habitat 
preferences, reproductive behaviors, and diet is important for both the improvement of 
husbandry standards and the optimization of their use in physiological and pharmacological 
studies. The zebrafish is native to South Asia and broadly distributed in the lower reaches of 
the major river drainages of India, Bangladesh, Nepal, Myanmar and Pakistan. This 
geographic region is characterized by its monsoon climate with pronounced rainy and dry 
seasons.155 Understanding the habitat types and zebrafish behavior in the wild allows to 
optimize the husbandry and to control laboratory conditions. 
Olfactory cues play an important role in zebrafish reproduction and spawning behavior. 
Males release pheromones into the water.156 When the females are stimulated by the 
pheromones, this will cause ovulation, which is followed by female release of postovulatory 
pheromones. As soon as males sense pheromones, the fish will express chasing behavior 
which triggers mating and spawning. Moreover, according to recent research nutrition, 
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feeding, water quality and genetic management could also determine the reproductive 
success in zebrafish.  
 
Figure 1.19 The husbandry of zebrafish (A and B) and representative examples of zebrafish 
spawning technology (C-E) in our lab.  
The embryos are selected and transferred to a 10 L tank. In laboratory conditions, zebrafish 
larvae naturally hatch within 2.5–3 days post-fertilization (dpf). After hatching, they stick to 
hard surfaces by means of specialized cells on the head, displaying low levels of 
spontaneous activity. The larvae have the ability to swim after 5-7 dpf. The zebrafish usually 
attains its sexual maturity within 3–6 months post fertilization in laboratory settings and 
females housed with males spawn once a week (Figure 1.19). 
In our group, the zebrafish is bred and maintained according to the methods described by 
Christiane Nuesslein-Volhard and Ralf Dahm.157 Briefly, the zebrafish is raised on 14-h light-
10-h dark cycles at 26.0 ± 0.5°C. The zebrafish are fed twice per day, about 3 to 5 mg/fish 
aquarium fish food (Tetra ™) as well as white/red mosquito larvae for adults. The juveniles 
are fed 0.1-0.3 mg/fish aquarium fish food. In addition, bloodworms, which are an important 
component of the diet of wild zebrafish, are supplied once a week. In order to maintain 
adequate water quality, 30-50% of water is exchanged every week.  
1.5.2.  Zebrafish as a tool in Alzheimer's disease research 
The mouse is the main model used to model neurodegenerative pathology. However, non-
mammalian species have become very popular alternative organisms in neurotoxicological 
study. Some non-mammals provide facile husbandry and share relevant physiological and 
pharmacological properties with human beings.151,158 As a model organism, the zebrafish 
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presents many advantages to study human disease. The vertebrate zebrafish genome and 
anatomy indicate ~420 million years of divergence from the human lineage. Thus, most 
human genes have clearly identifiable orthologues in zebrafish.159 
Small molecule screening takes advantages of the small size, permeability and optical 
transparency of the zebrafish embryo in the early stage.160 The effects can be observed in 
the transparent embryos using microscopy. As a result, defects in numerous organ systems 
including the CNS and BBB have been identified.151 Therefore, the zebrafish is a favorite 
model organism for developmental geneticists and high-throughput screenings in 
applications including small molecule discovery and toxicology research.152,161 
According to the hypothesis, the pathologic hallmarks of AD are extracellular Aβ plaques and 
intracellular NFTs. Early-onset AD is associated with three gene mutations involved in Aβ 
proteolysis displaying autosomal-dominant inheritance pattern in humans: APP, Presenilin 1 
(PS1), and Presenilin 2 (PS2). Late-onset AD is linked to a number of genetic risk factors 
including the apolipoprotein E (ApoE), neuronal sortilin-related receptor (SORL1) and 
MAPT.159,162 Except MAPT, other human genes have been found with a high percent of 
amino acid similarity in zebrafish.163 Two paralogues of MAPT in zebrafish, named mapta 
and maptb has been identified.  Both of mapta and maptb mRNAs were expressed in the 
developing CNS. The zebrafish CNS is comparable to human CNS: the zebrafish CNS also 
contains microglia, cells with astrocytic properties, oligodendrocytes, myelin and the BBB. It 
implicates that the zebrafish shows conservation of basic brain organization and several key 
neuroanatomical and neurochemical pathways with relevance to neurological human 
diseases.164 Moreover, zebrafish embryos develop BBB functions by 3 dpf. Although the BBB 
may not be fully mature until 5 dpf, however, it has a structure similar to that in higher 
vertebrates. The functioning BBB in the transparent embryo brain can still serve as model to 
study drug permeation in the nervous system and efficacy of CNS drugs.165 
The zebrafish is an excellent model transiently expressing mutant human tau. It assists to 
understand the MAPT contribution to tau pathology and tau redistribution from neuronal 
axons to neuronal soma forming pathogenic neurofibrillary tangles. Current research 
suggested that the mouse models express only 4R tau in the brain. This feature limited 
comprehensive and accurate study of tauopathies like AD. Conversely, like human tau, the 
zebrafish tau isoforms with different kinds of microtubule-binding repeats are expressed in 
the CNS.166 Changes in the subcellular ratio of 3R and 4R isoforms can cause the 
pathological consequences in mammals. Therefore, the major production of the 4R or 6R 
isoforms from mapta and of the 3R isoforms from maptb suggests that zebrafish embryos will 
be a valuable tool to study the discrete functions and interactions of the 3R and 4R MAPT 
isoforms.167 The various and externally fertilized embryos of the zebrafish are easily 
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subjected to the methods for manipulating gene and protein activity, like injection of 
antisense oligonucleotides, mRNAs or transgenes. These technologies may be applied to 
arrayed in microtitre plates to screen drug libraries.  
The mouse is a typical animal model, but in vivo whole animal imaging requires some special 
techniques and complex manipulations. Oppositely, the zebrafish has a long transparent 
period (almost 3 weeks) during early development and short generation times (2-3 months) 
for in vivo imaging in a variety of biological investigations. Currently, some groups use 
fluorescent probes to stain the tau protein in transgenic fish to monitor progression of 
pathology and genetic inheritance in vivo.168,169 This technology has potential applications for 
the zebrafish imaging. Using the transgenic zebrafish to express fluorescent proteins in vivo 
suggested that the zebrafish is a valuable tool for the spatio-temporal detection and analysis 
of many biological processes.170 
1.5.3.  The use of in vivo zebrafish assays in drug toxicity screening 
The mammalian models like mouse remain the gold standard for evaluating developmental 
toxicity. Nevertheless, acceptance of zebrafish as a toxicology model is increasing in the 
USA and Europe. In the process of looking for alternative models for toxicity testing, the 
zebrafish offers several noteworthy advantages including low costs, small amount of drugs 
required, convenience of drug treatment, short treatment time, easy husbandry in large 
numbers, limitless range of morphological and functional assays, optically transparent 
embryo and good correlation between results in mammals and humans.   
Compared with other animal models, rapid development is one of the most significant 
advantages for assessing compound developmental toxicity in zebrafish (Figure 1.20). The 
precursor cells and tissues of the brain, eyes, heart and musculature will be established at 
24 hours post-fertilization (hpf). Basically, most of the internal organs, such as the 
cardiovascular system, gut, liver and kidney, develop rapidly in the first 24-48 hpf and the 
zebrafish completes embryogenesis in the first 72 hpf. Since the stages for initiating and 
terminating compound treatment are vital parameters for evaluating toxicity, the 
organogenesis is essentially completed within the first 5 days of development. This stage is 
usually used to terminate compound treatment. Usually, the stage for compound treatment is 
about 6 hpf but not later than 24 hpf. Due to transparency, organs of zebrafish can be easily 
visualized in vivo by light microscopy without use of complicated dissecting procedures. 
Furthermore, chemicals can be directly added to the solution of embryonic development to 
simplify the drug dispensing and promote high-throughput screening. For these reasons, 
zebrafish permit highly efficient phenotype analysis and fast in vivo drug screening. 
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Figure 1.20 Four kinds of fish used to study toxicity in our lab. Gold zebrafish (A), wild-type 
zebrafish (B), casper (C) and medaka (D). 
Shorter treatment time increases throughput and is normally sufficient for evaluating 
compound toxicity in the cardiovascular system, nervous system and specific sections in the 
brain. Cardiotoxicity, neurotoxicity, digestive system, genotoxicity, DNA microarrays and 
metabolic enzymes are in the habit of determining compound toxicity.171-174 The lethality 
concentration (LC50), toxicity concentration (also called effective doses) (EC50) and % 
apoptosis are mostly used as parameters for toxicity studies.156  The percent incidence and 
teratogenic index (TI), which defined as the LC50/EC50 ratio, were used to clarify the effects of 
hazardous chemicals. 
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2. Objectives 
Novel non-invasive imaging may improve the in vivo diagnosis of Alzheimer’s disease (AD). 
Currently, several compounds have been developed in order to detect β-amyloid (Aβ) plaque 
pathologies in brains of AD patients. However, only few compounds have been reported 
which can specifically target neurofibrillary tangles (NFTs). Therefore, the main objective of 
my work presented in this thesis was to design and synthesize series of imaging probes 
which specifically bind to Aβ plaques or NFTs. These compounds may be used in the future 
as potential in vivo imaging markers for the diagnosis of AD. Based on this purpose, the 
following tasks were carried out: 
 Design and synthesis of various fluorescent dyes with sensitivity and specificity to 
detect Aβ plaques or NFTs.  
 In vitro histological evaluation of different sets of probes, visible by fluorescence 
microscopy, using hippocampus sections of AD patient brains.  
 Quantification of the binding affinity of several active probes by a new competitive 
Thiazine Red R displacement assay. 
 Selected candidates were profiled in the in vitro liver hepatocellular carcinoma cell 
assay and in the in vivo wild-type zebrafish embryo development assay for 
toxicological studies. 
 The solubilities of candidate probes were evaluated in order to optimize these 
compounds for further use as potential in vivo agents for the diagnosis of AD.  
 Selected tau active probes were applied to detect tau deposits in the olfactory 
epithelium tissues. 
Due to the lack of imaging probes for the detection of α-synuclein aggregates in Parkinson's 
disease (PD), the second aim of this thesis was to explore and evaluate some fluorescent 
probes for effectively visualization of α-synuclein aggregates. These compounds may be 
used as potential biomarkers for the early detection of PD. 
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3.  Results and Discussion 
An ideal noninvasive imaging biomarker may be used to evaluate the efficacy of therapeutic 
agents and to diagnose the AD in the early stage. However, current probes tend to have 
relatively poor selectivity. Thus, modification of known structures and development of next 
generation imaging probes will be an important step to accelerate our understanding of AD. 
The investigation of a clinically useful radiolabeled derivative has become subject of 
worldwide research.175 There are two fundamental principles for the development of 
molecular probes to image Aβ plaques and NFTs in cases of AD. First, molecules should be 
able to bind specifically to SPs or NFTs with high affinities in both in vitro and in vivo studies. 
Second, they should have adequate lipophilicities to cross the BBB. From the point of view of 
molecular design the association of imaging probes with small molecule inhibitors should be 
of high importance. Based on previous research there is a strong possibility that small-
molecule inhibitors of Aβ or tau aggregation will provide sufficient guidelines for the core-
structural design. Finally, the novel probes may be used for the imaging of Aβ plaques or 
NFTs.176 It is important to recognize that the core structure may be responsible for its binding 
affinity to proteins. In vitro binding affinity should be taken as the first standard for a rational 
probe design. Thus, small molecules that bind to Aβ such as CR (24), ThT (26) and curcumin 
(36) are important tools to study Aβ aggregation and will serve as core structures for further 
optimization of imaging probes.  
 
3.1.  Design, synthesis and evaluation of benzothiazole derivatives for Aβ and 
tau imaging  
3.1.1.  Design, synthesis and evaluation of phenyldiazenyl benzothiazole 
derivatives 
Over the past ten years, several AD imaging agents were developed for PET and SPECT. 
Theoretically the core structure of these probes can be assembled by two building blocks: an 
aromatic moiety comprised of two or more aromatic rings as well as a linker that may also 
serve as an affinity binding modifier.176 The most commonly used agents for Aβ imaging in 
vitro include CR (24) and ThT (26).177 However, ThT (26) contains a positively charged 
quaternary heterocyclic nitrogen which may limit the compound to cross the BBB.177 To 
overcome this problem Klunk et al. synthesized a number of neutral ThT analogs without the 
methyl group on the nitrogen of the thiazole ring. These uncharged compounds did not only 
retain binding ability, but showed 6-fold increased binding affinity for aggregated Aβ. It was 
also observed that removal of the charge improved the lipophilicity and showed very good 
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brain penetration.178 Further research suggested that removal of the methyl group on the 6-
carbon of the benzothiazole moiety does not effect the affinity.179 The removal of one of the 
two methyl groups on the amine nitrogen in the 4’-position significantly increases the affinity 
for Aβ, with the best result having a 40-fold improved affinity.180 It was reported that CR (24) 
directly binds to Aβ, blocks aggregation and fibril formation in vitro. However, the large 
structure prevents itself to cross the BBB and be further used for in vivo studies.175   
N
S
N
ThT 26
N
S
N
R2
R1R
N N
NN
NH2 H2N
SO3--O3S
CR 24
Uncharged 2-aryl benzothiazoles
N
S
N
N Ar
N
S
N
R1R
H
Aß specifictau specific
Aß or tau specific agents?
 
Figure 3.1 Design strategy for phenyldiazenyl benzothiazoles. 
According to pervious research, ThT (26) is a non-specific imaging marker of Aβ aggregates. 
It binds to many types of proteins such as tau and ASN. Thus, the combination of the core 
structure of ThT (2-aryl benzothiazole) and the azobenzene of CR may be attractive to 
design novel scaffolds with high affinity and selectivity to the targets. It may provide an 
excellent chance to develop new probes for the detection of Aβ or tau aggregates in AD 
(Figure 3.1). The terminal aryl groups on this scaffold may improve the affinity and the 
specificity of these probes. It was reported that compounds with a N,N-dimethyl group may 
display higher binding affinity to tau than to Aβ aggregates, while compounds with a terminal 
N-methyl group have higher binding affinity to Aβ.180,181 In order to investigate the novel 
scaffold for the imaging of Aβ plaques and NFTs in AD brain, seven phenyldiazenyl 
benzothiazoles have been synthesized and evaluated in post-mortem brain tissues (Table 
3.1).   
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Scheme 3.1 Synthesis of phenyldiazenyl benzothiazole derivatives. 
Table 3.1 Structures and properties of phenyldiazenyl benzothiazoles 
Entry BSc No. Ar cLogP[a] Yield (%)[b] Staining effect[c] 
50a BSc4211 N
 
7.02 71 
Aβ: - 
NFT: - 
50b BSc4212 
N
N
 
6.40 63 
Aβ: - 
NFT: - 
50c BSc4213 N
HO
 
6.63 67 
Aβ: - 
NFT: - 
50d BSc4214 
H
N
 
6.28 46 
Aβ: - 
NFT: - 
50e BSc4215 
H
N
 
6.62 49 
Aβ: - 
NFT: - 
50f BSc4295 HO
N
H
 
6.94 81 
Aβ: - 
NFT: - 
50g BSc4296 
H
NHO
 
6.08 48 
Aβ: - 
NFT: - 
[a] Determined by CS ChemOffice 10.0; [b] Isolated yields; [c] - stands for no staining. 
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The commercially available 4-nitrobenzoyl chloride (47) was treated with 2-
aminobenzenethiol (46) at 100 °C in NMP to afford the 2-(4-nitrophenyl)benzo[d]thiazole (48). 
Due to its poor solubility in organic solvents, this compound was only characterized by HPLC. 
By reduction of the aromatic nitro group using stannous chloride, 4-(benzo[d]thiazol-2-yl) 
aniline 49 was obtained in 92% yield. The key process involved initial diazotization of 49 with 
sodium nitrite in hydrochloric acid solution to furnish the diazonium salt (Scheme 3.1). 
Followed by coupling with aryl compounds, all of the phenyldiazenyl benzothiazole 
derivatives in Table 3.1 (50a-g) were purified by column chromatography and characterized 
by NMR spectroscopy and mass spectrometry. Compounds 50d-g with a free secondary 
amine may improve the solubility in buffer solution. This property may affect the interaction 
between probes and proteins.182  
The introduction of a hydroxyl group in the ortho position of the azo group (50c, 50f and 50g) 
may form intramolecular hydrogen bonds within the molecule. It may hinder the free rotation 
of the molecule and make it more rigid. Therefore, it may improve the optical properties for 
Aβ plaques or NFTs imaging. Aromatic α-hydroxy azo compounds may undergo fast 
intramolecular proton transfer between the enol azo form 50c and the keto hydrazone form 
50c’ (Scheme 3.2). This equilibrium has been studied by a variety of spectroscopic 
techniques. The 1H-NMR and 13C-NMR showed that the neutral form of this substance 
almost completely adopts the enol azo form rather than the keto hydrazone form in solution. 
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Scheme 3.2 The enol azo form 50c and the keto hydrazone 50c’. 
Unlike ThT and its analogs, all of these phenyldiazenyl benzothiazoles (50a-g) are colored 
but not fluorescent. In order to investigate the binding effect of these dyes (50a-g) to Aβ 
plaques and NFTs, probes were evaluated by staining hippocampal sections of human AD 
brain tissue and analyzed by fluorescence microscopy. However, neither Aβ plaques nor 
NFTs were detected by fluorescence microscopy using the DAPI- or FITC-filters. Recently, 
Saji et al. reported that phenyldiazenyl benzothiazoles with strong binding affinity toward tau 
aggregates. Several probes may be used as potential PET imaging agents in vivo.110,111,183 
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This suggests that our dyes may also bind to Aβ plaques and/or NFTs, while the 
fluorescence properties will limit the detection by the DAPI- or FITC-filters employed in 
fluorescence microscopy. 
3.1.2. Synthesis and evaluation of phenylhydrazone benzothiazole derivatives 
for Aβ and tau imaging  
The phenyldiazenyl benzothiazoles did not exhibit fluorescence upon binding to the proteins. 
To overcome this limitation, this work focused on the synthesis and optimization of a 
hydrazone linkage strategy to enhance the photophysical properties of these probes by 
extending the π system.181 Subsequently, different terminal aryl substituents were explored 
on the hydrazone group. It was found that the phenylhydrazone benzothiazoles can be 
synthesized in a one-pot reaction from the hydrazine formation to produce 52a-v in isolated 
yields ranged from 44 % to 81 % (Table 3.2). The E-Z configurated isomers were 
synthesized by known methods, or with slight modifications, which are depicted in Scheme 
3.3.   
N
S
NH2
1. NaNO2, H2O, HCl
2. SnCl2, HCl, THF N
S
NH
NH2
S
N
NH
N
Ar
KOH, THF, ref lux
ArCHO
49 51
52a-v
 
Scheme 3.3 Synthesis of phenylhydrazone benzothiazole derivatives. 
The hydrazine 51 was coupled with a range of aldehydes to afford hydrazone derivatives. 
The reaction was monitored by thin layer chromatography (TLC) and HPLC. After purification 
by column chromatography these products were characterized by NMR spectroscopy and 
mass spectrometry. In the 1H-NMR spectra of these probes, the proton signals of the NH 
group were observed as a singlet at 10.48-11.45 ppm and the proton of the N=CH group was 
observed as a singlet at 7.84-8.22 ppm. Furthermore, 13C-NMR spectra revealed that these 
probes lack the signals of the methylene group. All of these data indicate that probes 
adopted the hydrazone form 52 I but not the azo form 52 II (Scheme 3.4). The NH group of 
the hydrazone may be useful to improve the affinity to Aβ plaques and to lower the 
calculated LogP values to appropriate range, which may contribute to cross the BBB in vivo.   
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Scheme 3.4 The hydrazone form and the azo form of phenylhydrazone benzothiazoles. 
Notably, substituent changes in the electron donor group may affect the intensity of 
fluorescence emission upon binding to targets. Initially, these probes with different 
substitutents at various positions of the phenyl group (52a-l and 52o) were evaluated by 
neuropathological staining of AD brain sections. The structure-activity relationship (SAR) 
analysis revealed that most of these probes were weak in staining Aβ plaques and/or NFTs. 
The NH group of the hydrazone may be important to increase the fluorescence and binding 
affinity to proteins in comparison to the azo compounds. Compounds 52j and 52l showed 
that the hydroxyl group in the para position may affect the visualization of Aβ aggregates. 
The comparison of 52e-f with 52j indicates that one electron-withdrawing group only in the 
phenyl ring is not sufficient to warrant target affinity. The comparison of compound 52k with 
compounds 52d, 52g and 52o suggested that probes bear electron-donating groups in the 
meta and the para positions, showed a relative good activity towards Aβ aggregates. It is 
assumed that an electron-donating group such as methylamino, dimethylamino, methoxy, 
methylthio or hydroxy groups in the meta and the para positions may play an important role 
for binding affinity to Aβ plaques and/or NFTs. The electron-donating atoms (N, O, S) may 
enhance the hydrogen bond between the substituents and proteins. However, the exchange 
of various substituents at the phenyl ring does not significantly affect the imaging effects. 
This indicates that the aryl ring does not have a major impact on binding. 
Table 3.2 Structures and properties of phenylhydrazone benzothiazoles. 
Entry BSc No. Ar cLogP[a] Yield (%)[b] Staining effect[c] 
52a BSc4216 N
 
7.02 76 
Aβ: + 
NFT: - 
52b BSc4217 N
 
6.40 73 
Aβ: - 
NFT: - 
52c BSc4219 
OH
O
 
6.63 46 
Aβ: + 
NFT: - 
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52d BSc4220 
OHO
 
6.28 53 
Aβ: ++ 
NFT: - 
52e BSc4297 
Br
O
 
6.62 80 
Aβ: - 
NFT: - 
52f BSc4298 
O
F
 
6.94 78 
Aβ: + 
NFT: ++ 
52g BSc4299 
HO
 
6.08 50 
Aβ: + 
NFT: - 
52h BSc4300 
OH
 
5.30 61 
Aβ: + 
NFT: - 
52i BSc4301 
N
HO
 
6.26 81 
Aβ: - 
NFT: - 
52j BSc4302 
F
F
 
6.00 80 
Aβ: - 
NFT: - 
52k BSc4303 
HO
 
5.30 68 
Aβ: - 
NFT: - 
52l BSc4304 
F
F
OH
 
5.61 61 
Aβ: ++ 
NFT: - 
52m BSc4330 
H
N
 
5.23 52 
Aβ: +++ 
NFT: - 
52n BSc4331 
N
 
5.46 48 
Aβ: - 
NFT: - 
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52o BSc4332 S
 
6.13 71 
Aβ: ++ 
NFT: - 
52p BSc4333 N
 
4.47 44 
Aβ: +++ 
NFT: ++ 
52q BSc4334 
S Br
 
6.38 73 
Aβ: ++ 
NFT: +++ 
52r BSc4335 
S S
 
7.38 66 
Aβ: +++ 
NFT: - 
52s BSc4336 N
HO
HO
 
4.09 75 
Aβ: - 
NFT: - 
52t BSc4337 
N
 
4.35 78 
Aβ: + 
NFT: + 
52u BSc4342 
N
 
6.52 67 
Aβ: +++ 
NFT: + 
52v BSc4565 N
 
5.86 46 
Aβ: ++ 
NFT: - 
[a] Determined by CS ChemOffice 10.0; [b] Isolated yields; [c] +++ stands for efficient 
staining, ++ stands for normal staining, + stands for weak staining and - stands for no 
staining. 
The in vitro staining assay revealed that probes with terminal phenyl substituents poorly 
stained Aβ plaques and NFTs. To overcome this shortcoming, we intended to improve the 
fluorescence intensity of these probes to improve histology results. It was reported that the  
π-conjugation length affects the fluorescence emission efficiency.184 For this purpose, 
compound 52u has been synthesized by an 8-methyl-9H-carbazole domain replacement of 
the terminal phenyl ring. Remarkably, Aβ plaques and NFTs were clearly observed by 
fluorescence microscopy (Figure 3.2). Furthermore, the replacement of the carbazole moiety 
with the indole moiety (52m) and 2,2'-bithiophene moiety (52r) led to probes that showed 
excellent visualization of Aβ plaques in human brain sections. However, no NFTs have been 
observed by fluorescence microscopy. Probes 52p-q and 52s-t display diminished π-
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conjugation of the five- or six-membered heterocyclics to the aromatic core. The in vitro 
staining assay indicated that Aβ plaques and NFTs were clearly stained with these probes 
(52p-q and 52s-t) as shown in Figure 3.2. It was assumed that the electron-donating atoms 
(N, O, S) of the heterocyclics may form hydrogen bonds between probe and proteins and 
thus improve the binding affinity.  
Additionally, we synthesized compound 50v which features an extended π conjugation 
between the hydrazone and the terminal phenyl ring. The comparision of probe 50v (Figure 
3.2, T) with probe 50a (Figure 3.2, A) did not provide distinct biological profiles against Aβ 
plaques. It implies that the effective π conjugation may not be a crucial factor in fluorescence 
imaging. 
 
Figure 3.2 Neuropathological staining of brain sections from the hippocampus of an AD patient 
(Tissues: hippocampus; Patient: female, 89 years old; CERAD Score: 3; NFTs-level: V). 
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To quantify the binding affinity of these probes, a new Thiazine Red R displacement assay 
has been developed and selected candidates were profiled toxicologically. The probes 52l-m, 
52o and 52r stained Aβ plaques clearly in human brain tissues as seen in the in vitro staining 
assay, whereas NFTs in the same brain sections were not visualized. This observation 
stands in contrast to the activity in the Thiazine Red R displacement assay, where compound 
52l-m, 52o and 52r present almost equipotent affinity to aggregated tau and Aβ40. The lack 
of NFT staining in the human brain sections may be due to interference with the fluorescence 
properties upon binding to tau aggregates, e.g. a fluorescence reduction or effect on the 
Stokes shift, which limit the detection by the DAPI- or FITC-filters employed in fluorescence 
microscopy.  
Compound 52p displayed ~2-5-fold higher affinity to tau aggregates and ~8-20-fold higher 
affinity to Aβ40 aggregates than the rest of the compounds in this series. Remarkably, these 
probes displayed ~5-25-fold higher affinity to tau aggregates and ~7-140-fold higher affinity 
to Aβ40 aggregates than PIB (30), which was used in the same system for comparison. It 
indicates sufficient affinity of these probes for the imaging of tau and Aβ aggregates in vivo.  
Five of these phenylhydrazone benzothiazoles (52p-r, 52t and 52u) have been evaluated 
further at different concentrations in the wild-type zebrafish embryo development assay. 
These embryos were collected and maintained in E2 medium at 26 °C. Afterwards, the 
embryos were treated with solutions containing 5 µM and 10 µM of compounds at 50-75% 
epiboly, approximately 6-8 hpf. The phenotypes were observed using the Axio Scope A1 
microscope system from Carl Zeiss at 24 hpf and 72 hpf (Figure 3.3) to explore their in vivo 
cytotoxicity. 
 
Figure 3.3 In vivo cytotoxicity studies of embryos of wild-type zebrafish with 10 µM 
phenylhydrazone benzothiazoles after 24 (A-F) and 72 (G-L) hpf. Controlled (A and G), Probe 52p (B 
and H), 52q (C and I), 52r (D and J), 52t (E and K) and 52u (F and L). 
It was found that the embryos developed well at different concentrations up to 10 µM at 24 
hpf and 72 hpf and did not display any lesions in eyes, yolks, tail and heart beat (~60-70 bpm 
after 24 hpf and ~140-150 bpm after 72 hpf). This evidence suggests that phenylhydrazone 
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benzothiazoles have negligible cytotoxicity against zebrafish embryos which indicates 
sufficient safety for in vivo evaluation in mouse models. 
 
3.2. Synthesis and evaluation of imidazo[1,2-a]pyridines and imidazo[1,2-
a]pyrimidines based probes for tau imaging 
3.2.1. Synthesis and evaluation of imidazo[1,2-a]pyridine derivatives for tau 
imaging 
[123I]IMPY (35) has been characterized as a potential ligand for SPECT-based imaging of Aβ 
plaques in the past decade. In vivo biodistribution after an intravenous injection of [125I]IMPY 
in normal mice showed a high initial brain uptake and fast washout.106,185 However, the 
signal-to-noise ratio for Aβ plaques labeling is not as high as that of [11C]PIB (30). The low 
contrast limited its use in clinical trails. As mentioned before, the removal of one of these two 
methyl groups on the amine in the 4’-position, such as PIB, significantly increases the affinity 
toward Aβ aggregates. Hence, we planned to remove either one or two substituents on the 
nitrogen in the 4’-position of 4-(imidazo[1,2-a]pyridin-2-yl)aniline and evaluate the derivatives 
by staining of AD brain sections. Additionally, it may reduce the lipophilicity to an appropriate  
level and thus to promote the probe to penetrate the BBB in humans.  
We selected the -CH2CF3 group as a substituent of the amino group for further research. The 
CF3 group enjoys a privileged role in the field of medicinal chemistry because its 
incorporation into small molecules frequently improves efficacy. It promotes electrostatic 
interactions with biological targets, improves cellular membrane permeability and increases 
robustness of the oxidative metabolism of drugs.186 It is reported that the electronic inductive 
effect of the 2,2,2-trifluoroethyl residue is equal to the inductive effect of the hydrogen atom. 
In some respects, the -NHCH2CF3 residue in the derivatives behaves like a primary amine.187 
Moreover, the fluoride compound is easy to be radiolabeled. It may serve as precursor probe 
for PET and MRI imaging in vivo.  
The commercially available 2-aminopyridine 53 and α-bromoketone 54 were refluxed in 
EtOH to form imidazo[1,2-a]pyridines 55 in good yield. The free anilin 56 (BSc4485) was 
readily prepared via 55 by reduction with stannous chloride. To a solution of 56 in 
trifluoroacetic acid was added trifluoroacetic anhydride under ice-cooling. The resulting 
solution was stirred at room temperature overnight to afford the mono-substituted anilin 57 
(BSc4436) in 86 % yield.188 Finally, the reduction of compound 57 with LiAlH4 in THF 
afforded the 2,2,2-trifluoroethyl substituted compound 58 (BSc4439) (Scheme 3.5). 
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Scheme 3.5 Synthesis of imidazo[1,2-a]pyridines 
To further investigate the binding effects to Aβ plaques and/or NFTs in AD brain sections, we 
performed neuropathological fluorescent staining with compounds 56, 57 and 58. However, 
all of these three compounds failed to detect Aβ plaques by fluorescence microscopy. 
However, a weak NFT staining was observed for compounds 56 and 57 (Figure 3.4, A and 
B). Probe 58 stained the NFTs but the fluorescence was absent. It was assumed that in the 
presence of 2,2,2-trifluoroethyl residue the fluorescence may be quenched upon binding to 
tau aggregates. 
 
Figure 3.4 In vitro histochemical staining of postmortem AD brain tissues with compounds 56, 57 
and 70. (Tissues: hippocampus; Patient: female, 89 years old; CERAD Score: 3; NFTs-level: V) 
3.2.2. Synthesis and evaluation of imidazo[1,2-a]pyridines derivatives based on 
[8+2] cycloaddition reaction 
Imidazo[1,2-a]pyridines displayed poor contrast between NFTs and background (Chapter 
3.2.1). In order to achieve the necessary improvement for imaging, it was planned to 
increase the fluorescence intensity of molecules by extension of the π conjugation. The 
efficient [8+2] cycloaddition of imidazo[1,2-a]pyridines with electron-deficient 2π systems 
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was recently reported. A number of tetracyclic compounds, which exhibit interesting 
photophysical properties, were synthesized.189  
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Scheme 3.6 Synthesis of the imidazo[1,2-a]pyridines by 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate. 
The bicyclic heterocycles 57 (BSc4436) and 58 (BSc4439) are suitable substrates for [8+2] 
cycloaddition reaction. The reactions are feasible under classical heating using 2-
(trimethylsilyl)phenyl triflates 59 as benzyne precursors. The heating process promoted the 
ortho-elimination of 59 in the presence of CsF and 18-crown-6. The [8+2] cycloaddition of the 
intermediate o-benzyne with imidazo[1,2-a]pyridines yield compound 61 (BSc4437) and 62 
(BSc4441) in moderate isolated overall yields (Scheme 3.6). In order to improve the 
efficiency of the reaction, microwave irradiation was investigated. However, it did not 
significantly affect the reaction yields. The benzyne precursor 59 was replaced by an 
economic substance to reduce the costs. The o-benzyne intermediate 60 was achieved by 
thermal decomposition of benzendiazonium 2-carboxylate which was obtained by aprotic 
diazotization of 2-aminobenzoic acid in THF.190 We investigated the direct reaction between 
o-benzyne and bicyclic heterocycles compounds 57 and 58 under microwave irradiation and 
classical heating conditions.191 However, [8+2] cycloaddition products were not observed by 
HPLC. 
As shown in Scheme 3.7, initially, we intended to substitute a phenyl group on the primary 
amine of 56. Nevertheless, the reaction did not convert to compound 65 but underwent [8+2] 
cycloaddition to form the compound 64 (BSc4484). It suggested that bromobenzene 63 
converted to the o-benzyne under thermodynamic condition. The o-benzyne further reacted 
with the imidazo[1,2-a]pyridines 56 to form tetracyclic compound 64 in the presence of t-
BuOK. 
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Scheme 3.7 Synthesis of imidazo[1,2-a]pyridine derivative 64. 
To demonstrate that the [8+2] cycloaddition derivatives enhance the fluorescence to bicyclic 
imidazo[1,2-a]pyridines, we studied the photophysical properties of compounds 57, 58, 61 
and 62. All of these four compounds were prepared as 1.0 µmol/mL solution in EtOH. The 
color photographs of these compounds were obtained upon irradiation the solution with the 
UV lamp (365 nm) (Figure 3.5). It is consistent with the underlying assumption that the 
tetracyclic compounds have higher fluorescence intensity than the bicyclic compounds. 
Comparision of compounds 57, 61 with compounds 58, 62 suggested that the fluorescence 
may significantly be enhanced by reducing the electron-withdrawing ability of the substituent 
on the amine group. 
 
Figure 3.5 Photographs of 57 (BSc4436), 61 (BSc4437), 58 (BSc4439) and 62 (BSc4441) (from 
left to right) with UV (365 nm,) illumination. The concentration is 1 µmol/mL. 
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These tetracyclic probes were evaluated using post-mortem AD brain tissues. However, they 
failed to detect Aβ plaques and NFTs by fluorescence microscopy. It was assumed that the 
three dimensions of the tetracyclic compounds are too large to allow insertion into the 
binding channel of Aβ or tau fibrils, which may cause them to be inactive in imaging assay. 
3.2.3. Synthesis and evaluation of imidazo[1,2-a]pyrimidine derivatives for tau 
imaging 
The results of the phenylhydrazone benzothiazoles (Chapter 3.1.2) suggested to modify 
imidazo[1,2-a]pyridines 56 and imidazo[1,2-a]pyrimidine 68 with phenylhydrazone moiety. 
However, only the hydrophilic imidazo[1,2-a]pyrimidine derivative 68 can be substituted with 
a hydrazone moiety. The compound 70 (BSc4456) was synthesized using the same 
procedures depicted in Chapter 3.1.2. The pyrimidin-2-amine 66 and α-bromoketone 54 
were refluxed in EtOH to form the imidazo[1,2-a] pyrimidine 67. Followed by reduction with 
stannous chloride, the free amino compound 68 was obtained in quantitative yield. 
Employing a one-pot synthesis, compound 70 was purified by column chromatography and 
characterized by NMR spectroscopy.  
N
N
NH2
O
Br
NO2
+
N
N N
NO2
EtOH, reflux EtOH, SnCl2
ref lux, 4 h
N
N N
NH2
overnight
66 54 67
68
1. NaNO2, H2O, HCl
2. SnCl2, HCl, THF
70 (BSc4456)
N
N N
NH
N
N
OHC
N
69
+
3. THF, ref lux
 
Scheme 3.8 Synthetic route for imidazo[1,2-a] pyrimidine derivative 70. 
To further confirm the binding affinity of compound 70 to Aβ plaques and NFTs, a fluorescent 
staining of AD brain sections was carried out. A selective but weak NFTs staining was 
observed by fluorescence microscopy (Figure 3.4, C). Taken together, it was assumed that 
the low contrast may be due to the relatively low binding affinity for tau aggregates, which 
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may cause the fast washout from AD brain sections. The low signal-to-noise ratio is an 
adverse factor which limits the use of these compounds for NFT imaging in vivo.  
 
3.3. Synthesis and evaluation of tetrazine derivatives as potential imaging 
probes in Alzheimer’s disease 
1,2,4,5-Tetrazine, so-called s-tetrazine, is a well established heterocycle, which was 
discovered more than 100 years ago. It contains an electron poor aryl ring with four nitrogens. 
S-Tetrazines are attractive molecules that can be used as strong electron acceptors. 
Because of the four electronegative nitrogen atoms in the aryl ring they have a relatively high 
reversible reduction potential. Recently, s-tetrazines have been applied in various functional 
molecular systems, such as polymers and metal complexes.192 It was reported that all the s-
tetrazines are highly colored, while the electroactive heterocycles exhibit a very high electron 
affinity.193 In many cases, the first excited state of s-tetrazines has a very long decay time, 
involving a forbidden n-π* transition in the timescale of 10-160 ns. It is noteworthy that many 
s-tetrazines are known to display high fluorescence quantum yields because of the 
substitution with heteroatoms such as chlorine and oxygen.192 Some of these derivatives 
display fluorescence properties in the crystalline state, which positively makes them as the 
smallest organic fluorophores and therefore attractive for imaging applications.194 Taken 
together, this class of compounds may be used to develop some imaging agents for the 
detection of Aβ plaques and NFTs in AD. 
We anticipated that the bis-pyrazole 74 (BSc4338) may display higher affinity than the highly 
fluorescent bis-heteroatom compounds. As shown in Scheme 3.9, the reaction of guanidine 
hydrochloride 71 and hydrazine hydrate in dioxane gave triaminoguanidine 72 in quantitative 
yield. Upon reacting with acetylacetone to give compound 73, the solid was oxidized with 
sodium nitrite to afford the red fluorescent compound 74. Furthermore, we utilized this 
scaffold to synthesize tetrazines 75a-c (BSc4339, BSc4340 and BSc4341) via nucleophilic 
substitution. It was found that only one pyrazole group of compound 74 can be replaced with 
phenylamine under classical heating or microwave condition in the presence of acetonitrile. 
However, the second substitution can not proceed even with forcing reaction conditions. 
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Scheme 3.9 Synthesis of tetrazines and structures of 74 and 75a-c. 
Unexpectedly, the aryl substituted compounds 75a-c are highly colored but poorly 
fluorescent. Compounds 74 and 75a-c were evaluated by neuropathological staining of AD 
brain sections. The brain tissues were investigated by fluorescence microscopy employing a 
DAPI- or FITC- filters. The in vitro staining experiments showed that the red fluorescent 
compound 74 poorly stained NFTs. It was assumed that fluorescence may be quenched 
upon binding to tau aggregates. On the other hand, the weakly fluorescent compounds 75a-c 
stained Aβ plaques and NFTs as shown in Figure 3.6. It was hypothesized that tetrazines 
may have a relative binding affinity toward Aβ and tau aggregates in vitro. However, the lack 
of sufficient fluorescence properties limits them to be used as imaging probes for the 
detection of Aβ plaques and NFTs in vitro. 
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Figure 3.6 In vitro histochemical staining of postmortem AD brain tissues with 74 (BSc4338) and 
75a-c (BSc4339, BSc4340 and BSc4341) (Tissues: hippocampus; Patient: female, 89 years old; 
CERAD Score: 3; NFTs-level: V). 
 
3.4. Design, synthesis and evaluation of bisstyryl derivatives for Aβ and tau 
imaging 
A design strategy was applied to arrive at molecules with large two-photon absorption cross-
section. The bisstyrylbenzenes with donor-π-acceptor-π-donor structural motifs exhibit 
exceptionally large two-photon absorption cross-section values. The enhanced value allows 
lower laser intensities to be used for excitation and reduces optical damage to preserve the 
tissue.195 The two-photon absorption cross-section correlates with the electron affinity of the 
central ring. The higher the reduction potential on the central ring, the higher the two-photon 
absorption cross-section.196 Based on these guiding principles, a series of donor-π-donor 
derivatives containing substituted phenyl as the π-core have been investigated. Generally, 
the donors are connect to the π-core by C=C bonds. The highly conjugated molecules with 
extended π-system result in strong fluorescence, which could be induced by absorption of 
either one or two photons and high excitation intensity. The strong two-photon excited 
fluorescence and stimulated emission are attractive factors for the fluorescence imaging of 
Aβ plaques and NFTs in AD brain.  
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Figure 3.7 Design strategies for the bisstyryl derivatives as imaging probes. 
The presence of Aβ aggregates in the human retina was reported by several groups, yet is 
subject to ongoing debate. Curcumin is currently used in imaging evalutions and suggested 
the identification of Aβ deposits in the mouse retina. The Aβ deposits have been monitored 
in the mouse retina by fluorescence microscopy after high dosage of curcumin.197,198 
However, systemic application of curcumin to humans at the necessary concentration is 
likely to cause adverse events. It is reported that curcumin is photo labile and toxic to most 
human cell lines > 50 µmol/L.  
Generally, curcumin can exist in several tautomeric forms, such as the 1,3-diketo form and 
the enol forms (Figure 3.7). The enol form of curcumin is more energetically stable in the 
solid phase and in solution. Based on the structure of curcumin and Congo Red (CR) many 
bisstyryl derivatives have been synthesized in the past decade.50,95,199-202 The aromatic cores 
with a high electron-withdrawing character as acceptor connect with the terminal donor group 
resulting in a highly fluorescent push-pull system. Excitingly, several compounds displaying 
good affinities to Aβ aggregates have been studied in mice experiments in vivo. Only few 
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compounds for targeting NFTs have been reported. The lack of NFTs specific fluorescent 
probes imposes a limit on the in vivo quantification of neurofibrillary pathology in AD patients. 
Hence, the challenge still remains to develop novel fluorescent probes with improved affinity 
and selectivity to NFTs. For this reason, further modification of known scaffolds that affect 
the lipophilicity and fluorescence properties may improve the imaging probes to enable them 
for in vitro, in vivo and clinical applications. In this study we synthesized many bisstyryl 
derivatives with different core structures as π-center (Figure 3.7). The histological and 
toxicological evaluation guided the optimization of these probes for the detection of Aβ 
plaques and NFTs in vivo. 
 
3.4.1. Synthesis and evaluation of 1,4-bisstyryl-2-methoxybenzene derivatives 
for Aβ and tau imaging 
Because of the appropriate lipophilicity and excellent fluorescence properties, Methoxy-X04 
can successfully stain Aβ and tau aggregates in the postmortem sections of AD brain. In 
2002, Klunk et al. reported that Methoxy-X04 (28) enters the brain and retains sufficent 
binding affinity for Aβ in vitro.50 In vivo imaging of Aβ plaques in the transgenic mouse brain 
suggested that [11C]Methoxy-X04 is a viable candidate for in vivo application.203 However, no 
Methoxy-X04 derivatives specially targeting NFTs have been reported until now. 
In the present study, we employed 2-methoxybenzene as π-center core. The replacement of 
the phenol group by substituted phenyl ring or heterocyclic ring may lead to molecules with 
high conjugation length and excellent fluorescence properties. Moreover, the functional 
groups may affect the lipophilicity and the specificity for tau aggregates. 
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Scheme 3.10 Synthesis of 1,4-bisstyryl-2-methoxybenzenes 79a-b. 
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1,4-Bisstyryl-2-methoxybenzenes were obtained by using the procedure described by Klunk 
et al. with several modifications.50 Initially, the 1,4-bis(bromomethyl)-2-methoxybenzene 
intermediate 77 was obtained through benzylic bromination of 2-methoxy-1,4-
dimethylbenzene 76 in the presence of N-bromosuccinimide (NBS) and 2,2’-
azobis(isobutyronitrile) (AIBN). The compound 78 was synthesized in quantitative yield by 
employing a Michaelis–Arbuzov reaction (Scheme 3.10).  
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Scheme 3.11 Synthesis of 1,4-bisstyryl-2-methoxybenzenes 83. 
As illustrated in Scheme 3.11 we synthesized 5-(dimethylamino)thiophene-2-carbaldehyde 
82 by the nucleophilic aryl substitution of 5-bromothiophene-2-carbaldehyde 80 in the 
presence of K2CO3 and dimethylamine (40% in water). The product was obtained using 
microwave radiation in the Biotage Initiator 300 (1h, 120 °C). The key step was the Wittig–
Horner coupling reaction between phosphonate 78 and corresponding benzaldehydes that 
produced 1,4-bisstyryl-2-methoxybenzenes (79a-b and 83) as a sole products (Scheme 3.10 
and Scheme 3.11). These compounds were purified by column chromatography and 
characterized by NMR spectroscopy. The products are generated as trans isomers within the 
limits of NMR detection by the coupling constant for the vinylic protons (J = 16.0-16.5 Hz) in 
the 1H-NMR spectra. It was found that all of these derivatives exhibit excellent fluorescence 
under UV light.  
Probe 79a (BSc4482) with a 1-pyrrolidine moiety stains Aβ plaques clearly but only 
minimally stains NFTs. In order to reduce lipophilicity and to improve the water solubility, 
probe 79b (BSc4483) bearing a 4-methylpiperazine group was synthesized. In contrast, 
probe 79b improved the staining effect on NFTs but stains amyloid to a lesser extent. Probe 
83 (BSc4979) was obtained by the replacement of the donor group by a 5-
(dimethylamino)thiophene moiety. Excitingly, numerous NFTs can be clearly observed in the 
post-mortem brain tissue of AD patient (Figure 3.8, F). Furthermore, the central core 
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plaques were detected in the same tissue with high contrast relative to the background 
(Figure 3.8, B).  
 
Figure 3.8 In vitro histochemical staining of postmortem AD brain tissues with 1,4-bisstyryl-2-
methoxybenzenes (Tissues: hippocampus; Patient: male, 71 or 89 years old; CERAD Score: 3; NFTs-
level: V). 
The compound with good staining in the series 83 was tested in an in vitro binding assay. It 
provided excellent IC50 values for Aβ40-aggregates and tau aggregates. The displacement 
ability of these 1,4-bisstyryl-2-methoxybenzene derivatives was compared against the known 
probes Methoxy-X04 under same assay conditions. It displayed ~5-fold higher affinity to Aβ40 
aggregates and ~3-fold higher affinity to tau aggregates in comparison to Methoxy-X04. It 
indicates sufficient affinity of this probe for imaging of Aβ and tau aggregates in vivo. 
Furthermore, it may be radiolabeled with 11CH3, 18F and 123I at the N position and evaluated 
as PET and SPECT radioligands for Aβ and tau imaging in vivo.  
In order to demonstrate the cytotoxicity of compound 83, we performed a wild-type zebrafish 
embryo development assay. Due to the poor solubility in distilled water, these embryos were 
treated with solutions containing 1 µM of compound 83 at 6-8 hpf. The phenotypes were 
compared at 24 hpf and 72 hpf. It was found that the embryos developed well at 24 hpf and 
72 hpf, and did not display any lesions in eyes, yolks, tail and heart beat (Figure 3.9). 
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Figure 3.9 In vivo cytotoxicity studies of embryos of wild-type zebrafish in 1 µM probe 83 at 24 
hpf and 72 hpf. Controlled (A and C) and probe 83 (B and D). 
The absorption spectrum indicated that the absorption maximum of probes 79a and 79b 
were 407.0 and 390.5 nm in EtOH, respectively. They are close to the value of Methoxy-X04 
(λ = 380 nm in methanol).204 On the other hand, it was found that compound 83 shows a 
redshifted absorption spectrum (λ = 434.0 nm in ethanol) due to the introduction of the 
terminal N,N-dimethylthiophen-2-amine unit.  
We hypothesized that this redshift is preferable. It may place the fluorescence emission in 
the ideal viewing region. This result may facilitate the detection of Aβ or tau aggregates by 
the DAPI- or FITC-filters employed in fluorescence microscopy. Taken together, these 
results indicate that fluorescent probes with good photophysical properties and high affinity 
may assist to handle and be applicable in biological and histological staining.   
 
3.4.2.  Synthesis and evaluation of 1,4-bisstyryl-2-bromobenzene and 1,4-
bisstyryl-2,5-dibromobenzene derivatives for the detection of Aβ plaques  
Recently a lot of attention has been directed toward the derivatization of CR to develop small 
molecules as potential diagnostic tools for AD. (E,E)-1-Bromo-2,5-bis(3-hydroxycarbonyl-4-
hydroxy)styrylbenzene (BSB) has been reported by Skovronsky and coworkers as a typical 
ligand which sensitively labels SPs in AD brain sections. Furthermore, it could detect Aβ 
plaques with high specificity in a mouse model of AD. However, it was also reported that 
NFTs can be stained brightly with BSB both in vitro and in vivo.202,205 Additionally, the 
carboxylic acid moiety of BSB derivatives would be mostly ionized in the physiological pH 
range, which may reduce its ability to cross the BBB in humans. 
As shown in Scheme 3.12, the replacement of the salicylic acid moiety by a 1-methyl-1H-
pyrrole moiety resulted in 2,2'-(1E,1'E)-2,2'-(2-bromo-1,4-phenylene)bis(ethene-2,1-
diyl)bis(1-methyl-1H-pyrrole) 88 (BSc4575). Bis(diethylphosphonate) 86 was coupled with 1-
methyl-1H-pyrrole-2-carbaldehyde 87 to afford the (E,E)-isomer 88 as the sole product which 
has been characterized by 1H-NMR spectroscopy. 
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Scheme 3.12 Synthesis of 1,4-bisstyryl-2-bromobenzene derivative 88. 
The red shift of the absorption maximum in the two-photon excitation spectra and the cross-
section value mainly depend on the electron deficiency on the central benzene ring. In order 
to improve the cross-section value and the photostability, we replaced the electron-
withdrawing central ring. The 1,4-bisstyryl-2,5-dibromobenzenes 92a-c (BSc4575, BSc4576 
and BSc4580) in Scheme 3.13 were obtained using previously reported procedures. 
Alternatively, bis(diethylphosphonate) 91 was used for the Wittig-Horner reaction with 
corresponding aldehydes and the compounds 92a-c were obtained as the sole product in 
good yields. According to the 1H-NMR and HPLC spectrum, there were no other isomers 
present. 
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Scheme 3.13 Synthesis and structures of 1,4-bisstyryl-2,5-dibromobenzenes 92a-c. 
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The compounds 88 and 92a-c displayed poor solubility in buffer solution or in DMSO. This 
creates significant challenges for further in vitro and in vivo studies of these compounds. In 
order to address this shortcoming, we further modified the product by replacing the bromine 
with an amide group on the central core. The compound 94 (BSc4574) was synthesized 
using the procedure described by Jiang et al with few modifications.206 With the replacement 
of the catalyst palladium (II) chloride and triphenylphosphine by 
bis(triphenylphosphine)palladium(II) dichloride, the reaction was carried out using the aryl 
bromide 92a and isocyanides 93 in the presence of CsF and DMSO (Scheme 3.14) under a 
mild reaction condition. 
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Scheme 3.14 Synthesis of amide via palladium-catalyzed amidation of 1,4-bisstyryl-2,5-
dibromobenzene derivative. 
All of these five probes have been evaluated for the fluorescent staining of Aβ plaques and 
NFTs in postmortem AD brain sections (Figure 3.10). Probes 92b and 94 selectively labeled 
Aβ plaques in the brain tissues. However, probes 88, 92a and 92c failed to detect Aβ 
plaques and NFTs by the fluorescence microscopy. It was assumed that the lipophilicity may 
affect the staining results of these probes. Further modification of probes 88 and 92b-c 
aimed to improve the hydrophilicity of these scaffolds. 
 
Figure 3.10 In vitro histochemical staining of postmortem AD brain tissues with 92b and 94 
(Tissues: hippocampus; Patient: male, 71 years old; CERAD Score: 3; NFTs-level: V). 
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3.4.3. Synthesis and evaluation of 1,4-bisstyryl-2-fluorobenzene and 1,2,4,5-
tetrafluoro-3,6-bisstyrylbenzene derivatives for  Aβ and tau imaging  
3.4.3.1. Synthesis and evaluation of 1,4-bisstyryl-2-fluorobenzene derivatives for Aβ 
and tau imaging 
According to the heavy atom effect, the fluorescence intensity of fluoro-substitution is usually 
greater than that of corresponding bromo-substituted compounds. In order to replace the 
bromine on the central ring, we planned to exploit an analogous compound to BSB that 
contains a fluoro group. In addition, in an in vivo experiment, the probe with smaller 
molecular weight may be favorable for improving the ability to penetrate the BBB and the 
rapid clearance from the brain. Currently, 18F-labeled ligands have been developed to 
overcome the limitation of short half-life of 11C. The fluoro-substituted probes may have the 
potential to be used as PET/MRI agents to detect Aβ or tau aggregates in AD.199  
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O
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Scheme 3.15 Synthesis of methyl 5-formyl-2-methoxybenzoate 96. 
The acidic hydrogen of carboxyl and hydroxyl groups may not be compatible with the Wittig-
Horner reaction. They were protected by methylation of 5-formyl-2-hydroxybenzoic acid 95 in 
acetonitrile at room temperature, which formed the compound 96 in quantitative yield 
(Scheme 3.15). The progress of the reaction was monitored by TLC and HPLC. After the 
completion of the reaction, the solution was concentrated under reduced pressure and the 
product was purified by column chromatography.  
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Scheme 3.16 Synthesis of 1,4-bisstyryl-2-fluorobenzenes 100a-e. 
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Table 3.3 Structures and properties of 1,4-bisstyryl-2-fluorobenzenes 100a-e. 
Entry BSc No. Ar Yield/% cLogP[a] MW[a] Staining effect[b] 
100a BSc4740 
O
O
O
 
57 5.96 476.2 
Aβ: +++ 
NFT: +++ 
100b BSc4975 N
 
55 4.13 306.2 
Aβ: + 
NFT: ++ 
100c BSc4976 S N
 
39 7.48 398.1 
Aβ: - 
NFT: + 
100d BSc4977 N
 
62 7.77 438.2 
Aβ: +++ 
NFT: ++ 
100e BSc4978 
N
 
66 3.90 302.1 
Aβ: +++ 
NFT: + 
[a] Determined by CS ChemOffice 10.0; [b] +++ stands for efficient staining, ++ stands 
for normal staining, + stands for weak staining, - stands for no staining. 
The synthetic pathway for preparing compounds 100a-e is depicted in Scheme 3.16. The 2-
fluoro-1,4-dimethylbenzene 97 was brominated using NBS under mild condition to generate  
the dibromide 98. Followed by Michaelis–Arbuzov reaction to form the bisdiethylphosphonate 
99 in high yield, the key step was carried out by base catalyzed Wittig-Horner reaction. The 
corresponding benzaldehydes and compound 99 were reacted in DMF at 80 °C to form the 
compounds 100a-e (Table 3.3). Finally, compounds 100a-e were purified by column 
chromatography and characterized by NMR spectroscopy. All of these compounds display 
excellent fluorescence under UV light, which allows them to be used to detect Aβ and tau 
aggregates in AD brain tissue.  
To confirm the binding affinities of these derivatives for Aβ plaques and NFTs in the brain, in 
vitro fluorescent staining of brain sections from AD patients was carried out. In postmortem 
brain tissue many NFTs were clearly stained with 100a and 100d as seen in the in vitro 
assay (Figure 3.11, A and F), whereas Aβ plaques can be observed in the same brain 
section from hippocampus (Figure 3.11, B and G). The 1-methyl-1H-pyrrole derivative 100b 
stains NFTs superior to Aβ plaques (Figure 3.11, C and D). In contrast, the pyridine 
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derivative 100e strongly stains Aβ plaques but poorly stains NFTs (Figure 3.11, H and I). 
Especially, probe 100c selectively binds to NFTs (Figure 3.11, E). On the basis of 
histological staining of Aβ plaques and NFTs, the staining effect seems to be determined by 
the styryl substituent of the probe. Based on these results, further radiolabeled these probes 
may be applied as PET radioligands for Aβ plaques and/or NFT imaging in vivo. 
 
Figure 3.11 In vitro histochemical staining of postmortem AD brain tissues with 1,4-bisstyryl-2-
fluorobenzenes (Tissues: hippocampus; Patient: males, 71 and 72 years old; CERAD Score: 3; NFTs-
level: V). 
To quantify the binding affinities of 100b and 100d-e for Aβ40 and tau aggregates, a new 
Thiazine Red R displacement assay was carried out. Probe 100b displayed higher binding 
affinity for both Aβ40 and tau aggregates. It is noteworthy that compound 100d displays > 5-
fold higher affinity to tau over Aβ40. This result is consistent with the underlying assumption 
that probe with a 4-phenylpyrrolidine moiety may be conducive to present a specific affinity 
for tau aggregates in AD brain sections. Unfortunately, the binding affinities of probe 100e for 
Aβ40 and tau aggregates are out of the range of valid values.  
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3.4.3.2. Synthesis and evaluation of 1,2,4,5-tetrafluoro-3,6-bisstyrylbenzene 
derivatives for the detection of Aβ plaques 
Higuchi et al. have proposed the monofluoro bisstyrylbenzene derivative FSB for the 
visualization of Aβ plaques in APP transgenic mice by 19F-MRI. However, the low sensitivity 
of 19F-MRI limits its further use to detect Aβ plaques in human brain.207 In order to overcome 
this limitation and to enhance two photon excitation, we planned to design several 
bisstyrylbenzene ligands with a highly fluorinated tetrafluorophenyl core. Flaherty et al. 
reported that the binding affinity of the tetrafluorophenyl bisstyrylbenzene derivative 
increased 360-fold in comparison to its monofluorophenyl counterpart. Besides, it suggested 
that bisstyrylbenzenes with carboxylic acid functional groups have lower Aβ binding affinities 
than their neutral counterparts.95 Hence, we were interested to develop several 
tetrafluorphenyl bisstyryl derivatives to investigate their ability to detect Aβ plaques and NFTs 
in postmortem sections.  
The bisstyrylbenzene derivatives 104a-h were synthesized using the procedures described 
by Flaherty et al. as shown in Scheme 3.17. The 1,4-bis(bromomethyl)-2,3,5,6-
tetrafluorobenzene 102 was obtained in a one-step benzylic bromination of commercially 
available compound 101 using NBS and AIBN. The coupling precursor 
bisdiethylphosphonate 103 was prepared by the Michaelis–Arbuzov reaction between 
compound 102 and triethyl phosphite. Finally, the bisstyrylbenzene ligands 104a-h (Table 
3.4) were obtained using the classic Wittig-Horner coupling between bisdiethylphosphonate 
and corresponding aldehydes in DMF at 80 °C for 16 h. All of these compounds were 
recrystallized from EtOAc and further characterized by NMR spectroscopy. The 1H-NMR 
spectrum revealed that the two doublets correspond to trans configured olefinic protons with 
a large coupling constant (J = 16.5-17.0 Hz). However, several compounds (104b and 104e-f) 
could not be characterized by 13C-NMR spectroscopy. This was due to poor solubility. 
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Scheme 3.17 Synthesis of 1,2,4,5-tetrafluoro-3,6-bisstyrylbenzenes 104a-g. 
 Page 63 
Table 3.4         Structures and properties of 1,2,4,5-tetrafluoro-3,6-bisstyrylbenzenes 104a-g. 
Entry BSc No. Ar Yield/% cLogP[a] MW[a] Staining effect[b] 
104a BSc4566 N
 
69 4.61 360.4 
Aβ: - 
NFT: - 
104b BSc4567 N
 
65 7.62 440.5 
Aβ: +++ 
NFT: - 
104c BSc4569 
S S
 
66 10.44 530.6 
Aβ: +++ 
NFT: - 
104d BSc4570 
N
 
62 4.37 356.3 
Aβ: + 
NFT: - 
104e BSc4571 S
 
59 7.93 446.5 
Aβ: ++ 
NFT: - 
104f BSc4572 CN
 
53 7.11 404.4 
Aβ: - 
NFT: - 
104g BSc4573 N
 
59 8.97 496.6 
Aβ: - 
NFT: - 
[a] Determined by CS ChemOffice 10.0; [b] +++ stands for efficient staining, ++ stands for 
normal staining, + stands for weak staining and - stands for no staining. 
The qualitative selective binding of the fluorescent probes to Aβ plaques was evaluated in 
the primary screen on hippocampal sections of human AD brain tissue and analyzed by 
fluorescence microscopy. Remarkably, numerous fluorescent spots were detected by the 
probes 104b-c (Figure 3.12, A and B). These results reveal that probes 104b-c are useful 
as specific fluorescent probes for the detection of Aβ aggregates in the brain sections of AD 
patient. Probes 104d-e resulted in faint plaque staining. In addition, due to the poor solubility, 
we observed tiny crystals of compounds 104d-e on the brain sections (Figure 3.12, C and D). 
Unfortunately, probes 104a and 104f-g failed to detect Aβ plaques and NFTs by 
fluorescence microscopy. These results indicate that the electron-donor groups or electron-
withdrawing groups in the para position of styryl groups may not affect the staining results. 
 Page 64 
 
Figure 3.12 In vitro histochemical staining of postmortem AD brain tissues with 1,2,4,5-tetrafluoro-
3,6-bisstyrylbenzenes (Tissues: hippocampus; Patient: male, 71 years old; CERAD Score: 3; NFTs-
level: V). 
The selected compound 100a and two of 1,2,4,5-tetrafluoro-3,6-bisstyrylbenzenes 104b-c 
have been further evaluated at different concentrations in the wild-type zebrafish embryo 
development assay. The embryos incubated with compound 100a developed well and no 
lesions were found at different concentrations up to 5 µM at 24 hpf and 72 hpf (Figure 3.13, 
B and G). However, the juvenile fish incubated with 10 µM of compound 100a showed spinal 
curvature after 72 hpf (Figure 3.13, H). This result suggested that probe 100a might be 
cytotoxic at concentrations higher than 5 µM. On the other hand, due to the poor solubility, 
the embryos were only treated with 1 µM of probes 104b-c. The passable results have 
shown that these embryos developed well in the presence of 1 µM probes 104b-c at 24 hpf 
and 72 hpf (Figure 3.12). The cytotoxicity study suggested that these probes have negligible 
cytotoxicity against zebrafish embryos at the same concentration that was used for histology 
experiments on human AD brain tissue (1 µM). In conclusion, further modification should aim 
to improve the solubility of these compounds.  
 
 Page 65 
 
Figure 3.13 In vivo cytotoxicity studies of embryos of wild-type zebrafish with 5 µM (B and G) and 
10 (C and H) µM 100a and embryos with 1 µM 104b-c at 24 hpf and 72 hpf. Controlled (A and C), 
probe 104b (D and I) and probe 104b (E and J). 
 
3.4.4. Synthesis and evaluation of 1,4-bisstyryl-2-bromo-5-cyanobenzene 
derivatives for Aβ and tau imaging 
It is reported that introduction of the fluorophore group on the central ring may enhance the 
two-photon absorption cross-section value.208 For this purpose, we synthesized a series of 
1,4-bisstyryl-2-bromo-5-cyanobenzenes as to exploit the effect for the detection of Aβ 
aggregates and NFTs in human postmortem sections. Subsequently, different substituents 
on the para position of styryl groups were explored to investigate the interaction with Aβ or 
tau aggregates. 
The mono-cyano substituted compounds 108a-e were synthesized in four steps. A mixture of 
commercially available 1,4-dibromo-2,5-dimethylbenzene 89 and an equivalent of CuCN in 
DMF at 80 °C for 1 h afforded the mono-cyano substrate 105. The reaction was monitored by 
TLC and the product was purified by column chromatography. Followed by benzylic 
bromination and Michaelis–Arbuzov reaction, bisdiethylphosphonate 107 was coupled with 
the corresponding aldehydes in DMF at 80 °C to afford the 1,4-bisstyryl-2-bromo-5-
cyanobenzenes 108a-e (Scheme 3.18, Table 3.5). The products were recrystalled from 
EtOAc and characterized by NMR spectroscopy.  
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Scheme 3.18 Synthesis of 1,4-bisstyryl-2-bromo-5-cyanobenzenes 108a-e. 
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Scheme 3.19 Synthesis of 1,4-bisstyryl-2-bromo-5-cyanobenzenes108f-g. 
The phenolic bis-styrylbenzene 108f was obtained by subsequent boron tribromide 
demethylation in dichloromethane at room temperature (Scheme 3.19, Table 3.5). Due to 
the poor solubility, the compound 108f was only characterized by mass spectrometry and the 
purity was analyzed by HPLC. Finally, the deprotected salicylic acid derivative 108g was 
obtained by ester hydrolysis and the conformation was determined by 1H-NMR.  
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Table 3.5 Structures and properties 1,4-bisstyryl-2-bromo-5-cyanobenzenes108a-g. 
Entry BSc No. Ar Yield/% cLogP[a] MW[a] Staining effect[b] 
108a BSc4577 N
 
77 9.20 528.5 
Aβ: ++ 
NFT: - 
108b BSc4578 N
 
73 4.84 392.3 
Aβ: - 
NFT: - 
108c BSc4580 
N
 
82 4.60 388.3 
Aβ: ++ 
NFT: + 
108d BSc4581 
O
O
O
 
66 6.66 562.4 
Aβ: ++ 
NFT: - 
108e BSc4582 O
 
69 7.02 446.3 
Aβ: + 
NFT: - 
108f BSc4642 
OH
O
O
 
97 6.14 534.4 
Aβ: +++ 
NFT: ++ 
108g BSc4702 
OH
COOH
 
84 5.61 506.3 
Aβ: ++ 
NFT: ++ 
[a] Determined by CS ChemOffice 10.0; [b] +++ stands for efficient staining, ++ stands for 
normal staining, + stands for weak staining, - stands for no staining. 
The biological evaluation of these compounds for Aβ plaques and NFTs was accomplished 
by fluorescent staining of brain sections (Figure 3.14). Probes 108a and 108d-e stained Aβ 
plaques specifically but with poor contrast to the background in AD brain sections. Due to the 
poor solubility, tiny crystals of compound 108a on brain sections were observed by 
fluorescence microscopy. In addition, probes 108c and 108f-g were observed to bind to Aβ 
plaques and NFTs in AD brain tissues. Especially, at the beginning, probes 108f and 108g 
labeled Aβ plaques and NFTs clearly. However, the fluorescence was prone to 
photobleaching within few seconds. It was assumed that the presence of the phenolic moiety 
or active hydrogen on this scaffold may restore the fluorescence in the bleached region upon 
binding to the proteins. To our surprise, the most soluble compound (108b) in this set failed 
to detect both Aβ and tau aggregates. It indicates that lipophilicity may not affect the staining 
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effects of these ligands. However, the poor solubility and permeability are adverse properties 
which limit the potential use of these compounds in vivo. 
 
Figure 3.14 In vitro histochemical staining of postmortem AD brain tissues with 1,4-bisstyryl-2-
bromo-5-cyanobenzenes (Tissues: hippocampus; Patient: male, 71 years old; CERAD Score: 3; 
NFTs-level: V). 
 
3.4.5. Synthesis and evaluation of bis(arylvinyl)pyrimidine derivatives as 
imaging probes for Aβ and tau imaging 
According to previous studies by our group, the replacement of the central ring of the 
Methoxy-X04 by pyrimidine as aromatic core may lead to molecules with a enlarged π-
conjugation. The bis(arylvinyl)pyrimidines displayed good fluorescence properties in an in 
vitro binding experiment.49 Nevertheless, the poor solubility (< 0.1 g/L) might limit the use in 
living human subjects. In order to address this shortcoming, we focused on the introduction 
of different functional groups to improve physicochemical properties and reduce lipophilicity 
of probes. 
CHO
N
F
CHO
F
F
K2CO3, H2OH
N+
DMSO, MW, 60oC
109 81 110
 
Scheme 3.20 Synthesis of 4-(dimethylamino)-3-fluorobenzaldehyde 110. 
In this series, aldehydes 82, 110 and 113 were not commercially available. As shown in 
Scheme 3.20, in the presence of K2CO3, 4-(dimethylamino)-3-fluorobenzaldehyde 110 was 
prepared by the 3,4-difluorobenzaldehyde 109 and  dimethylamine solution (40% in water) 
under microwave irradiation. In addition, CuI-catalyzed coupling reaction was carried out 
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using L-proline as promoter. The reaction of 4-bromobenzaldehyde 111 and 2-aminoethanol 
112 proceeded at 80 °C under microwave condition to form 4-(2-hydroxyethylamino) 
benzaldehyde 113 in 93 % yield (Scheme 3.21). 
O
H
Proline, CuI, K3PO4
HN
O
H
Br
HO
HO NH2+
DMSO, MW, 80oC
111 112 113
 
Scheme 3.21 Synthesis of 4-(2-hydroxyethylamino)benzaldehyde 113. 
According to the previously reported procedure, bis(arylvinyl)pyrimidines 115a-d were 
formed in an atom efficient reaction by condensation of 4,6-dimethylpyrimidine 114 and  aryl 
aldehydes. The experimental procedure is straightforward and rather economic because it 
does not require any organic solvent.209 The reaction was carried out in 5 M NaOH solution 
using Aliquat 336 as phase transfer catalyst. According to the coupling constant (J = 15.0-
16.0 Hz) in 1H-NMR spectroscopy (Table 3.6), purification by column chromatography 
provided the trans isomers only.  
N N
ArAr
N N
+
NaOH, H2O
Aliquat, 80oCAr
CHO
114 115a-d
 
Scheme 3.22 Synthesis of bis(arylvinyl)pyrimidines 115a-d.  
In order to evaluate the binding effects to Aβ plaques and NFT in AD brain sections, we 
performed neuropathological fluorescent staining with these bis(arylvinyl)pyrimidines (Figure 
3.15). The most soluble probe 115a clearly binds to Aβ and tau aggregates. In addition, 
probes 115b and 115d displayed selectivity for NFTs in hippocampal tissue sections from 
AD human brain. This suggested these compounds may be used as tau specific fluorescent 
probe for in vivo quantification of neurofibrillary pathology. Further radiolabeling of 115b and 
115d may extend their use to the in vivo imaging of tau aggregates in the brain. 
Unfortunately, probe 115c failed to detect Aβ plaques and NFTs by fluorescence microscopy. 
However, bromine-containing moiety may be used to synthesize the 125I-labeled radioligand 
for tau imaging in vitro and in vivo.  
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Table 3.6 Structures and properties of bis(arylvinyl)pyrimidines. 
Entry BSc No. Ar Yield/% cLogP[a] MW[a] Staining effect[b] 
115a BSc4919 
NH
OH
 
82 3.29 402.2 
Aβ: +++ 
NFT: ++ 
115b BSc4921 N
F
 
77 6.21 406.2 
Aβ: - 
NFT: + 
115c BSc4959 
S Br
 
62 6.71 451.9 
Aβ: - 
NFT: - 
115d BSc4960 S N
 
76 6.24 382.1 
Aβ: - 
NFT: +++ 
[a] Determined by CS ChemOffice 10.0; [b] +++ stands for efficient staining, ++ stands for 
normal staining, + stands for weak staining and - stands for no staining. 
 
 
Figure 3.15 In vitro histochemical staining of postmortem AD brain tissues with 
bis(arylvinyl)pyrimidines (Tissues: hippocampus; Patient: male, 72 years old; CERAD Score: 3; NFTs-
level: V). 
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Three compounds were tested in a new in vitro affinity assay to determine the IC50 values 
versus Thiazine Red R displacement from aggregated tau and Aβ40. It was found that probe 
115a showed 5.4-fold higher affinity to aggregated tau over Aβ40. In contrast, probes 115b 
and 115d displayed the opposite performance. The probe 115b displayed 1.4-fold higher 
affinity for tau aggregates. Remarkably, probe 115d displayed excellent affinity to both Aβ40 
and tau aggregates in the low-nanomolar range, which suggested sufficient affinity of the 
probe for imaging of tau aggregates in vivo. 
To investigate the cytotoxicity of bis(arylvinyl)pyrimidines, probe 115a was evaluated at 
different concentrations in the wild-type zebrafish embryo development assay. As shown in 
Figure 3.16, the embryos developed well and no lesions were found at different 
concentrations up to 10 µM at 24 hpf and 72 hpf. It implied that probe 115a displays 
negligible cytotoxicity at the corresponding concentrations. Further modification with 
improved solubility may further this series as potential in vivo imaging agents for AD. 
 
Figure 3.16 In vivo cytotoxicity studies of embryos of wild-type zebrafish in 10 µM with 115a at 24 
hpf and 72 hpf. Controlled (A and C) and probe 115a (B and D). 
 
3.5. Design, synthesis and evaluation of spiropyran derivatives as specific 
tau imaging probes  
3.5.1.  Design, synthesis and spectroscopy of spiropyran derivatives  
In the past few decades, thermochromic and photochromic indolinobenzospiropyrans have 
been suggested as classic photoswitchable molecules. They show reversibe structural 
conversion between the closed spiropyran (SP) form and the opened merocyanine (ME) 
form upon external optical, thermal, or chemical stimulations. They have been widely utilized 
for colorimetric and fluorescent detections of chemical or biological species.210 Generally, SP 
molecules are known to be unstable, whereas ME molecules are relatively stable, either 
thermally or photochemically.211  
The initial idea was that SP dye may engage in specific interaction to bind to Aβ or tau 
aggregates. Furthermore, the external optical stimulation may promote the conversion from 
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the SP component to the corresponding ME conformation. As a result, the fluorescent 
species may be detected by fluorescence microscopy or other imaging technologies. Toward 
this goal, we employed a series of fluorescent photoswitch dyes, which were applied to 
detect Aβ and tau aggregates in AD brain sections. 
N O
R2
R4
N
R2
R1 OHC
R4HO
+
EtOH, reflux R
1
X-
R1 = H, F, Br, OCH3
R3
R5
R3
R5
N
H
N
NH2
+
OHCl
CH3COOH, 120oC Alkylation/PEGylation
117
R1
R1
overnight
R2 = CH3, n-Bu, -CH2CH2OCH3
R3 = H, OH, NO2, CH3, F, CH3
R4 = H, N(CH2CH3)2
R5 = H, OCH3
120a-l
116a: R1 = H
116b: R1 = F
116c: R1 = Br
116d: R1 = OCH3
118a: R1 = H
118b: R1 = F
118c: R1 = Br
118d: R1 = OCH3
119a: R1 = H, R2 = CH3, X = I
119b: R1 = H, R2 = n-Bu, X = I
119c: R1 = F, R2 = CH3, X = I
119d: R1 = Br, R2 = CH3, X = I
119e: R1 = OCH3, R2 =CH3, X = I
119f: R1 = H, R2 = CH2CH2OCH3, X = Cl  
Scheme 3.23 Synthesis of spiropyran derivatives. 
As shown in Scheme 3.23 and Table 3.7, the indolinospiropyrans were synthesized in three 
steps starting from the commercially available phenylhydrazines 116a-d and 3-methyl-2-
butanone 117. Typically, they were condensed to generate the intermediate hydrazone and 
further converted by Fischer indole synthesis to obtain the 3H-indoles 118a-d. Methylation of 
compounds 118a-d in acetonitrile under reflux formed the indolium 119a and 119c-e as 
colorless solids in quantitative yields. The colorless solids were used in the following step 
without further purification. In addition, indolenine 118a and 1-iodobutane were stirred under 
reflux in ethylmethylketone to obtain the indolium 119b as pale yellow solid in a yield of 73 %. 
After PEGylation with 2-methoxyethyl 4-methylbenzenesulfonate in the N-position of 
compound 118a, the crude product was purified by column chromatography. Finally, the 
salicylaldehydes condensed with 119a-f via a carbinol intermediate to form the spiropyrans 
120a-l in moderate yields. 
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Table 3.7 Structures and staining effect of spiropyran derivatives. 
Entry BSc No. R1 R2 R3 R4 R5 Staining effect[a] 
120a BSc4452 H Me H N(Et)2 H 
Aβ: - 
NFT: +++ 
120b BSc4453 H Me H H OMe 
Aβ: - 
NFT: - 
120c BSc4454 H Me OH H H 
Aβ: - 
NFT: - 
120d BSc4455 H Me NO2 H H 
Aβ: - 
NFT: + 
120e BSc4487 H Me F H H 
Aβ: - 
NFT: - 
120f BSc4488 H Me H H H 
Aβ: - 
NFT: - 
120g BSc4489 H Me Me H H 
Aβ: - 
NFT: - 
120h BSc4744 H n-Bu H N(Et)2 H 
Aβ: - 
NFT: +++ 
120i BSc4807 F Me H N(Et)2 H 
Aβ: - 
NFT: - 
120j BSc4808 Br Me H N(Et)2 H 
Aβ: + 
NFT: + 
120k BSc4809 OMe Me H N(Et)2 H 
Aβ: + 
NFT: - 
120l BSc4903 H CH2CH2OMe H N(Et)2 H 
Aβ: - 
NFT: +++ 
[a] +++ stands for efficient staining, + stands for weak staining, - stands for no staining. 
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The compound 120d was used as an example to study and evaluate the absorbance values 
of each conformation via UV spectroscopy. The structures of each conformation have been 
characterized using 1H-NMR and 13C-NMR spectroscopic data. 
The absorption spectrum of a colorless solution of SP 120d in EtOH displayed the maximum 
absorption wavelength around 320 nm, but it did not show any bands at wavelengths greater 
than 450 nm. In order to study the ring closure state, 120d was first irradiated in EtOH for 1 h 
by sunlight. However, the maximum absorption wavelength at ~330 nm suggested that the 
compound almost completely adopted the SP form in solution. Furthermore, upon 
illumination of this solution with ultraviolet light (365 nm, 220 V, 50 Hz) for 1 h, the colorless 
SP switches to the dark purple ME. The appearance of an absorption band at 539 nm in this 
process may be due to the ring opening form lead to a large planar π-system. Furthermore, 
upon addition of 10% CH3COOH to the purple ME solution, ME switched completely to the 
yellow-green MEH+. Consistently, the absorption band at 539 nm disappeared (Figure 3.17). 
Finally, upon irradiation with visible light, MEH+ released a proton and switched to SP state in 
the anticlockwise cycle (Figure 3.18).210,212 
 
Figure 3.17 The absorption spectra of a solution of 10 µM 120d in EtOH (blue) and the same 
solution after irradiation with ultraviolet light (red), as well as addition of 10% CH3COOH (green). 
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Figure 3.18 The switching cycle associated with three states of 120d. 
 
Figure 3.19 The 1H-NMR spectrum of compound 120d. 
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The structures of the condensed products have been characterized by 1H-NMR and 13C-
NMR spectroscopic data. The chiral spirocenter of 120d imposed two different environments 
on the methyl protons Ha and Hb. However, in case of the ME conformation, the methyl 
protons He and Hf are place in the same chemical environments, the loss of the chiral 
spirocenter simplifies the NMR signal. As a result, two distinct singlets were observed at 1.20 
ppm and 1.10 ppm in 1H-NMR spectrum, which corresponded to the methyl protons Ha and 
Hb, respectively (Figure 3.19). Additionally, two doublets at 5.97 ppm and 7.20 ppm 
corresponded to olefinic protons Hc and Hd, respectively. The relatively smaller coupling 
constant of 10.5 Hz suggested that these two protons are in a cis-arrangement relative to the 
interposed double bond. On the other hand, the coupling constant for the olefinic protons of 
Hg and Hh are around 16 Hz. In fact, the conformation of SP was forced into a cis 
configuration, but ME is proned to adopt trans configuration.  
3.5.2. Evaluation of spiropyran derivatives as specific tau imaging probes  
To confirm the selectivity of SP derivatives for the detection of Aβ plaques and NFTs in the 
brain, in vitro staining of hippocampal sections from human postmortem AD was carried out. 
Initially, probes 120a-g with different acceptor or donor substituents (R3-R5) on the aryl ring 
have been studied. The results indicate that compounds 120a and 120d selectively stained 
NFTs in human brain sections (Figure 3.20, B and C). In addition, probe 120a provided a 
good contrast versus Aβ plaques and background (Figure 3.20, A and B). 
 
Figure 3.20 In vitro histochemical staining of postmortem AD brain tissues with spiropyrans  
(Tissues: hippocampus; Patient: male, 71 years old; CERAD Score: 3; NFTs-level: V). 
Considering these results, we explored the strategy to construct fluorescent derivatives 
based on these scaffold. The probe 120a was selected as a standard compound by 
changing the substituents on the 1’-position of the indole ring. Probes 120h and 120l were 
synthesized according to our previously synthetic procedure. Obviously, numerous NFTs 
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were detected by fluorescence microscopy. The SAR analysis revealed that probes with a 
diethylamine group in the 7-position may play a critical role in visualization of NFTs in AD 
brain sections. Furthermore, compounds 120i-k were synthesized to investigate the effect of 
the different functional groups on the 5’-position of indole ring. However, these probes faintly 
stained tau aggregates, while probe 120j also weakly stained Aβ plaques in postmortem 
tissue (Figure 3.20). The absorption spectrum showed that efficacious probes 120a, 120h, 
120j and 120l adopt ME conformations (λmax ≈ 550 nm) in EtOH, while inactive derivatives 
may correspond to SP conformations (λmax ≈ 300 nm). It was assumed that the ME 
conformation rather than the SP conformation may be responsible for the binding of Aβ and 
tau aggregates. These data suggested that probes with diethylamine group on the 7-position 
but without substitution on the 5’-position of indole ring may be an ideal scaffold for selective 
binding to NFTs. Further modifications on the 1’-position of indole ring may improve the 
solubility of these compounds.  
In order to quantify the cytotoxicity of compounds 120a and 120h, we performed a zebrafish 
embryo development assay (Figure 3.21). The embryos were treated with solutions 
containing compounds at 6-8 hpf, and the phenotypes were compared at 24 hpf. The 
embryos developed well and no lesions were found at different concentrations up to 5 µM at 
24 hpf and 72 hpf. In addition, we profiled the probe 120a in a liver hepatocellular carcinoma 
cell assay (HepG2) in vitro to evaluate the cytotoxicity in human cells. The EC50 was 
calculated via the best-fitted trendline of cell vitality as a function of dye concentration. It 
showed an EC50 > 20 µM after 24 h of incubation. These results suggested that SP 
derivatives display negligible cytotoxicity against zebrafish embryos and HepG2 at the 
concentration employed for the histology experiments on human AD brain tissue (1 µM). 
These probes may be suitable for further in vivo applications.  
 
Figure 3.21 In vivo cytotoxicity studies of embryos of wild-type zebrafish with 120a and 120h at 24 
hpf and 72 hpf. Controlled (A and D), probe 120a (B and E) and probe 120h (C and F). 
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3.6. Design, synthesis and evaluation of merocyanine derivatives for Aβ and 
tau imaging 
3.6.1.  Design, synthesis and properties of merocyanine derivatives  
The lead structure for AD imaging was selected from a set of established high fluorescent 
dyes and evaluated for the silk dying properties versus wool reserve, which indicated β-sheet 
binding of dye. The cyanines were advanced due to their structural analogies to known tau 
ligands and evaluated against other lead structures, such as bisstilbenes and squaric acid 
derivatives.49,213 However, the bisstilbenes displayed limited solubility and the squaric acid 
derivatives did not display sufficient binding.204,214 The ring-opening ME formed a extended 
planar π-system, which may lead to improved photostability and fluorescence intensity 
(Chapter 3.5.2). In order to achieve this purpose, we designed and synthesized a series of 
low cytotoxic, water-soluble ME derivatives as potential diagnostic tools for the detection of 
NFTs in AD.  
The synthesis of 3,3-dimethyl-2-styrylindolium derivatives employed known methods or slight 
modifications thereof,215 which is depicted in Scheme 3.24. The key transformation to the 
target 3,3-dimethyl-2-styrylindolium derivatives 121a-k (Table 3.8) was achieved by the 
Knoevenagel condensation of the  N-alkylated indolium backbone 119a-e and corresponding 
aldehydes in ethanol under reflux. Furthermore, compounds 121i-k introduced an additional 
acceptor or donor group on the 5-positon of the cationic indolium moiety. All of these 
compounds were isolated in good yields by standard chromatographic purification on silica 
gel.  
N
R2
R1
Ar
CHO
+
EtOH, ref lux
I-
121a-k119a-e
N Ar
I- R2
R1
 
Scheme 3.24 Synthesis of 3,3-dimethyl-2-styrylindolium derivatives. 
The 1H-NMR spectrum revealed that the two doublets at 8.56-8.20 ppm and 7.59-7.17 ppm 
correspond to the trans configured olefinic protons with a large coupling constant (J = 15.5-
16.5 Hz). According to the 1H-NMR spectra, the 3,3’-geminal methyl protons are placed in 
the same chemical environment because they appeared as a singlet at 1.78-1.73 ppm for the 
six equivalent methyl protons. This observation was confirmed by the 13C-NMR spectra.  
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Table 3.8 Structures and affinity data of indolium derivatives 
Entry BSc No. R1 R2 Ar cLogP[a] MW[b] Staining effect[c] 
121a BSc4743 H n-Bu N
 
3.58 502.5 
Aβ: + 
NFT: +++ 
121b BSc4745 H Me N
 
1.39 432.3 
Aβ: + 
NFT: ++ 
121c BSc4746 H Me O
 
1.34 419.3 
Aβ: - 
NFT: +++ 
121d BSc4747 H Me N
 
2.14 460.4 
Aβ: - 
NFT: +++ 
121e BSc4748 H Me OH
 
0.81 405.3 
Aβ: + 
NFT: +++ 
121f BSc4749 H Me N N
 
1.28 487.4 
Aβ: + 
NFT: +++ 
121g BSc4750 H Me N
 
1.79 458.4 
Aβ: + 
NFT: +++ 
121h BSc4751 H Me NH
 
1.52 428.3 
Aβ: + 
NFT: +++ 
121i BSc4815 F Me N
 
2.28 478.4 
Aβ: + 
NFT: - 
121j BSc4816 OMe Me N
 
2.17 490.4 
Aβ: + 
NFT: - 
121k BSc4817 Br Me N
 
2.92 539.3 
Aβ: ++ 
NFT: - 
[a] LogP values were calculated using the Molinspiration Cheminformatics software (V2011. 
04); [b] Determined by CS ChemOffice 10.0; [c] +++ stands for efficient staining, ++ stands 
for normal staining, + stands for weak staining, - stands for no staining. 
In order to investigate the effect of the geminal methyl groups on visualization of Aβ and tau 
aggregates, we replaced one of the geminal methyls with an ethyl moiety to twist the alkyl 
plane. 3-methyl-3’-ethyl-2-styrylindolium derivatives were prepared by a route similar to the 
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previous experiment (Scheme 3.24). The phenylhydrazine hydrochloride 116a has been 
condensed with 3-methylpentan-2-one 122 to yield the corresponding hydrazones and 
further converted by Fischer indole synthesis to obtain cyclized compound 123. Methylation 
of the indolenine in acetonitrile under reflux formed the indolium 124 in quantitative yield, 
which was used without further purification in the next step. Finally, compounds 125a-d were 
obtained in good yields by the Knoevenagel condensation between indolium 124 and 
corresponding aldehydes in refluxing ethanol. The products were purified by column 
chromatography and characterized by NMR spectroscopy. The compounds adopt trans 
configuration as assigned by the coupling constants for the olefinic protons 1H-NMR spectra 
(J = 15.0-16.0 Hz).  
N
+
I-
N
H
N
NH2
+
OHCl
CH3COOH, 120oC CH3I, CH3CN
122
overnight
116a 123
reflux
Ar
CHO EtOH, ref lux
125a-d
N Ar
I-
124
 
Scheme 3.25 Synthesis of 3-methyl-3’-ethyl-2-styrylindolium derivatives. 
Table 3.9 Structures and affinity data of indolium derivatives. 
Entry BSc No. Ar cLogP[a] MW[b] Staining effect[c] 
123a BSc4813 N
 
2.46 474.4 
Aβ: ++ 
NFT: + 
123b BSc4814 N
 
1.71 446.4 
Aβ: ++ 
NFT: - 
123c BSc4865 NH
 
1.81 442.3 
Aβ: - 
NFT: - 
123d BSc4866 N
 
2.11 472.4 
Aβ: ++ 
NFT: - 
[a] LogP values were calculated using the Molinspiration Cheminformatics software 
(V2011. 04); [b] Determined by CS ChemOffice 10.0; [c] ++ stands for normal staining, 
+ stands for weak staining, - stands for no staining. 
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Moreover, in order to obtain a better understanding of the influence of 3,3’-geminal methyl 
moiety, we synthesized two compounds comprising a cationic benzoxazolium acceptor. The 
pyrrolidin electron-donating functionality was introduced to bias affinity to tau aggregates. 
The synthetic routes to compounds 129 (BSc4905) and 131 (BSc4906) are depicted in 
Scheme 3.26.  
N
O
N
O
CHON
EtOH, reflux
N
O
I-
N
N
O
I-
NN
O
N
O
120oC, neat
CH3I, CH3CN
ref lux
n-BuI
126
I-
I-
127 129 (BSc4905)
126 130 131 (BSc4906)
128
128
EtOH, reflux
 
Scheme 3.26 Synthesis of 3-methyl-3’-ethyl-2-styrylindolium derivatives. 
The mixture of commercially available 2-methylbenzo[d]oxazole 126 and iodomethane was 
stirred in refluxing acetonitrile to afford the 2,3-dimethylbenzo[d]oxazol-3-ium iodide 127. 
Alternatively, compound 126 and 1-iodobutane were heated at 120 °C without any solvent to 
form 3-butyl-2-methylbenzo[d]oxazol-3-ium iodide 130. Followed by Knoevenagel 
condensation with 4-(pyrrolidin-1-yl)benzaldehyde 128, compounds 129 and 131 were 
obtained in good yields.  
Probes with appropriate lipophilicity and low molecular weights may display sufficient 
permeability to cross the BBB and rapid clearance from the body, when they were used as 
an in vivo probe.216 The calculated LogP values of these compounds in Table 3.8 and Table 
3.9 were found to be in the range of 0.81 and 3.58. In addition, the calculated LogP values of 
compounds 128 and 129 are 1.18 and 2.62, respectively. All of LogP values have been 
calculated using the Molinspiration Cheminformatics software (V2011. 04). In addition, the 
molecular weights of 3,3-dialkyl-2-styrylindolium iodide derivatives are below 540 Daltons 
(Table 3.8 and Table 3.9). Simultaneously, the molecular weights of probes 129 and 131 
determined by CS ChemOffice 10.0 gave 432.3 and 474.4 Daltons, respectively. Taken 
together, these properties are in the range of accepted lipophilicity criteria for the BBB 
permeation after intravenous injection. These observations suggested merocyanine probes 
as potential in vivo imaging agents for neurodegeneration diseases.  
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3.6.2. Evaluation of merocyanine derivatives as imaging probes for Aβ and tau 
imaging 
The qualitative selective binding of fluorescent probes to Aβ plaques and NFTs was 
evaluated in the primary screen on hippocampal sections of human AD brain tissue and 
analyzed by fluorescence microscopy. This low throughput screen secured binding of these 
probes to tau aggregates in human AD pathology, as different tau isoforms may result in 
different binding sites on in vitro aggregates or tau transgenic mouse models.217 The 2-styryl-
indolium probes 121a-h stain NFTs in human tissue (Figure 3.22) and provide a good 
contrast versus Aβ plaques and background, especially probes 121a, 121d and 121g. These 
probes displayed an excellent staining of NFTs (Figure 3.22, B, F and J) in comparison to 
Aβ plaques (Figure 3.22, A, E and I). The results suggested a good affinity to the NFTs, 
which required quantification in a ligand binding assay to both Aβ and tau aggregates. 
Remarkably, the probes 121a-h stained NFTs strongly in human tissue as observed by 
fluorescence microscopy, whereas plaques in the same brain preparations were stained just 
weakly. This observation stands in contrast to the activity in the Thiazine Red R 
displacement assay, where compound 121a displayed almost equipotent affinity to Aβ40-
aggregates and tau aggregates (Table 3.10). The lack of potent plaque staining in the 
human tissue preparations may be due to interference with the fluorescence properties upon 
plaque binding, e.g. a fluorescence reduction or effect on the Stokes shift, which limit the 
detection by the DAPI- or FITC-filters employed in fluorescence microscopy. Besides, the 
Thiazine Red R assay may not reflect the binding sites in human tissues. However, these 
results indicate that 3,3-dimethyl-2-styrylindolium probes 121a-h may be useful for the post 
mortem detection of NFTs in the brain of AD patients.214  
The probes with different substitutents in the 5-position of cationic indolium core (121i-k) 
were evaluated by neuropathological staining of AD brain sections. However, only Aβ 
plaques were observed by fluorescence microscopy (Figure 3.22, L, M and N). On the basis 
of histological staining, probe 123a depicted an excellent Aβ plaques staining while only 
faintly staining NFTs. Additionally, 3-methyl-3’-ethyl-2-styrylindolium derivatives 123b and 
123d intensely and specificilly stained Aβ plaques on postmortem AD brain sections. In 
conclusion, the red emission dyes 121i-k, 123a-b and 123d may prevent interference with 
autofluorescence from tissue and other small molecule components in the assay system. 
Further radiolabeling of these probes may result in specific PET radioligands for Aβ plaques 
imaging in vivo. 
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Figure 3.22 In vitro histochemical staining of postmortem AD brain tissues with ME derivatives 
(Tissues: hippocampus; Patient: male, 71 years old; CERAD Score: 3; NFTs-level: V). 
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However, benzoxazolium derivatives 129 and 131 failed to detect Aβ plaques and NFTs by 
fluorescence microscopy. Only astrocytes have been stained and observed by fluorescence 
microscopy. Therefore, it is hypothesized that the indolium core may play an important role in 
the recognition of Aβ and tau aggregates in the hippocampal sections of AD brain. 
Furthermore, the probes with 3,3’-geminal methyl moiety but without electron-donating or 
electron-withdrawing group in the 5-position of the indolium core may exhibit remarkable 
selectivity for tau aggregates. In contrast, probes with a 3,3’-geminal methyl moiety and 
electron-donating or electron-withdrawing group in the 5-positions of the indolium core may 
allow to detect Aβ plaques in postmortem brain tissue.  
At the same time, we further evaluated the solubility of these tau specific probes. The 
solubility of the N-methylated probes 121a-g is higher than 0.5 g/L while the value of probe 
121h is greater than 0.25 g/L at 25 °C in distilled water. According to the calculated LogP 
values in Table 3.8, the lipophilicity increased which is due to the introduction of a bulky 
structure on the 1-position of the indole ring (121a). Thus, the N-butylated probe 121a only 
displayed a solubility of > 0.1 g/L at 25 °C in distilled water. It is consistent with the 
underlying assumption that, in some respects, the LogP value may relate to solubility in 
water. Particularly, probe 121f with the 1-methyl-4-phenylpiperazine moiety significantly 
increases the solubility in aqueous media (> 1.0 g/L) in comparison to the rest of the 
compounds. The solubility of established imaging agents: FDDNP, Methoxy-X04 and BF-158, 
are in the same range or inferior to the solubility of these 3,3-dimethyl-2-styrylindolium 
derivatives.214  
Table 3.10 Competitive Thiazine Red R displacement from Tau aggregates for probes 121a, 
121g, Methoxy-X04, FDDNP, PIB and BF158.214 
Compound Aggr.Tau-IC50/nM Aggr. Aβ40-IC50/nM 
121a 1.41 1.37 
121g 5.10 ND 
Methoxy-X04 246 140 
FDDNP 1635 1467 
PIB 3255 5190 
BF-158 >10000 >10000 
ND, not determined due to spectral overlap with the 
reference compound in the displacement assay. 
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Unfortunately, the affinity of most probes to tau aggregates could not be quantified in the 
competition binding assays in vitro. This was due to spectral overlap with the reference 
ligand Thiazine Red R. Thiazine Red R was selected as reference ligand for the 
displacement assay, because it was shown to be superior to ThS or immune histochemical 
detection of aggregated Tau and Aβ40.48 The affinity of the probes 121a and 121g to Tau 
aggregates was determined indirectly (IC50 values of 5.1 nM and 1.4 nM, respectively) in the 
displacement assay for Tau affinity versus the reference ligand Thiazine Red R. Remarkably, 
the pyrrolidyl substituent results in higher affinity than N,N-diethyl derivative. This may be 
due to the locked conformation of the N-alkyl chain. In addition, the displacement ability of 
these 2- styrylindolium derivatives was compared against the standard probes, such as 
Methoxy-X04, FDDNP, PIB and BF-158, under the same assay conditions. Significantly, 3,3-
dimethyl-2-styrylindolium derivatives 121a and 121g displayed ~50-7000 fold higher affinity 
to tau aggregates (Table 3.10). This indicates sufficient affinity of these probes for imaging of 
tau aggregates in vivo. Furthermore, the series may be radiolabeled with 11CH3, 18F and 123I 
at either O or N position and evaluated as PET and SPECT radioligands for NFT-imaging in 
vivo.214 
Four of the 3,3-dimethyl-2-styrylindolium compounds (121a, 121c-d and 121g) have been 
further evaluated at different concentrations in the wild-type zebrafish embryo development 
assay.214 The embryos developed well and no lesions were found at different concentrations 
up to 10 µM at 24 hpf. After 72 hpf, only the juvenile fish incubated with compound 121a 
have shown small lesions in the yolk sac (Figure 3.23, G). The HepG2 cell proliferation 
assay of these four compounds was used to evaluate the cytotoxicity in human cells. The 
EC50 were calculated via the best-fitted trendline of cell vitality as a function of dye 
concentration. Compounds 121a, 121c-d and 121g showed EC50 values of 0.93, 10.93, 8.57 
and 8.31 µM, respectively, after 24 h incubation. Compound 121a displayed higher 
cytotoxicity in both assays than other compounds in this series. Both cytotoxicity studies 
suggested that 3,3-dimethyl-2-styrylindolium probes have negligible cytotoxicity against 
zebrafish embryos and HepG2 at the concentration employed for the histology experiments 
on human AD brain tissue (1 µM). 
Taken together these results suggest that 3,3-dimethyl-2-styrylindolium compounds should 
be advanced to in vivo mice experiments in transgenic mice. However, the 4R tau transgenic 
mice available to the project are all based on the 4R tau repeat and deposit very little 
amounts of Tau. Moreover, these 4R Tau mouse models seem to be void of the tau 
aggregate binding site present in humans.39,181 The presence of at least two different binding 
sites on tau aggregates was demonstrated for the tau probe THK523 recently.113  
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Figure 3.23 In vivo cytotoxicity studies of embryos of wild-type zebrafish with 3,3-dimethyl-2-
styrylindolium compounds after 24 (A-E) and 72 (F-G) hpf. Controlled (A and F), 121a (B and G), 121c 
(C and H), 121d (D and I) and 121g (E and J). 
In conclusion, we have developed a series of water soluble 3,3-dimethyl-2-styrylindolium 
probes for fluorescence imaging of NFTs in human AD brain. The results of the in vitro 
fluorescent staining protocol used brain sections of AD patient. They suggest potent NFT 
imaging and low nonspecific binding. The cytotoxicity experiments with wild-type zebrafish 
embryos and HepG2 cells suggest that these probes may be suitable for further in vivo 
applications. This indicates sufficient safety for in vivo evaluation in mouse models.214 
 
3.7. Design, synthesis and evaluation of trimethine cyanine derivatives for Aβ 
and tau imaging  
3.7.1.  Design, synthesis of trimethine cyanine derivatives 
In the past decade the histological staining of Aβ aggregates by fluorescent dyes is crucial 
for the diagnosis of AD. The fluorescent compounds ThT (26), ThS (27) and CR (24) are the 
most used dyes for the detection of amyloid aggregates in vitro. However, CR is not a 
fluorescent dye, while ThT and ThS are blue-emission dyes that may interfere with 
autofluorescence from tissue or some small molecule components in the assay system.218,213 
Thus, the design of new selective dyes capable to detecte hallmark proteins is important for 
the basic pathology research in AD. In order to achieve this purpose, we evaluated cyanine 
dyes as more sensitive and benign probes to stain biological tissue. Especially, cyanine dyes 
have high affinity for Aβ or tau aggregates, which implied that these compounds may be 
suitable as fluorescent probes for the in vivo diagnosis of AD.213,219  
As shown in Scheme 3.27, 4-nitrophenyl hydrazine 132 and 3-methylbutan-2-one 117 were 
condensed and followed by Fischer indole synthesis to obtain the indole 133. 
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Scheme 3.27 Synthesis of 2,3,3-trimethyl-5-nitro-3H-indole. 
Several indolium salts have been synthesized as shown in Chapter 3.5.1. In addition, 
methylation of the compound 133 with iodomethane in acetonitrile formed the indolium 134a 
in good yield (Scheme 3.28). Indolenine 118a and 1-bromodecane were refluxed in 
acetonitrile for 4 days to prepare the indolium salts 134b as waxy solid. Furthermore, 2-(2-(2-
methoxyethoxy)ethoxy)ethanol, 2-(2-methoxyethoxy)ethanol and 3-methoxypropan-1-ol were 
reacted with 4-toluene sulfonyl chloride to form the corresponding 4-
methylbenzenesulfonates. After PEGylation on the N position of indolenine 118a, the 
products 134c-e were purified by column chromatography and characterized by NMR 
spectroscopy.  
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Scheme 3.28 Synthesis of trimethine cyanines 135a-l. 
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Table 3.11 Structures, calculated LogP and staining effect of trimethine cyanines 
Entry BSc No. R1 R2 R3 X cLogP[a] Staining effect[b] 
135a BSc4704 H CH3 CH3 I 2.77 
Aβ: - 
NFT: +++ 
135b BSc4705 NO2 CH3 CH3 I 2.64 
Aβ: + 
NFT: ++ 
135c BSc4737 H CH3 n-decyl Br 9.55 
Aβ: + 
NFT: +++ 
135d BSc4738 H CH3 (CH2CH2O)3CH3 Cl 1.93 
Aβ: + 
NFT: + 
135e BSc4739 H CH3 n-Bu I 5.64 
Aβ: + 
NFT: ++ 
135f BSc4741 H CH3 CH2CH2OCH3 Cl 2.74 
Aβ: + 
NFT: +++ 
135g BSc4742 Br CH3 CH3 I 4.34 
Aβ: - 
NFT: +++ 
135h BSc4806 F CH3 CH3 I 3.05 
Aβ: - 
NFT: + 
135i BSc4810 OCH3 CH3 CH3 I 2.84 
Aβ: +++ 
NFT: - 
135j BSc4811 H Et CH3 I 3.42 
Aβ: - 
NFT: + 
135k BSc4818 H CH3 (CH2CH2O)2CH3 TsO 2.33 
Aβ: - 
NFT: - 
135l BSc4920 H CH3 CH2CH2CH2OCH3 Cl 3.28 
Aβ: - 
NFT: ++ 
[a] LogP values were calculated using the Molinspiration Cheminformatics software 
(V2011. 04); [b] +++ stands for efficient staining, ++ stands for normal staining, + stands 
for weak staining and - stands for no staining. 
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In the presence of pyridine as a base and solvent, the trimethine cyanines were formed by a 
condensation reaction between triethyl orthoformate and the corresponding indolium salts 
(Scheme 3.28). A series of cyanine dyes has been synthesized as summarized in Table 
3.11. According to the coupling constants of the olefinic protons (J = 13.0-13.5 Hz), 
symmetric trimethine cyanines adopt the thermodynamically favorable trans conformer. 
During chromatography, the tosylate counterion of 135d, 135f and 135l were exchanged for 
chloride ions once the mobile phase involved 2% triethylamine. The process has been 
judged by absence of tosylate protons in the 1H-NMR spectra.220 
Table 3.12 Structures, properties and staining effect of trimethine cyanine based on 
benzothiazolium and benzoxazolium. 
Entry BSc No. R1 X Y cLogP[a] MW[b] Staining effect[b] 
138a BSc4706 CH3 I S 1.77 464.4 
Aβ: +++ 
NFT: + 
138b BSc4867 CH2CH2O3CH3 TsO S 1.74 596.8 
Aβ: - 
NFT: - 
138c BSc4868 (CH2CH2O)3CH3 TsO S 0.92 773.0 Aβ: + 
NFT: - 
138d BSc4904 CH3 I O 0.48 432.3 
Aβ: - 
NFT: - 
138e BSc4907 n-Bu I O 3.36 516.4 Aβ: - 
NFT: - 
[a] LogP values were calculated using the Molinspiration Cheminformatics software 
(V2011. 04); [b] Determined by CS ChemOffice 10.0. [c] +++ stands for efficient staining, 
++ stands for normal staining, + stands for weak staining, - stands for no staining. 
By further replacement of the indolium cores with benzothiazolium or benzoxazolium, we 
synthesized five trimethines as shown in Scheme 3.29 and Table 3.12. The commercially 
available 2-methylbenzo[d]thiazole 136 and iodomethane were refluxed in acetonitrile to 
afford the 2,3-dimethylbenzo[d]thiazol-3-ium iodide 137a, which can be used in the next step 
without further purification. Additionally, PEGylation of 2-methylbenzo[d]thiazole 136 with 2-
methoxyethyl 4-methylbenzenesulfonate and 2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate was carried out to synthesize the benzothiazolium salts 137b-c, 
respectively. Similarly, cyanine dyes 138a-e were readily prepared via the classical route 
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involving the condensation of the heterocyclic quaternary salts (127, 130 and 137a-c) with 
triethyl orthoformate in dry pyridine. Consistently, the structures adopt the trans configuration, 
which is indicated by the coupling constant of the olefinic protons around 12.5-13.5 Hz. 
However, in the case of absence of triethylamine in the mobile phase for column 
chromatography, the tosylate moiety was retained (138b-c). The results were confirmed by 
tosylate protons in the 1H-NMR spectra. 
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Scheme 3.29 Synthesis of trimethine cyanines based on benzothiazolium and benzoxazolium cores. 
3.7.2. Evaluation of trimethine cyanine derivatives as specific Aβ or tau 
imaging probes 
In order to evaluate the ability to visualize Aβ plaques and NFTs, hippocampus sections from 
confirmed AD cases were stained with the trimethine cyanines and evaluated by 
fluorescence microscopy (Figure 3.24). It is noteworthy that the trimethine cyanine derivative 
135a displayed a remarkably higher selectivity for aggregated tau. With the replacement of 
the methyl group on the nitrogen of indolenine with different length alkyl chains, probes 135c 
and 135e stained NFTs in human tissue strongly as observed by fluorescence microscopy, 
whereas plaques in the same brain preparations were stained just weakly. However, the long 
alkyl chains increase the LogP values, which may lead to reduce the solubility in some 
respects. To overcome this limitation, we introduced the poly(ethylene glycol) moieties on the 
nitrogen position of indolenine (135d, 135f and 135k-l). By increasing the length of 
poly(ethylene glycol) moieties, compound 135d (> 1.0 g/L) is more soluble in distilled water 
than compound 135f (> 0.5 g/L). Oppositely, probe 135f exhibited a better staining to tau 
aggregates in comparison to probe 135d. These results indicate that the binding effect may 
not be associated with the lipophilicity of our probes. On the other hand, the probe 135k with 
tosylate moiety failed to detect Aβ and tau aggregates by fluorescence microscopy. It was 
hypothesized that the size of the tosylate counterion is bigger than the chloride ion, which 
exceeds the width of ‘binding channel’ in unsullied staining protocols. Finally, the steric 
hindrance may prevent the probe to interact with Aβ or tau aggregates. Furthermore, 
compounds bearing an electron-donating or an electron-withdrawing group at the 5-position 
of indolium core were investigated. In the presence of an electron-withdrawing group, probes 
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135b (NO2) and 135g (Br) displayed excellent NFTs staining while only faintly staining Aβ 
plaques. However, probe 135h with a fluoro-substitutent poorly stained tau aggregates with 
low contrast to the background. In the presence of the electron-donating group such as 
OCH3, probe 135i displayed a remarkably higher staining of Aβ plaques.  
 
Figure 3.24 In vitro histochemical staining of postmortem AD brain tissues with ME derivatives 
(Tissues: hippocampus; Patient: male, 71 years old; CERAD Score: 3; NFTs-level: V). 
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Moreover, we performed neuropathological fluorescent staining with the benzothiazolium 
cyanine dye 138a. Many NFTs were clearly stained with probe 138a as seen in the in vitro 
assay. However, replacement of the methyl group on the nitrogen of the indolenine 
benzothiazole with different length of poly(ethylene glycol) moieties gave negative staining 
results. It was found that only probe 138c poorly stained Aβ plaques with low contrast to the 
background. In addition, replacement of the sulfur atom with oxygen at the Y position of 
benzothiazolium (Scheme 3.29), provided the probes 138d-e, which failed to detect Aβ and 
tau aggregates in postmortem AD brain tissues. These results suggest that 3,3-geminal 
methyl of these scaffolds may be important for the selective visualization of NFTs by 
fluorescence microscopy. 
The affinity of most probes to Aβ or tau aggregates could not be quantified due to spectral 
overlap with the reference ligand Thiazine Red R. Fortunately, the affinities of several probes 
to tau aggregates were determined indirectly in the displacement assay for tau affinity versus 
the reference ligand Thiazine Red R using aggregated recombinant human microtubule 
associated tau protein purified from E. coli and aggregated synthetic Aβ40 as reported 
previously. Probes 135a, 135e and 135g showed ~1480-10000 fold higher affinity to tau 
aggregates in comparison to the value of PIB under the same assay conditions. It indicates 
sufficient affinity of probes for further imaging of tau aggregates in vivo.  
Five trimethine cyanines (135a, 135c and 135e-g) have been further evaluated in the wild-
type zebrafish embryo development assay. It was found that the embryos treated with 
probes 135a, 135c and 135e-f developed well at different concentrations up to 10 µM at 24 
hpf. However, probe 135g showed cytotoxicity at 10 µM at 24 hpf, while the embryos 
developed well at 5 µM concentration. In the same concentration the juvenile fish incubated 
with compounds 135c and 135f developed well until 72 hpf. Unfortunately, in the presence of 
probes 135a, 135e and 135g, the juveniles stopped growing and died at 2 dpf (Figure 3.25).  
Seven compounds were evaluated for their cytotoxicity in the HepG2 cell proliferation assay. 
The EC50 values of compounds 135a-g and 135l were thus obtained. Both cytotoxicity 
studies concluded that tau selectivity probes 135a and 135g have negligible cytotoxicity 
against zebrafish embryos and HepG2 at the concentration employed for the histology 
experiments on human AD brain tissue (1 µM). 
 Page 93 
 
Figure 3.25 In vivo cytotoxicity studies of embryos of wild-type zebrafish with 5 µM (F and L) or 10 
µM (B-E and H-K) trimethine cyanines after 24 (A-F) and 72 (G-K) hpf. Controlled (A and G), 135a (B 
and H), 135c (C and I), 135e (D and J), 135f (E and K) and 135g (F). 
The tau specific imaging probes 135a-g, 135i and 135l were evaluated for solubility in 
distilled water. The solubilities of 135a, 135d, 135f and 135l are higher than 0.5 g/L while the 
rest of probes are lower than 0.1 g/L in distilled water at 25 °C. However, the solubility of 
established imaging agents: FDDNP, Methoxy-X04 and BF-158, is in the same range or 
inferior to the solubility of our trimethine cyanines. 
On the basis of histological staining of Aβ plaques and NFTs, the trimethine cyanines 135a-g, 
135i and 135l stained NFTs in human tissue strongly as detected by fluorescence 
microscopy, whereas plaques in the same brain preparations were not stained or just stained 
weakly. These results suggest that cyanine dyes 135a-g, 135i and 135l may be applied as 
potential fluorescent probes for the detection of tau deposits on the olfactory epithelium of 
AD patients. Furthermore, these probes may be radiolabeled with 11CH3, 18F and 123I at the 
nitrogen position and evaluated as PET and SPECT radioligands for NFT-imaging in vivo. 
 
3.8. Synthesis and evaluation of N-2-aryl-1,2,3-triazole derivatives as specific 
tau imaging probes 
As a new class of UV/blue-light-emitting fluorophores, the N-2-aryl-1,2,3-triazoles may 
provide tunable emission and flexible Stokes shift through planar intramolecular charge 
transfer. In spite of both N-1-aryl-1,2,3-triazoles and N-2-aryl-1,2,3-triazoles gave a strong 
absorption, only the N-2-analogous showed excellent fluorescence emission in the UV/blue 
range with high efficiency in different solvents.221,222 For these reasons, the symmetrical N-2-
aryl-1,2,3-triazoles are more potent ligands than unsymmetrical N-1-analogous in biological 
imaging (Figure 3.26). It was reported that N-2-aryl-triazole displayed ~17-fold higher 
intensity than N-1-aryl isomer. 221,222 This observation suggested the possible use of N-2-aryl-
1,2,3-triazoles as fluorescent probes for the detection of Aβ and tau aggregates in AD.  
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Figure 3.26 The isomers of N-substituted-1,2,3-triazoles. 
Previous research in our group suggested that compounds with a dimethylamino and 
diethylamino group may display good affinity to tau aggregates. In the present work, we have 
synthesized several N-2-aryl-triazoles containing dimethylamino or diethylamino on the 4-
position of the 2-aryl ring.  In addition, we investigated the effect of the electron-donating or 
electron-withdrawing group on the 5-position of benzotriazole ring for staining. The synthetic 
route used to prepare N-2-aryl-triazoles was shown in Scheme 3.30.223 
Obviously, N-1-substituted or N-3-substituted 1,2,3-triazoles can be efficiently prepared by 
general reaction conditions. In contrast, regioselective synthesis of N-2-substituted-1,2,3-
triazoles in good yields is still a challenge for organic chemists. The synthesis of N-2-
substituted-1,2,3-triazoles is outlined in Scheme 3.30. The process involved initial 
diazotization of 4-substituted-2-nitroanilines 139a-d with sodium nitrite in hydrochloride 
solution to form the diazonium salt. Followed by coupling with the molar equivalent of N,N-
dimethylaniline or N,N-diethylaniline at 0-5 °C, the reactions were carried out immediately 
with a change in color from pale yellow to deep brown to afford the corresponding azo 
compounds 141a-g.  
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Scheme 3.30 Synthesis of benzo[d][1,2,3]triazol derivatives. 
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Table 3.13 Structures, properties and staining effect of benzo[d][1,2,3]triazoles. 
Entry BSc No. R1 R2 cLogP[a] MW[a] Staining effect[b] 
142a BSc4954 CN N(CH3)2 3.81 263.3 
Aβ: + 
NFT: +++ 
142b BSc4955 H N(CH3)2 3.78 238.3 
Aβ: + 
NFT: +++ 
142c BSc4956 H N(CH2CH3)2 4.45 266.3 
Aβ: ++ 
NFT: ++ 
142d BSc4957 CH3 N(CH3)2 4.26 252.3 
Aβ: + 
NFT: +++ 
142e BSc4958 CH3 N(CH2CH3)2 4.94 280.4 
Aβ: + 
NFT: + 
142f BSc5043 OCH3 N(CH3)2 3.65 268.3 Aβ: - 
NFT: - 
142g BSc5044 OCH3 N(CH2CH3)2 4.33 296.4 Aβ: - 
NFT: - 
[a] Determined by CS ChemOffice 10.0. [b] +++ stands for efficient staining, ++ 
stands for normal staining, + stands for weak staining, - stands for no staining. 
As shown in Scheme 3.30, the reaction of 2-nitroazobenzenes with sodium azide obtained 
the intermediates, which immediately released nitrogen under thermodynamic condition to 
afford the N-2-aryl-1,2,3-triazoles 142a-g (Table 3.13). The N-2-aryl-1,2,3-triazoles were 
purified by column chromatography and characterized by NMR spectroscopy. 
To further confirm the binding of -2-aryl-1,2,3-triazoles for NFTs in the AD brain, fluorescent 
staining was carried out by using of brain tissue sections (Figure 3.27). It was found that 
many NFTs were clearly stained with 142a-e as seen in the in vitro assay, whereas Aβ 
plaques in the same brain sections were stained just weakly. To our surprise, probes 142f-g 
with methoxy in the 5-position of benzotriazole ring failed to detect both Aβ and tau 
aggregates by fluorescence microscopy. 
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Figure 3.27 In vitro histochemical staining of postmortem AD brain tissues with N-2-aryl-1,2,3-
triazoles (Tissues: hippocampus; Patient: male, 72 years old; CERAD Score: 3; NFTs-level: V). 
The affinities of these probes 142b-e to Aβ and tau aggregates were determined in the 
displacement assay for Aβ and tau affinity versus the reference ligand Thiazine Red R. 
Unfortunately, the affinities of probes 142b-d to Aβ and tau aggregates could not be 
quantified because the values were out of the measureable range. It is noteworthy that probe 
142e shown the higher binding affinity for both Aβ and tau aggregates in the low- to mid-
nanomolar range. It displayed ~17-fold higher affinity to tau aggregates in comparison to PIB 
which uses the same system for comparison. 
Compounds 142c-d have been further evaluated at different concentrations in the wild-type 
zebrafish embryo development assay (Figure 3.28). The embryos were treated with 
solutions containing compounds at 6-8 hpf, and the phenotypes were compared at 24 hpf 
and 72 hpf. It was found that the embryos developed well and did not display any lesions in 
eyes, yolks, tail and heart beat at different concentrations up to 10 µM. The cytotoxicity 
analysis proposes that N-2-aryl-1,2,3-triazoles have negligible cytotoxicity against wild-type 
zebrafish embryos at the concentration employed for the histology experiments on human 
AD brain tissue (1 µM). 
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Figure 3.28 In vivo cytotoxicity studies of embryos of wild-type zebrafish with 10 µM N-2-aryl-
1,2,3-triazoles at 24 hpf and 72 hpf. Controlled (A and D) probe 142c (B and E) and probe 142d (C 
and F). 
In conclusion, we sought that N-2-aryl-1,2,3-triazoles containing a 
dimethylamino/diethylamino group in the 4-position of the 2-aryl ring have good fluorescence 
characteristics appropriate for the detection of tau aggregates in the brain tissue. The in vitro 
binding assay and the cytotoxicity experiments with zebrafish embryos suggest that N-2-aryl-
1,2,3-triazoles may be used as potential imaging agents for tau pathology in AD. 
 
3.9. Nasal mucous membranes as a potential diagnosing approach for 
Alzheimer’s disease 
A key obstacle in the development of diagnostics for AD is the blockage of drug entrance into 
the CNS by the BBB. From 1970s, there was a range of publications starting to clarify the 
neural connection between nasal mucosa and brain.224,225 Due to the absence of a BBB 
between nose and brain, it suggested that the nasal cavity may enable drugs to access the 
brain and the nervous system by pathways involving the olfactory epithelium and the 
olfactory bulb. Therefore, the human olfactory system may be conducive to diagnose and 
treat brain disorders, such as AD and PD (Figure 3.29). 
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Figure 3.29 Nasal mucous membranes, a type of tissue that lines the nasal cavity, and 
immunohistochemical staining with antibodies against tau deposits on the olfactory epithelium tissues. 
Comparing 20 confirmed AD patients and 5 healthy controls, our group discovered that the 
typical nasal tau-protein may deposit in nasal mucous membranes, particularly in the nasal 
Bowman’s glands and olfactory epithelium.204,226 The severity of tau accumulation in the 
Bowman’s glands and its correlation to AD is subject to ongoing investigation.49 However, 
this observation has shown potential for the noninvasive diagnosis of AD via changes in the 
olfactory epithelium in the early stages of disease.227  
Table 3.14 Staining effect of selected probes on olfactory epithelium tissues. 
Entry BSc No. Staining effect[a] 
52p BSc4333 - 
52q BSc4334 - 
52u BSc4342 - 
83 BSc4979 - 
100a BSc4740 + 
100b BSc4975 ++ 
115a BSc4919 +++ 
115d BSc4960 +++ 
142c BSc4956 ++ 
[a] +++ stands for efficient staining, ++ stands for normal staining, 
+ stands for weak staining, - stands for no staining. 
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Several tau probes identified by brain histology (Table 3.14 and Table 3.15) were used for 
the detection of tau deposits on the olfactory epithelium tissues in vitro. Unexpectedly, the 
phenylhydrazone benzothiazoles (52p-q and 52u) and 1,4-bisstyryl-2-methoxybenzenes (83) 
failed to stain tau deposits. It was assumed that the high lipophilicity and poor water solubility 
limit these probes to penetrate the tissues, which lead to insufficient imaging. Thus, the poor 
cell permeability of imaging probe may prevent the visualization of tau deposits on the 
olfactory epithelium tissues. 
 
Figure 3.30 In vitro histochemical staining of postmortem AD olfactory epithelium tissues with 1,4-
bisstyryl-2-methoxybenzenes (Tissues: olfactory epithelium; Patient: male, 78 years old; Braak: V, 
CERAD Score: 3). 
The N-2-aryl-1,2,3-triazole derivative (142c), the 1,4-bisstyryl-2-fluorobenzenes (100a-b) and 
the bis(arylvinyl)pyrimidines (115a and 115d) stained tau deposits on the olfactory epithelium 
tissues (Figure 3.30 and Figure 31). As detected by fluorescence microscopy, in human 
olfactory epithelium tissue, the N-2-aryl-1,2,3-triazoles stained tau deposits strongly in 
comparison to bisstyryl derivatives. These results indicate that the relatively efficacious 
compounds (115a, 115d and 142c) may exhibit greater cell permeability, whereas less cell 
permeability compounds (100a-b) poorly stained tau deposits and limited the detection by 
the DAPI- or FITC-filters employed in fluorescence microscopy. 
 
Figure 3.31 In vitro histochemical staining of postmortem AD olfactory epithelium tissues with 
bis(arylvinyl)pyrimidines and N-2-aryl-1,2,3-triazoles (Tissues: olfactory epithelium; Patient: male, 78 
years old; Braak: V, CERAD Score: 3). 
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Table 3.15 Staining effect of selected cyanine dyes on olfactory epithelium tissues. 
Entry BSc No. Staining effect[a] 
120a BSc4452 +++ 
120h BSc4744 +++ 
121a BSc4743 +++ 
121d BSc4747 +++ 
121g BSc4750 +++ 
135a BSc4704 +++ 
135c BSc4737 +++ 
135e BSc4739 +++ 
135g BSc4742 +++ 
[a] +++ stands for efficient staining. 
 
 
Figure 3.32 In vitro histochemical staining of postmortem AD olfactory epithelium tissues with 
spiropyrans and cyanine dyes (Tissues: olfactory epithelium; Patient: male, 78 years old; Braak: V, 
CERAD Score: 3). 
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Remarkably, many tau deposits were clearly stained with the spiropyrans (120a, 120h and 
120l), merocyanines (121a, 121d and 121g) and trimethine cyanines (135a, 135c, 135e and 
135g) as seen in the in vitro assay (Figure 3.32). The tau deposits can be observed by 
fluorescence microscopy under green and red filters (more details see experimental 
sections). These results suggested that cyanine dyes were efficacious fluorescent probes for 
the detection of tau deposits on the olfactory epithelium tissues. The good solubility in water 
and negligible cytotoxicity suggested that these probes may be suitable for further in vivo 
applications in the near future. 
In conclusion, we developed six classes of fluorescent probes to detect nasal tau-protein 
deposits. Since olfactory epithelium and olfactory bulb are not confined by the BBB, the 
efficiency of the drug depends on cell permeability rather than brain penetration. Therefore, 
the fluorescent labeling and histological examination suggested that nasal mucous 
membranes may be a potential tool for the detection of AD in the early stages. 
 
3.10. Evaluation imaging probes to detect α-synuclein aggregates for 
Parkinson’s disease 
ASN is a component of LBs which are found in the brain of PD patients. ASN has been 
widely studied since 1997. Afterwards, plenty of articles describing the role of ASN in PD 
have been published.137 In contrast to AD imaging agents, until now, only a handful of 
studies regarding fluorescent probes for the detection of ASN have been reported. 
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Figure 3.33 Imaging agents for the detection of ASN aggregates in vitro. 
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The fluorescent compound ThT (26) is the most classic fluorescent dye which used for 
detection of amyloid structures including ASN. Besides, BF-227 (143) can be used for the 
detection of ASN-positive LBs and LNs via in vitro postmortem examination. In addition, 
cyanine dyes T-284 (144) and SH-516 (145) (Figure 3.33) were examined as sensitive and 
specific fluorescent probes for monitoring and characterizing ASN aggregations in vitro.228-230  
Table 3.16 Staining effects of trimethine cyanine dyes for AD and PD. 
Entry BSc No. Staining effect in AD and PD brain sections[a] 
135a BSc4704 Aβ: - NFT: +++ ASN: ++ 
135b BSc4705 Aβ: + NFT: ++ ASN: - 
135c BSc4737 Aβ: + NFT: +++ ASN: - 
135d BSc4738 Aβ: + NFT: + ASN: +++ 
135e BSc4739 Aβ: + NFT: ++ ASN: ++ 
135f BSc4741 Aβ: + NFT: +++ ASN: ++ 
135g BSc4742 Aβ: - NFT: +++ ASN: +++ 
135h BSc4806 Aβ: - NFT: + ASN: +++ 
135i BSc4810 Aβ: +++ NFT: - ASN: +++ 
135j BSc4811 Aβ: - NFT: - ASN: +++ 
135k BSc4818 Aβ: - NFT: - ASN: - 
135l BSc4920 Aβ: - NFT: ++ ASN: +++ 
138b BSc4867 Aβ: - NFT: - ASN: ++ 
138c BSc4868 Aβ: + NFT: - ASN: +++ 
138d BSc4904 Aβ: - NFT: - ASN: +++ 
138e BSc4907 Aβ: - NFT: - ASN: - 
[a] +++ stands for efficient staining, ++ stands for normal staining, + stands for 
weak staining, - stands for no staining. 
The cyanine dyes exhibit a significant increase in fluorescence intensity in the presence of 
fibrillar ASN.120 Unfortunately, cyanine dyes have shown potential as fluorescent probes for 
detection of biomolecules (DNA, lipid and protein) which indicates unselective binding. With 
the aim of searching novel fluorescent probe for the detection of ASN aggregates, we 
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explored strategies to construct fluorescent derivatives based on the compounds 144 and 
145.  
We conducted a histochemical staining of postmortem PD brain tissues with 16 trimethine 
cyanines (Table 3.16). The stained brain tissues were investigated under a fluorescence 
microscopy employing DAPI- and FITC-filters. Excitingly, these in vitro assays revealed that 
12 trimethine cyanine dyes effectively stained hallmark lesions of PD including LBs and LNs 
(Figure 3.34). Numerous fluorescent spots were observed in the sections of substantia nigra 
from PD brain. It indicates the potential application of trimethine cyanine dyes as imaging 
agents for the detection of ASN aggregates in PD. Meanwhile, different substituents in 1-
position or 5-position of the indolium cores did not have a significant impact on histological 
staining. It is noteworthy that probes 135j, 138b and 138d could specifically detect ASN 
aggregates by fluorescence microscopy while they failed to detect Aβ plaques or NFTs in AD 
subjects under same assay conditions. The ongoing radiolabeling of these probes as PET or 
SPECT imaging agents may be conducive to diagnose PD in the early stages.  
 
Figure 3.34 In vitro histochemical staining of postmortem PD brain tissues with trimethine 
cyanines (Tissues: midbrain; Patient: male, 76 years old).  
However, the probes 135b-c, 135k and 138e failed to detect ASN aggregates by 
fluorescence microscopy. The fact that ASN aggregates are undetectable by these 
fluorescent dyes may be due to the lower density of LBs or LNs presented in the brain 
sections (around four times lower than Aβ plaques and NFTs in AD). However, this 
assumption needs to be confirmed by further experiments.  
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Furthermore, the biological evaluation of 6 ME derivatives based on indolium cores were 
accomplished by fluorescent staining of PD brain sections (Table 3.17). It was found that five 
probes intensely stained ASN aggregates under these assay conditions (Figure 3.35, A-E). 
It appears that the chain length of the PEGylation or alkylation has no affect on the staining 
results. Simultaneously, the introduction of an electron-donating or electron-withdrawing 
group in the 5-position of cationic indolium core reduced unspecific binding and improved the 
visualization of ASN aggregates in the PD brain sections. However, the replacement of one 
of the geminal methyl groups by an ethyl moiety in the 3-position, probe 123b stained ASN 
aggregates in human midbrain tissue strongly as observed by fluorescence microscopy, 
while 123d failed to detect human midbrain ASN aggregates by fluorescence microscopy. 
We hypothesized that this result may be caused by the density of ASN aggregates in 
postmortem substantia nigra sections from PD brain. 
Table 3.17 Staining effects of ME dyes. 
Entry BSc No. Staining effect in AD and PD brain sections[a] 
121a BSc4743 Aβ: + NFT: +++ ASN: ++ 
121b BSc4745 Aβ: + NFT: ++ ASN: +++ 
121j BSc4816 Aβ: + NFT: - ASN: +++ 
121k BSc4817 Aβ: ++ NFT: - ASN: +++ 
123b BSc4814 Aβ: ++ NFT: - ASN: +++ 
123d BSc4866 Aβ: ++ NFT: - ASN: - 
[a] +++ stands for efficient staining, ++ stands for normal staining, 
+ stands for weak staining, - stands for no staining. 
Finally, the N-2-aryl-1,2,3-triazoles 142a-g were examined by neuropathological staining of 
PD brain sections. Unfortunately, these derivatives did not stain ASN aggregates in the 
human brain section but poorly stained nerve fibrils with a low contrast to the background 
(Figure 3.35, F). 
From the above results, it can be concluded that the cyanine moiety may play a critical role 
in the binding to ASN aggregates. The charged aryl group may contribute to increased 
fluorescence upon binding to aggregated ASN. Further research on cyanine dyes as 
potential imaging agents for ASN aggregates in PD is needed. These data provide a 
direction for the development of non-invasive agents for early in vivo detection of ASN 
aggregates in PD using PET and SPECT. 
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Figure 3.35 In vitro histochemical staining of postmortem PD brain tissues with ME dyes (Tissues: 
midbrain; Patient: male, 76 years old).  
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4. Summary 
Design, synthesis and evaluation of potential imaging agents for Alzheimer’s disease  
Based on the modification of known structures with good binding affinities to β-sheet rich 
proteins, we prepared a diverse set of imaging agents for the detection of β-amyloid (Aβ) 
plaques and neurofibrillary tangles (NFTs) in Alzheimer’s disease (AD). This resulted in six 
sets of probes, such as benzothiazoles, bis(styryl) derivatives, spiropyrans, indolium 
derivatives, trimethine cyanines and N-2-aryl-1,2,3-triazoles, which clearly stained Aβ 
plaques and NFTs in human tissues as observed by fluorescence microscopy. Several 
compounds provided highly specific visualization of Aβ plaques or NFTs in brain tissues of 
AD patients. 
Due to the absence of fluorescence, the phenyldiazenyl benzothiazoles (50a-g) failed to 
visualize Aβ plaques and NFTs in the neuropathological staining of AD brain sections 
(Chapter 3.1.1). In order to overcome this shortcoming, we developed a set of fluorescent 
phenylhydrazone benzothiazoles (52a-v). The histological results of the probes 52f, 52p-q 
and 52t-u displayed excellent staining of both Aβ plaques and NFTs (Chapter 3.1.2) (Figure 
4.1). In addition, probes 52a, 52c-d, 52g-h, 52l-o, 52r and 52v specifically visualize Aβ 
plaques. It is noteworthy that the replacement of terminal phenyl groups by heteroaryls may 
increase fluorescence intensity upon binding to the targets. These compounds can provide 
improved signal-to-noise ratio for Aβ plaques and NFTs in comparison to IMPY derivatives 
(Chapter 3.2.1). The cytotoxicity analysis suggested that phenylhydrazone benzothiazoles 
have negligible cytotoxicity against zebrafish embryos at the concentration employed for 
further in vivo applications. 
 
Figure 4.1 In vitro histochemical staining of phenylhydrazone benzothiazoles 52p (BSc4333), 
52p (BSc4334) and 52u (BSc4342) to Aβ plaques (A-C) and NFTs (D-E) (Tissues: hippocampus; 
Patient: female, 89 years old; CERAD Score: 3; NFTs-level: V). 
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Furthermore, we evaluated imidazo[1,2-a]pyridines (Chapter 3.2.1), imidazo[1,2-
a]pyrimidines (Chapter 3.2.3) and tetrazines (Chapter 3.3) for the histological staining of Aβ 
plaques and NFTs in postmortem AD brain sections. The imaging results indicate that these 
probes exhibit remarkable selectivity for tau aggregates in vitro. However, lack of 
fluorescence properties upon target binding and low signal-to-noise ratio may limit them for 
the visualization of NFTs in the brain of AD patients. However, due to the steric hindrance, 
the [8+2] cycloaddition tetracyclics (61, 62 and 65) may lose their capacity to fit into the fibril 
“binding channel”, which causes them to be inactive in the imaging assay. 
Due to the excellent optical properties, we designed and synthesized several bisstyryl 
derivatives to evaluate the staining of AD postmortem brain sections. It appears that 1,2,4,5-
tetrafluoro-3,6-bisstyrylbenzenes 104b-c clearly and specific stained Aβ plaques in AD brain 
sections (Chapter 3.4.3). In contrast, the bis(arylvinyl)pyrimidine derivative 115d selectively 
binds NFTs in the hippocampal sections of human AD brain (Chapter 3.4.5). Additionally, 
the 1,4-bisstyryl-2-methoxybenzenes 83 and 4-bisstyryl-2-fluorobenzenes 100a can be used 
to stain both Aβ and tau aggregates and provide a good contrast versus background (Figure 
4.2). These results suggest that bisstyryl derivatives may be developed as potential ligands 
for imaging Aβ or tau aggregates in AD. However, the poor solubility (< 0.1 g/mL) and 
permeability are adverse properties which limits their use in vivo. In order to solve this major 
problem, it is necessary to find an effective way to improve the solubility and meet the 
lipophilicity criterion.  
 
Figure 4.2 In vitro histochemical staining of bisstyryl derivatives 83 (BSc4979), 100a (BSc4740), 
104b (BSc4567), 104c (BSc4569) and 115d (BSc4960) (Tissues: hippocampus; Patient: male, 71 or 
72 years old; CERAD Score: 3; NFTs-level: V). 
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The spiropyrans 120a, 120h and 120l, with a diethylamine group on the 7-position and 
different substituents on the 1’-position of the indole-ring, stained NFTs in human tissue 
clearly as observed by fluorescence microscopy, whereas plaques in the same brain 
preparations were not stained (Chapter 3.5) (Figure 4.3). Based on these structures, we 
further synthesized and evaluated water soluble merocyanines as specific Aβ or tau imaging 
agents (Chapter 3.6). The probes with a 3,3’-geminal methyl moiety (121a-h) exhibit highly 
specific staining to NFTs (Figure 4.3), which provides a good contrast versus Aβ plaques 
and background. However, the replacement of one of the geminal methyls by ethyl (123a-b 
and 133d) or the substitution of different function groups on the 5-position of the indolium 
core (121i-k), specifically labels Aβ plaques in AD brain tissues. Furthermore, cytotoxicity 
studies with wild-type zebrafish embryos and liver hepatocellular carcinoma cells (HepG2) 
indicate that spiropyrans and merocyanines were sufficiently safe for further in vivo 
evaluation in mouse models. 
We evaluated trimethine cyanine dyes as sensitive and specific probes for the detection of 
Aβ and tau aggregates by fluorescence microscopy (Chapter 3.7). We performed 
neuropathological fluorescent staining to confirm the ability to bind to Aβ plaques and NFT in 
postmortem AD brain sections. Probes 135a-g stain NFTs in human tissue and provide a 
good contrast versus Aβ plaques and background (Figure 4.3). The wild-type zebrafish 
embryo development assay indicated no adverse events at 5 µM at 24 hpf. Especially, 
PEGylation at the N position of indolenine may improve the solubility of these compounds. It 
provides a guideline to optimize these compounds for potential use as in vivo imaging agents 
for the diagnosis of AD.  
 
Figure 4.3 In vitro histochemical staining of tau specific dyes 120a (BSc4452), 121d (BSc4747) 
and 135a (BSc4704) (Tissues: hippocampus; Patient: male, 71 years old; CERAD Score: 3; NFTs-
level: V). 
To confirm the specific binding of N-2-substituted-1,2,3-triazoles to NFTs in vitro, 
neuropathological staining was performed on the brain sections of AD patients. The NFTs 
were clearly stained by compounds 142a-e, whereas Aβ plaques in the same brain sections 
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were stained just weakly (Chapter 3.8). The cytotoxicity experiments with zebrafish embryos 
suggest that these probes may be suitable for further in vivo applications in future. 
 
Figure 4.4 In vitro histochemical staining of N-2-substituted-1,2,3-triazoles 142a (BSc4954) and 
142b (BSc4955) (Tissues: hippocampus; Patient: male, 72 years old; CERAD Score: 3; NFTs-level: 
V). 
The affinities of these probes to aggregated tau and Aβ40 were determined by displacement 
of the reference dye Thiazine Red R, thus IC50 data obtained in the competition assay are 
reported rather than Ki values. Significantly, phenylhydrazone benzothiazoles, bisstyryl 
derivatives, spiropyrans and cyanine dyes displayed ~7-10000 fold higher affinity for Aβ40/tau 
aggregates in comparison to known compounds. This indicates sufficient affinity of these 
probes for the imaging of Aβ or tau aggregates in vivo. 
 
Figure 4.5 In vitro histochemical staining of selected probes 100b (BSc4975), 115d (BSc4960), 
120a (BSc4452), 121a (BSc4743), 135c (BSc4737) and 142c (BSc4956) for the detection of tau 
aggregates on the olfactory epithelium tissues (Tissues: olfactory epithelium; Patient: male, 78 years 
old; Braak: V, CERAD Score: 3). 
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20 probes for tau aggregates were selected and investigated as potential imaging agents for 
the detection of tau deposits in the olfactory epithelium tissue in vitro (Chapter 3.9). It is 
noteworthy that the N-2-aryl-1,2,3-triazole (142c), the 1,4-bisstyryl-2-fluorobenzenes (100a-
b) and the bis(arylvinyl)pyrimidines (115a and 115d) stain tau deposits in the olfactory 
epithelium tissues. Furthermore, the spiropyrans (120a, 120h and 120l), the merocyanines 
(121a, 121d and 121g) and the trimethine cyanines (135a, 135c, 135e and 135g) exhibit 
good to excellent staining of tau deposits and provide a good contrast versus background. 
They were clearly observed by fluorescence microscopy using green and red filters (Figure 
4.5). Since olfactory epithelium and olfactory bulb are not confined by the BBB, the 
fluorescent labeling suggested that nasal mucous membranes may give assess to detection 
method for the diagnosis of AD in the early stages. 
In conclusion, we successfully designed and synthesized sets of imaging agents for the 
selective detection of Aβ plaques and NFTs in postmortem AD brain sections. Selected 
candidates displayed higher affinity in the in vitro experiments in comparison to standard 
probes, such as PIB and Methoxy-X04. The cytotoxicity experiments with wild-type zebrafish 
embryos and HepG2 cells suggested that these probes displayed negligible cytotoxicity at 
the concentration employed for the histology experiments on human AD brain tissue (1 µM). 
Taken together, these results suggest that our candidates may be advanced to in vivo mice 
experiments in transgenic mice. These preferably fluorescent probes may be suitable for the 
detection of tau deposits on the olfactory epithelium of AD patients. Further optimization and 
radiolabeling of these probes may provide PET/SPECT imaging radiotracer for Aβ plaques 
and/or NFT imaging in vivo. 
Table 4.1 The 10 most tau selective dyes. 
Entry BSc No. cLogP MW[a] Histochemical staining 
120a BSc4452 6.80[a] 348.5 
 
120l BSc4903 6.64[a] 392.5 
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121a BSc4743 3.58[a] 502.5 
 
121d BSc4747 2.14[b] 460.4 
 
121g BSc4750 1.79[b] 458.4 
 
135a BSc4704 2.77[b] 484.4 
 
135e BSc4739 5.64[b] 586.6 
 
135f BSc4741 2.74[b] 481.1 
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142a BSc4954 3.81[a] 263.3 
 
142b BSc4955 3.78[a] 238.3 
 
[a] Determined by CS ChemOffice 10.0; [b] LogP values were calculated using the 
Molinspiration Cheminformatics software (V2011. 04). 
 
Evaluation of imaging probes to detect α-synuclein aggregates in Parkinson’s disease  
The second part of this thesis attempted to investigate several imaging agents for the 
detection of ASN aggregates in postmortem Parkinson’s disease (PD) brain sections 
(Chapter 3.9). It was found that 12 trimethine cyanine dyes and 5 merocyanine dyes strongly 
labeled ASN aggregates in the sections of substantia nigra. However, all the N-2-aryl-1,2,3-
triazoles failed to detect ASN aggregates by fluorescence microscopy. It indicated that 
cyanine moiety may play a critical role in binding to ASN aggregates in vitro.  
 
Figure 4.6 In vitro histochemical staining of cyanine dyes 135i (BSc4810) and 123b (BSc4814) 
to ASN aggregates (Tissues: midbrain; Patient: male, 76 years old). 
 Page 113 
5.  Outlook 
We successfully examined several imaging agents for the detection of Aβ plaques or NFTs in 
postmortem AD brain sections. Some of the results have been published or filed for patent 
application. At the same time, we evaluated cyanine dyes as sensitive probes for the 
detection of ASN aggregates in vitro. Therefore, further optimization of these compounds 
may have broad application prospects in neurodegenerative disease in future.  
The efficacy of central nervous system drugs for AD and PD depends on the sufficient 
lipophilicity to cross the BBB and enable rapid clearance from brain. Besides, poor solubility 
and cell permeability may limit their diagnostic potential for tau aggregates on the olfactory 
epithelium in vivo. In order to meet the solubility criteria and cross the BBB in humans, future 
work will have to focus on improved solubility of these compounds in aqueous media.  
Generally, the solubility of these imaging agents in water may be achieved by PEGylation. In 
addition, the introduction of a terminal 4-phenylpiperazine moiety is another feasible option to 
increase the solubility (Figure 5.1). These feasible approaches provide directions for 
improved of drug solubility. 
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Figure 5.1 Examples of optimization to improve the solubility of these structures.  
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Compounds 104b-c selectively visualize Aβ plaques in human brain tissue. The high fluorine 
contentmay make them particularly valuable for the development of a noninvasive probe for 
early detection of AD because all the fluorine atoms are chemically equivalent. By improving 
the water solubility, all of these probes may be used as imaging agents for the detection of 
Aβ aggregates.  
On the basis of increased solubility, the continuing research may focus on the development 
of radiolabeled compounds which can be applied as highly selective and specific 
PET/SPECT radiotracer for Aβ plaques or NFT imaging in vivo (Figure 5.2).  
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Figure 5.2 Examples of potential radiolabeled chemical structures for PET and SPECT imaging. 
The boron-containing compounds, with fluorescence covering a wide range from pure blue 
(450 nm) to saturated red (670 nm), have a wide range of applications as fluorescent probes 
in biological systems.231 The luminescent organic boron derivatives based on N,N- and N,O-
chelated boron complexes show excellent photophysical properties such as thermal and 
photochemical stability and high fluorescence quantum yield.232,233 Because of the poor 
staining effects of the phenylhydrazone benzothiazoles in Chapter 3.1.2 and the 
merocyanines in Chapter 3.6, additional structural changes (Figure 5.3) to form a rigid 
boronchelate fluorescent core may modify the fluorescence properties and improve their 
suitability for Aβ or tau imaging. 
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Figure 5.3 The N,O-chelated boron derivatives. 
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6.  Experimental section 
6.1.  General Information 
Melting points were measured by a Mettler FP5/51. The 1H-NMR spectra were recorded on a 
Bruker DRX 500 spectrometer at 500 MHz. The 13C-NMR spectra were recorded on a Bruker 
DRX 500 spectrometer at 125 MHz. Chemical shifts were reported downfield from Me4Si. IR 
was performed by PerkinElmer FT-IR spectrometer PARAGON 1000PC. UV-Vis spectra 
were recorded by Shimadzu UV-2401PC. Mass spectrometry was performed on a MAT 95 
double focussing sector field MS. Elemental analyses were performed by Elementar Vario 
EL. Flash column chromatography was carried out with Merck silica gel 60 (15-40 mm). Thin-
layer chromatography (TLC) was carried out with aluminum sheets precoated with silica gel 
60 F254 (0.2 mm, Merck). Chromatographic spots were visualized by UV light. All 
commercially available chemicals were used without further purification. 
 
6.2.  Synthesis of benzothiazole derivatives  
6.2.1. General procedures for synthesis of phenyldiazenyl benzothiazole 
derivatives 
2-(4-Nitrophenyl)benzo[d]thiazol (48) 
N
S
NO2
 
4-Nitrobenzoyl chloride (5.60 g, 30.0 mmol, 1.0 eq) was added to a solution of 2-
aminobenzothiol (3.2 mL, 30.0 mmol, 1.0 eq) in NMP (30 mL) by small portions under ice-
cooling. The reaction mixture was stirred at 100 °C for 2 h. After cooling down to room 
temperature, the mixture was added to ice water and treated with aqueous ammonia solution 
to pH=8-9. Precipitates were filtered off and washed with cold EtOH. 7.28 g of 2-(4-
nitrophenyl)benzo[d]thiazol was obtained as a yellow solid (yield: 95 %). 
4-(Benzo[d]thiazol-2-yl) aniline (49) 
N
S
NH2
 
Tin chloride (7.40 g, 39.0 mmol, 5.0 eq) was added to a solution of 2-(4-nitrophenyl) 
benzo[d]thiazol (2.00 g, 7.8 mmol, 1.0 eq) in EtOH (20 mL). The reaction was stirred and 
refluxed overnight. When the mixture was cooled to room temperature, the solvent was 
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evaporated in vacuo. The residue was dissolved in ethyl acetate, washed with NaOH 
solution (2 N, 3 x 30 mL), distilled H2O (2 x 30 mL) and brine (30 mL). The organic phase 
was dried over Na2SO4. After filtration, the solvent was evaporated in vacuo to afford 1.62 g 
of 4-(benzo[d]thiazol-2-yl) aniline as yellow solid.   
Yield: 92 %. 1H-NMR (300 MHz, CDCl3): δ = 8.00 (d, J = 8.1 Hz, 1H), 7.90 (d, J = 8.7 Hz, 
2H), 7.85 (d, J = 7.8 Hz, 1H), 7.45 (td, J = 8.1 Hz, J = 1.2 Hz, 1H), 7.32 (td, J = 8.1 Hz, J = 
1.2 Hz, 1H), 6.74 (d, J = 9.0 Hz, 2H), 3.95 (s, 2H)  ppm. 13C-NMR (75 MHz, CDCl3): δ = 
168.5, 154.3, 149.2, 134.6, 129.1, 126.0, 124.4, 124.0, 122.5, 121.4, 114.8 ppm. MS (EI, 70 
eV): m/z = 226 [M]+.  
 
General procedure for azo coupling reaction 
A solution of NaNO2 (76 mg, 1.1 mmol, 1.1 eq) in water (1 mL) was added dropwise to an 
ice-cold solution of 4-(benzo[d]thiazol-2-yl)aniline (226 mg, 1.0 mmol, 1.0 eq) in 6 N HCl (1 
mL), and the temperature was controlled under 5 °C. The reaction was stirred for 5 min and 
added to a solution of the corresponding aromatic compound (1.1 mmol, 1.1 eq) in a mixture 
of 6 N HCl (1.0 mL) and water (1.0 mL). Followed by 30 min of stirring at room temperature, 
the reaction mixture was poured onto a mixture of ice water (20 mL) and 6 N NaOH solution 
(2 mL). Precipitates were filtered off and washed with cold water. The crude product was 
purified by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:10) to furnish the 
corresponding compound with yields of 46-81 % (Table 3.1). 
(E)-4-((4-(Benzo[d]thiazol-2-yl)phenyl)diazenyl)-N,N-dimethylaniline (50a) 
N
S
N
N N
BSc4211
 
Yield: 71 %. 1H-NMR (500 MHz, CDCl3): δ = 8.21 (d, J = 8.5 Hz, 2H), 8.09 (d, J = 8.0 Hz, 
1H), 7.96 (d, J = 9.0 Hz, 2H), 7.92 (d, J = 9.0 Hz, 3H), 7.51 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 
7.40 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 3.12 (s, 6H) ppm. 13C-NMR 
(125 MHz, CDCl3): δ = 163.7, 154.3, 153.7, 148.3, 134.0, 128.3, 126.4, 126.0, 125.4, 125.2, 
123.3, 122.8, 121.6, 115.5, 111.5, 40.3 ppm. MS (EI, 70 eV): m/z = 358 [M]+. UV/Vis 
(Ethanol): λmax = 445.5 nm. 
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Absorption BSc4211 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
 
(E)-5-((4-(Benzo[d]thiazol-2-yl)phenyl)diazenyl)-N,N-dimethylpyridin-2-amine (50b) 
N
S
N
N
N
N
BSc4212
 
Yield: 63 %. 1H-NMR (300 MHz, CDCl3): δ = 8.85 (d, J = 2.1 Hz, 1H), 8.22 (d, J = 6.0 Hz, 
2H), 8.12-8.04 (m, 2H), 7.99-7.90 (m, 3H), 7.51 (td, J = 8.4 Hz, J = 1.2 Hz, 1H), 7.40 (td, J = 
8.4 Hz, J = 1.2 Hz, 1H), 6.61 (d, J = 9.4 Hz, 1H), 3.25 (s, 6H) ppm. MS (EI, 70 eV): m/z = 359 
[M]+. UV/Vis (Ethanol): λmax = 424.0 nm. 
Absorption BSc4212 (EtOH)
-0.4
-0.2
0
0.2
0.4
0.6
0.8
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
 
(E)-2-((4-(Benzo[d]thiazol-2-yl)phenyl)diazenyl)-5-(dimethylamino)phenol (50c) 
N
S
N
N N
HO
BSc4213
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Yield: 67 %. 1H-NMR (500 MHz, CDCl3): δ = 14.94 (s, 1H), 8.17 (d, J = 8.5 Hz, 2H), 8.08 (d, 
J = 7.5 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 9.5 Hz, 1H), 
7.50 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.39 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 6.46 (dd, J = 9.5 
Hz, J = 3.0 Hz, 1H), 6.07 (d, J = 3.0 Hz, 1H), 3.13 (s, 6H) ppm. 13C-NMR (125 MHz, CDCl3): 
δ = 167.3, 161.2, 155.0, 154.3, 150.7, 135.1, 135.1, 132.5, 131.9, 128.3, 126.4, 125.2, 123.2, 
121.6, 120.5, 107.2, 98.5, 40.3 ppm. MS (EI, 70 eV): m/z = 374 [M]+. UV/Vis (Ethanol): λmax 
= 478.0 nm. 
Absorption BSc4213 (EtOH)
0
0.5
1
1.5
2
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
 
(E)-2-(4-((1H-Indol-3-yl)diazenyl)phenyl)benzo[d]thiazole (50d) 
N
S
N
N NH
BSc4214
 
Yield: 46 %. 1H-NMR (500 MHz, CDCl3): δ = 8.66 (s, 1H), 8.62-8.57 (m, 1H), 8.24 (d, J = 8.5 
Hz, 2H), 8.12-8.08 (m, 2H), 8.01 (d, J = 8.5 Hz, 2H), 7.93 (d, J = 7.5 Hz, 1H), 7.51 (td, J = 8.0 
Hz, J = 1.0 Hz, 1H), 7.45-7.33 (m, 4H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 167.5, 165.8, 
154.3, 151.4, 137.4, 136.3, 135.9, 135.20, 133.8 131.5, 128.3, 126.4, 125.3, 124.7, 123.4, 
123.2, 122.5, 121.6, 111.4 ppm. MS (EI, 70 eV): m/z = 354 [M]+. UV/Vis (Ethanol): λmax = 
400.0 nm. 
Absorption BSc4214 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
300 350 400 450 500
W avelengt h [ nm]
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(E)-2-(4-((2-Methyl-1H-indol-3-yl)diazenyl)phenyl)benzo[d]thiazole (50e) 
N
S
N
N
NH
BSc4215
 
Yield: 49 %. 1H-NMR (500 MHz, CDCl3): δ = 8.56 (d, J = 8.0 Hz, 1H), 8.42 (s, 1H), 8.21 (d, J 
= 7.5 Hz, 2H), 8.10 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 7.5 Hz, 2H), 7.82 (d, J = 8.0 Hz, 1H), 
7.51 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.40 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.34-7.24 (m, 3H), 
2.87 (s, 3H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 167.7, 155.8, 154.3, 144.00, 135.2, 135.1, 
133.5, 133.2, 128.3, 126.4, 125.2, 123.8, 123.2, 122.6, 122.3, 121.6, 119.5, 110.5, 29.4 ppm. 
MS (EI, 70 eV): m/z = 368 [M]+. UV/Vis (Ethanol): λmax = 412.0 nm. 
Absorption BSc4215 (EtOH)
-0.2
0
0.2
0.4
0.6
0.8
250 300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
 
(E)-3-((4-(Benzo[d]thiazol-2-yl)phenyl)diazenyl)-9H-carbazol-2-ol (50f) 
S
N
N
N
HO
NH
BSc4295
 
Yield: 81 %. 1H-NMR (500 MHz, d6-DMSO): δ = 12.30 (s, 1H), 11.56 (s, 1H), 9.62 (s, 1H), 
8.30 (d, J = 9.0 Hz, 2H), 8.20-8.08 (m, 5H), 7.58 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 
7.45 (d, J = 7.5 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.96 (s, 1H) ppm. 
13C-NMR (125 MHz, d6-DMSO): δ = 166.2, 154.3, 153.6, 152.5, 144.5, 140.8, 134.6, 133.6, 
133.4, 128.3, 126.7, 125.6, 123.1, 122.9, 122.6, 122.3, 120.3, 120.1, 119.8, 117.6, 111.1, 
96.9 ppm. MS (EI, 70 eV): m/z = 420 [M]+. UV/Vis (Ethanol): λmax = 455.0 nm. 
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Absorption BSc4295 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
250 300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
 
(E)-3-((4-(Benzo[d]thiazol-2-yl)phenyl)diazenyl)-1H-indol-2-ol (50g) 
S
N
N
N
NH
HO
BSc4296
 
Yield: 48 %. 1H-NMR (500 MHz, d6-DMSO): δ = 12.88 (s, 1H), 11.08 (s, 1H), 8.13-8.06 (m, 
3H), 8.02 (d, J = 7.5 Hz, 1H), 7.62-7.57 (m, 3H), 7.53 (td, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.43 
(td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.28 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.08 (td, J = 7.5 Hz, J = 
1.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 166.8, 163.0, 
153.6, 145.0, 140.3, 134.1, 129.4, 129.1, 128.6, 126.4, 125.0, 122.4, 122.1, 121.9, 120.8, 
119.0, 114.5, 110.6 ppm. MS (EI, 70 eV): m/z = 370 [M]+. UV/Vis (Ethanol): λmax = 408.0 nm. 
Absorption BSc4296 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
250 300 350 400 450 500 550 600
Wa v e le ngt h [ nm]
 
6.2.2. General procedures for synthesis of phenylhydrazone benzothiazole 
derivatives  
A solution of NaNO2 (76 mg, 1.1 mmol, 1.1 eq) in water (1 mL) was added to an ice-cold 
solution of 4-(benzo[d]thiazol-2-yl) aniline (226 mg, 1.0 mmol, 1.0 eq) in 6 N HCl (1 mL), and 
the temperature was controlled under 5 °C. The reaction was stirred for 5 min and added 
slowly to a solution of SnCl2·2H2O in HCl (conc., 0.5 mL) at -5 °C. The reaction mixture was 
stirred at room temperature for 1 h.  
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Corresponding aldehydes (1 mmol, 1.0 eq) was dissolved in 30 ml THF, the solution of 
aldehydes were added to phenylhydrazine. The reaction mixture was stirred and refluxed for 
2 hours. When it was cooled, the mixture was extracted with THF twice. The organic phase 
was dried over Na2SO4, filtered, and concentrated. The residue was purified by column 
chromatography (SiO2; ethyl acetate: cyclohexane = 1:1) to furnish the corresponding 
compound with the yields of 44-81 % (Table 3.2). 
4-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-N,N-dimethylaniline (52a) 
S
N
NH
N
NBSc4216
 
Yield: 76 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.53 (s, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.97-
7.90 (m, 3H), 7.87 (s, 1H), 7.55-7.45 (m, 3H), 7.37 (td, J = 7.8 Hz, J = 0.9 Hz, 1H), 7.14 (d, J 
= 9.0 Hz, 2H), 6.75 (d, J = 9.0 Hz, 2H), 2.96 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ 
= 167.7, 153.9, 150.6, 128.2, 140.2, 133.8, 128.7, 127.3, 126.3, 124.5, 122.9, 122.3, 120.0, 
121.9, 112.0, 111.7, 39.9 ppm. MS (EI, 70 eV): m/z = 372 [M]+. UV/Vis (Ethanol): λmax = 
403.0 nm. 
Absorption BSc4216 (EtOH)
-0.5
0
0.5
1
1.5
2
300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
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4-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-N,N-diethylaniline (52b) 
S
N
NH
N
N
BSc4217
 
Yield: 73 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.48 (s, 1H), 8.05 (d, J = 7.5 Hz, 1H), 7.95-
7.91 (m, 3H), 7.84 (s, 1H), 7.50-7.46 (m, 3H), 7.37 (td, J = 8.0Hz, J = 1.5 Hz, 1H), 7.13 (d, J 
= 8.5 Hz, 2H), 6.69 (d, J = 9.0 Hz, 2H), 3.41-3.35 (m, 4H), 1.11 (d, J = 7.5 Hz, 6H) ppm. 13C-
NMR (125 MHz, d6-DMSO): δ = 167.6, 153.8, 148.1, 147.8, 140.2, 133.7, 128.6, 127.5, 
127.5, 126.2, 124.4, 122.1, 121.9, 121.8, 111.5, 111.2, 43.6, 12.4 ppm. MS (EI, 70 eV): m/z 
= 400 [M]+. UV/Vis (Ethanol): λmax = 407.5 nm. 
Absorption BSc4217 (EtOH)
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-2-methoxyphenol (52c) 
S
N
NH
N
OH
O
BSc4219
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Yield: 46 %. 1H-NMR (300 MHz, d6-DMSO): δ = 10.64 (s, 1H), 9.93 (s, 1H), 8.06 (d, J = 8.1 
Hz, 1H), 7.99-7.91 (m, 3H), 7.87 (s, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 
7.30 (d, J = 1.8 Hz, 1H), 7.18 (d, J = 8.7 Hz, 2H), 7.07 (dd, J = 8.1 Hz, J = 1.8 Hz, 1H), 6.81 
(d, J = 8.1 Hz, 1H), 3.85 (s, 3H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 167.6, 153.8, 148.0, 
147.9, 147.6, 139.6, 133.8, 128.9, 128.7, 126.7, 126.3, 124.5, 122.6, 121.9, 120.2, 115.5, 
111.8, 108.8, 55.5 ppm. MS (EI, 70 eV): m/z = 375 [M]+. UV/Vis (Ethanol): λmax = 384.5 nm. 
Absorption BSc4219 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
280 330 380 430 480
Wa v e l e ngt h [ nm]
 
 
2-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-6-methoxyphenol (50d) 
S
N
NH
N
HO
OBSc4220
 
Yield: 53 %. 1H-NMR (300 MHz, d6-DMSO): δ = 10.87 (s, 1H), 9.73 (s, 1H), 8.28 (s, 1H), 
8.07 (d, J = 7.8 Hz, 1H), 8.01-7.94 (m, 3H), 7.49 (td, J = 8.1 Hz, J = 1.2 Hz, 1H), 7.39 (td, J = 
8.1 Hz, J = 1.2 Hz, 1H), 7.29 (dd, J = 7.8 Hz, J = 1.5 Hz, 1H), 7.14 (d, J = 8.7 Hz, 2H), 6.95 
(dd, J = 8.1 Hz, J = 1.5 Hz, 1H), 6.84 (t, J = 7.8 Hz, 1H), 3.82 (s, 3H) ppm. 13C-NMR (75 
MHz, d6-DMSO): δ = 167.4, 153.7, 147.8, 147.3, 145.1, 137.8, 133.8, 128.8, 126.3, 124.6, 
123.2, 122.0, 120.9, 119.1, 118.2, 112.0, 111.9, 55.8 ppm. MS (EI, 70 eV): m/z = 375 [M]+. 
UV/Vis (Ethanol): λmax = 384.0 nm. 
Absorption BSc4220 (EtOH)
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-(4-(2-(3-Bromo-4-methoxybenzylidene)hydrazinyl)phenyl)benzo[d]thiazole (52e) 
S
N
NH
N
Br
OBSc4297
 
Yield: 80 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.81 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.98-
7.93 (m, 4H), 7.89 (s, 1H), 7.66 (dd, J = 8.5Hz, J = 2.0 Hz, 1H), 7.49 (td, J = 8.0Hz, J = 1.0 
Hz, 1H), 7.38 (td, J = 8.0Hz, J = 1.0 Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H), 7.17 (d, J = 8.5 Hz, 
1H), 3.89 (s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 167.5, 155.5, 153.7, 147.7, 137.2, 
133.8, 129.7, 129.4, 128. 7, 126.9, 126.3, 124.5, 123.1, 121.9, 112.7, 112.0, 111.1, 56.3 
ppm. MS (EI, 70 eV): m/z = 439 [M+2]+. UV/Vis (Ethanol): λmax = 386.0 nm. 
Absorption BSc4297 (EtOH)
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
 
2-(4-(2-(4-Fluoro-3-methoxybenzylidene)hydrazinyl)phenyl)benzo[d]thiazole (52f) 
S
N
NH
N
O
FBSc4298
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Yield: 78 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.85 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.98-
7.94 (m, 3H), 7.94 (s, 1H), 7.51-7.47 (m, 2H), 7.38 (td, J = 8.0Hz, J = 1.0 Hz, 1H), 7.27-7.21 
(m, 4H), 3.93 (s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 167.5, 153.7, 152.6, 150.7, 
147.6, 147.4, 137.9, 133.8, 132.3, 128.6, 126.3, 124.6, 123.2, 1221.0, 119.0, 116.1, 112.1, 
110.3, 55.9 ppm. MS (EI, 70 eV): m/z = 377 [M]+. UV/Vis (Ethanol): λmax = 383.5 nm. 
Absorption BSc4298 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
0.3
300 350 400 450 500
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-4-methylphenol (52g) 
S
N
NH
N
HO
BSc4299
 
Yield: 50 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.84 (s, 1H), 10.05 (s, 1H), 8.23 (s, 1H), 
8.06 (d, J = 8.0 Hz, 1H), 8.00-7.94 (m, 3H), 7.49 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.46 (d, J = 
2.0 Hz, 1H), 7.38 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.13 (d, J = 8.5 Hz, 2H), 7.02-6.98 (m, 1H), 
6.80 (d, J = 8.0 Hz, 1H), 2.25 (s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 167.4, 153.7, 
153.5, 147.3, 138.3, 133.8, 130.4, 128.8, 127.8, 126.7, 126.3, 124.6, 123.1, 120.00, 121.9, 
120.1, 115.8, 111.8, 20.0 ppm. MS (EI, 70 eV): m/z = 359 [M]+. UV/Vis (Ethanol): λmax = 
384.0 nm. 
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Absorption BSc4299 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
3-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)phenol (52h) 
S
N
NH
N
OH
BSc4300
 
Yield: 61 %. 1H-NMR (300 MHz, d6-DMSO): δ = 10.79 (s, 1H), 9.50 (s, 1H), 8.06 (d, J = 8.1 
Hz, 1H), 8.00-7.93 (m, 3H), 7.89 (s, 1H), 7.49 (td, J = 8.1 Hz, J = 1.2 Hz, 1H), 7.38 (td, J = 
7.8 Hz, J = 1.2 Hz, 1H), 7.25-7.14 (m, 4H), 7.09 (d, J = 7.8 Hz, 1H), 6.78-6.72 (m, 1H) ppm. 
13C-NMR (75 MHz, d6-DMSO): δ = 167.5, 157.5, 153.7, 147.7, 139.0, 136.5, 133.8, 129.6, 
128.7, 126.3, 124.6, 123.1, 122.0, 117.5, 115.8, 112.0, 111.8 ppm. MS (EI, 70 eV): m/z = 
345 [M]+. UV/Vis (Ethanol): λmax = 385.0 nm. 
Absorption BSc4300 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
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2-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-5-(diethylamino)phenol (52i) 
S
N
NH
N
N
HO
BSc4301
 
Yield: 81 %. 1H-NMR (300 MHz, d6-DMSO): δ = 10.54 (s, 1H), 10.44 (s, 1H), 8.10 (s, 1H), 
8.06 (d, J = 8.1 Hz, 1H), 7.95 (d, J = 8.7 Hz, 3H), 7.49 (td, J = 8.1 Hz, J = 1.2 Hz, 1H), 7.38 
(td, J = 8.1 Hz, J = 1.2 Hz, 1H), 7.29 (d, J = 8.7 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 6.27 (dd, J 
= 8.7 Hz, J = 2.4 Hz, 1H), 6.15 (d, J = 2.4 Hz, 1H), 3.42-3.27 (m, 4H), 1.11 (t, J = 7.2 Hz, 6H) 
ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 167.5, 157.8, 153.8, 149.1, 147.4, 141.7, 133.8, 
129.3, 128. 8, 126.2, 124.5, 122.3, 121.9, 111.2, 107.7, 103.7, 97.5, 43.7, 12.5 ppm. MS (EI, 
70 eV): m/z = 416 [M]+. UV/Vis (Ethanol): λmax = 405.0 nm. 
Absorption BSc4301 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
250 300 350 400 450 500
Wa v e le ngt h [ nm]
 
 
2-(4-(2-(3,5-Difluorobenzylidene)hydrazinyl)phenyl)benzo[d]thiazole (52j) 
S
N
NH
N
F
F
BSc4302
 
Yield: 80 %. 1H-NMR (300 MHz, d6-DMSO): δ = 11.10 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.02-
7.95 (m, 3H), 7.93 (s, 1H), 7.50 (td, J = 8.4 Hz, J = 1.2 Hz, 1H), 7.45-7.35 (m, 3H), 7.27 (d, J 
= 9.0 Hz, 2H), 7.17 (m, 1H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 167.7, 164.3 (d, J = 
13.4 Hz), 161.0(d, J = 13.6 Hz), 153.7, 147.2, 139.2 (t, J = 9.9 Hz), 136.0, 133.9, 128.6, 
126.3, 124.7, 123.9, 122.0 (d, J = 7.1 Hz), 112.5, 108.5 (d, J = 25.8 Hz), 103.26 (t, J = 26.1 
Hz) ppm. MS (EI, 70 eV): m/z = 365 [M]+. UV/Vis (Ethanol): λmax = 385.0 nm. 
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Absorption BSc4302 (EtOH)
0
0.2
0.4
0.6
0.8
1
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
 
2-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)phenol (52k) 
S
N
NH
N
HO
BSc4303
 
Yield: 68 %. 1H-NMR (300 MHz, d6-DMSO): δ = 10.87 (s, 1H), 10.28 (s, 1H), 8.27 (s, 1H), 
8.07 (d, J = 7.8 Hz, 1H), 8.02-7.93 (m, 3H), 7.66 (dd, J = 7.8 Hz, J = 1.5 Hz, 1H), 7.49 (td, J 
= 8.1 Hz, J = 1.2 Hz, 1H), 7.38 (td, J = 8.1 Hz, J = 1.2 Hz, 1H), 7.24-7.11 (m, 3H), 6.93-6.85 
(m, 2H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 167.4, 155.6, 153.7, 147.3, 138.1, 133.8, 
129.7, 128.8, 126.7, 126.3, 124.6, 123.2, 122.0, 121.9, 120.5, 119.4, 115.9, 111.8 ppm. MS 
(EI, 70 eV): m/z = 345 [M]+. UV/Vis (Ethanol): λmax = 384.5 nm. 
Absorption BSc4303 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
 
4-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-2,6-difluorophenol (52l) 
S
N
NH
N
F
F
OHBSc4304
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Yield: 61 %. 1H-NMR (300 MHz, d6-DMSO): δ = 10.87 (s, 1H), 10.47 (s, 1H), 8.07 (d, J = 7.2 
Hz, 1H), 7.99-7.92 (m, 3H), 7.84 (s, 1H), 7.50 (td, J = 8.4 Hz, J = 1.5 Hz, 1H), 7.42-7.34 (m, 
3H), 7.21 (d, J = 8.7 Hz, 2H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 167.5, 154.0 (d, J = 7.5 
Hz), 153.7, 150.8, 147.6, 136.8, 133.9 (d, J = 16.4 Hz), 133.8, 128.7, 126.3 (d, J = 8.6 Hz), 
124.6, 123.2, 122.0 (d, J = 2.4 Hz), 109.3, 109.2 ppm. MS (EI): m/z = 381 [M]+. UV/Vis 
(Ethanol): λmax = 386.0 nm. 
Absorption BSc4304 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
280 300 320 340 360 380 400 420 440
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-(4-(2-((1H-Indol-3-yl)methylene)hydrazinyl)phenyl)benzo[d]thiazole (52m)  
S
N
NH
N
N
HBSc4330
 
Yield: 52 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.43 (s, 1H), 10.44 (s, 1H), 8.30-8.25 (m, 
1H), 8.22 (s, 1H), 8.06 (d, J = 8.0, 1H), 7.97 (d, J = 9.0, 2H), 7.94 (d, J = 8.0, 1H), 7.72 (d, J 
= 2.0 Hz, 1H), 7.52-7.34 (m, 3H), 7.25-7.14 (m, 4H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ 
= 167.8, 153.9, 148.4, 146.2, 137.3, 137.0, 133.8, 128.9, 128.4, 126.3, 124.5, 124.2, 122.4, 
121.9, 121.9, 121.6, 120.2, 112.4, 111.8, 111.4 ppm. MS (EI, 70 eV): m/z = 368 [M]+. UV/Vis 
(Ethanol): λmax = 398.0 nm. 
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Absorption BSc4330 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
0.3
300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-(4-(2-((1-Methyl-1H-indol-3-yl)methylene)hydrazinyl)phenyl)benzo[d]thiazole (52n) 
S
N
NH
N
N
BSc4331
 
Yield: 48 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.45 (s, 1H), 8.29 (d, J = 7.5, 1H), 8.19 (s, 
1H), 8.05 (d, J = 7.5, 1H), 7.97 (d, J = 8.5, 2H), 7.94 (d, J = 8.0, 1H), 7.71 (s, 1H), 7.52-7.45 
(m, 2H), 7.37 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.28 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.24 (td, J 
= 8.0 Hz, J = 1.0 Hz, 1H), 7.17 (d, J = 8.5 Hz, 2H), 3.82 (s, 3H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 167.7, 153.8, 148.3, 137.4, 136.6, 133.7, 130.0, 128.8, 126.2, 124.5, 124.4, 
122.4, 121.9, 121.9, 121.8, 121.7, 120.4, 111.3, 110.0, 32.6 ppm. MS (EI, 70 eV): m/z = 382 
[M]+. UV/Vis (Ethanol): λmax = 397.0 nm. 
Absorption BSc4331 (EtOH)
0
0.05
0.1
0.15
300 350 400 450 500
Wa v e l e ngt h [ nm]
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2-(4-(2-(4-(Methylthio)benzylidene)hydrazinyl)phenyl)benzo[d]thiazole (52o) 
S
N
NH
N
SBSc4332
 
Yield: 71 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.96 (s, 1H), 8.06 (d, J = 7.5, 1H), 7.98-
7.93 (m, 4H), 7.63 (d, J = 8.5, 2H), 7.49 (td, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.38 (td, J = 8.5 Hz, 
J = 1.5 Hz, 1H),  7.29 (d, J = 8.5 Hz, 2H), 7.21 (d, J = 9.0 Hz, 2H), 2.51 (s, 3H) ppm. 13C-
NMR (125 MHz, d6-DMSO): δ = 167.5, 153.7, 147.7, 138.6, 138.4, 133.8, 131.9, 128.6, 
126.3, 126.3, 125.8, 124.5, 123.0, 121.9, 112.0, 14.4 ppm. MS (EI, 70 eV): m/z = 375 [M]+. 
UV/Vis (Ethanol): λmax = 393.5 nm. 
Absorption BSc4332 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
300 350 400 450 500
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-(4-(2-((1-Methyl-1H-pyrrol-2-yl)methylene)hydrazinyl)phenyl)benzo[d]thiazole (52p) 
S
N
NH
N
N
BSc4333
 
Yield: 44 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.49 (s, 1H), 8.04 (d, J = 8.0, 1H), 7.96-
7.90 (m, 4H), 7.48 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.37 (td, J = 8.0 Hz, J = 1.0 Hz, 1H),  7.09 
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(d, J = 8.5 Hz, 2H), 6.90 (t, J = 2.0 Hz, 1H), 6.40-6.37 (m, 1H), 6.08-6.06 (m, 1H), 3.90 (s, 
3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 167.6, 153.8, 148.0, 133.8, 133.2, 128.7, 
126.7, 124.4, 122.3, 121.9, 112.5, 111.6, 107.8, 36.2 ppm. MS (EI, 70 eV): m/z = 332 [M]+. 
UV/Vis (Ethanol): λmax = 396.0 nm. 
Absorption BSc4333 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
0.3
300 350 400 450 500 550
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-(4-(2-((5-Bromothiophen-2-yl)methylene)hydrazinyl)phenyl)benzo[d]thiazole (52q) 
S
N
NH
N
S
BrBSc4334
 
Yield: 73 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.04 (s, 1H), 8.10 (s, 1H), 8.06 (d, J = 7.5 
Hz, 1H), 7.96 (d, J = 8.5, 3H), 7.49 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.38 (td, J = 8.0 Hz, J = 
1.0 Hz, 1H),  7.20 (d, J = 4.0 Hz, 1H), 7.15-7.11 (m, 3H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 167.4, 153.7, 147.1, 142.2, 133.8, 133.3, 131.0, 128.7, 127.9, 126.3, 124.6, 
123.4, 122.0, 121.9, 112.1, 111.9 ppm. MS (EI, 70 eV): m/z = 415 [M+2]+. UV/Vis (Ethanol): 
λmax = 398.5 nm. 
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Absorption BSc4334 (EtOH)
0
0.2
0.4
0.6
0.8
1
300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-(4-(2-(2,2'-Bithiophen-5-ylmethylene)hydrazinyl)phenyl)benzo[d]thiazole (52r) 
S
N
NH
N
S
S
BSc4335
 
Yield: 66 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.14 (s, 1H), 8.17 (s, 1H), 8.06 (d, J = 8.0 
Hz, 1H), 7.99-7.94 (m, 3H), 7.54 (dd, J = 5.0 Hz, J = 1.0 Hz, 1H), 7.49 (td, J = 8.0 Hz, J = 1.0 
Hz, 1H),  7.40-7.36 (m, 2H), 7.26 (d, J = 4.0 Hz, 1H), 7.24 (d, J = 4.0 Hz, 1H), 7.17 (d, J = 9.0 
Hz, 2H), 7.13-7.10 (m, 1H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 167.5, 153.7, 147.2, 
139.1, 136.4, 136.3, 133.8, 128.7, 128.6, 128.4, 126.3, 125.7, 124.6, 124.3, 124.2, 123.3, 
120.0, 121.9, 112.0 ppm. MS (EI, 70 eV): m/z = 417 [M]+. UV/Vis (Ethanol): λmax = 420.5 nm. 
Absorption BSc4335 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
300 350 400 450 500 550
Wa v e le ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4-((2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)methyl)-5-(hydroxymethyl)-2-
methylpyridin-3-ol (52s) 
S
N
NH
N
N
HO
HO
BSc4336
 
Yield: 75 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.42 (s, 1H), 11.26 (s, 1H), 8.52 (s, 1H), 
8.09 (d, J = 7.5 Hz, 1H), 8.05 (d, J = 9.0 Hz, 2H), 7.99 (d, J = 7.5 Hz, 1H), 7.96 (s, 1H), 7.50 
(td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.40 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.12 (d, J = 9.0 Hz, 2H), 
5.34 (t, J = 5.5 Hz, 1H), 4.63 (d, J = 5.5 Hz, 2H), 2.44 (s, 3H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 167.1, 153.7, 149.2, 146.4, 145.8, 139.0, 138.4, 133.9, 131.3, 129.0, 126.3, 
124.8, 124.5, 122.1, 122.0, 121.3, 112.2, 59.0, 18.8 ppm. MS (EI, 70 eV): m/z = 390 [M]+. 
UV/Vis (Ethanol): λmax = 394.0 nm. 
Absorption BSc4336 (EtOH)
0
0.1
0.2
0.3
0.4
300 320 340 360 380 400 420 440 460 480 500
Wa v e l e ngt h [ nm]
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2-(4-(2-(Pyridin-3-ylmethylene)hydrazinyl)phenyl)benzo[d]thiazole (52t) 
S
N
NH
N
NBSc4337
 
Yield: 78 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.06 (s, 1H), 8.85 (d, J = 2.0 Hz, 1H), 8.51 
(dd, J = 5.0 Hz, J = 2.0 Hz, 1H), 8.12 (dt, J = 8.0 Hz, J = 2.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 
1H), 8.00-7.95 (m, 4H), 7.50 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.46-7.42 (m, 1H), 7.39 (td, J = 
8.0 Hz, J = 1.0 Hz, 1H), 7.25 (d, J = 8.5 Hz, 2H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 
167.4, 153.7, 149.0, 147.6, 147.3, 135.6, 133.8, 132.2, 131.1, 128.7, 126.3, 124.6, 123.7, 
123.6, 122.0, 121.9, 112.3 ppm. MS (EI, 70 eV): m/z = 330 [M]+. UV/Vis (Ethanol): λmax = 
387.0 nm. 
Absorption BSc4337 (EtOH)
0
0.2
0.4
0.6
0.8
1
300 320 340 360 380 400 420 440 460 480 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
2-(4-(2-((9-Methyl-9H-carbazol-3-yl)methylene)hydrazinyl)phenyl)benzo[d]thiazole (52u) 
NH
N
S
BSc4342
N
N
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Yield: 67 %. 1H-NMR (500 MHz, d6-DMSO): δ= 10.86 (s, 1H), 8.43 (s, 1H), 8.24 (d, J = 8.0 
Hz, 1H), 8.18 (s, 1H),  8.07 (d, J = 8.0 Hz, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.96 (d, J = 8.0 Hz, 
1H), 7.92 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 
7.52-7.47 (m, 2H), 7.38 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.28-7.23 (m, 3H), 3.91 (s, 3H) ppm. 
13C-NMR (125 MHz, d6-DMSO): δ= 167.6, 153.8, 148.1, 140.9, 140.8, 140.4, 133.8, 128.7, 
126.4, 126.2, 125.9, 124.5, 123.8, 123.7, 122.5, 122.1, 121.9, 121.5, 120.4, 119.4, 118.7, 
111.8, 109.5, 109.3, 29.0 ppm. MS (EI, 70 eV): m/z = 432 [M]+. UV/Vis (Ethanol): λmax = 
387.0 nm. 
Absorption BSc4342 (EtOH)
0
0.2
0.4
0.6
0.8
1
300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4-(3-(2-(4-(Benzo[d]thiazol-2-yl)phenyl)hydrazono)prop-1-enyl)-N,N-dimethylaniline 
(52v) 
NH
N
S
BSc4565
N
N
 
Yield: 46 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.60 (s, 1H), 8.06 (d, J = 7.5 Hz, 1H), 7.95-
7.91 (m, 3H), 7.76 (d, J = 7.5 Hz, 1H),  7.48 (td, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.42-7.35 (m, 
3H), 7.09 (d, J = 8.5 Hz, 2H), 6.80-6.76 (m, 2H), 6.70 (d, J = 9.0 Hz, 2H), 2.94 (s, 6H) ppm. 
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13C-NMR (125 MHz, d6-DMSO): δ = 167.5, 156.1, 153.7, 150.1, 142.7, 135.5, 132.8, 128.6, 
128.5, 127.7, 126.2, 125.2, 124.3, 122.6, 121.9, 121.3, 112.0, 111.7 ppm. MS (EI, 70 eV): 
m/z = 398 [M]+. UV/Vis (Ethanol): λmax = 412.5 nm. 
Absorption BSc 4565 (EtOH)
0
0.02
0.04
0.06
0.08
0.1
0.12
300 350 400 450 500 550
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
6.3.  Synthesis of imidazo[1,2-a]pyridines and imidazo[1,2-a]pyrimidines 
derivatives  
6.3.1.  General procedures for synthesis of imidazo[1,2-a]pyridines derivatives 
2-(4-Nitrophenyl)imidazo[1,2-a]pyridine (55) 
N
N
NO2
 
A mixture of 2-aminopyridine (0.94 g, 10.0 mmol, 1.0 eq) and α-bromoketone (2.44 g, 10.0 
mmol, 1.0 eq) was refluxed in ethanol (40 mL) overnight. The solvent was evaporated in 
vacuo. 5 N NaOH was added to adjust pH > 10, precipitates were filtered off and washed 
with brine and cooled ethyl acetate. The compound was dried under the high vacuum pump 
and 2.26 g of 2-(4-nitrophenyl)imidazo[1,2-a]pyridine was obtained as yellow solid. 
Yield: 95 %. 13C-NMR (125 MHz, d6-DMSO): δ = 146.4, 141.9, 140.4, 127.2, 126.2, 125.9, 
124.1, 116.9, 112.9, 111.6 ppm. MS (EI, 70 eV): m/z = 239 [M]+.   
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4-(Imidazo[1,2-a]pyridin-2-yl)aniline (56) 
N
N
NH2
BSc4485
 
To a suspension of 2-(4-nitrophenyl)imidazo[1,2-a]pyridine (2.39 g, 10 mmol, 1.0 eq) in 20 ml 
ethanol, SnCl2 (9.48 g, 50 mmol, 5.0 eq) were added. The mixture was heated to reflux 
temperature overnight. After cooling down to room temperature, the solvent was evaporated 
in vacuo. 5 N NaOH was added to adjust pH > 10. The mixture was extracted with ethyl 
acetate and washed with brine (3 x 30 mL), dried over Na2SO4. After filtration, the solution 
was evaporated to obtain 2.09 g of 4-(imidazo[1,2-a]pyridin-2-yl)aniline as yellow solid (yield: 
quant.).  
1H-NMR (500 MHz, d6-DMSO): δ = 8.43 (dt, J = 6.5 Hz, J = 1.0 Hz,  1H), 8.10 (s, 1H), 7.62 
(dt, J = 8.5 Hz, J = 2.0 Hz, 2H), 7.48 (dd, J = 9.0 Hz, J = 0.5 Hz, 1H), 7.20-7.15 (m, 1H), 6.82 
(td, J = 6.5 Hz, J = 1.0 Hz, 1H), 6.62 (dt, J = 8.5 Hz, J = 2.0 Hz, 2H), 5.22-5.17 (m, 2H) ppm. 
13C-NMR (125 MHz, d6-DMSO): δ = 148.6, 145.6, 144.7, 126.7, 126.5, 124.4, 121.6, 116.0, 
114.0, 111.9, 106.8 ppm. MS (EI, 70 eV): m/z = 209 [M]+. UV/Vis (Ethanol): λmax = 340.5 nm. 
Absorption BSc4485 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
250 300 350 400 450 500
W aveleng t h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
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2,2,2-Trifluoro-N-(4-(imidazo[1,2-a]pyridin-2-yl)phenyl)acetamide (57) 
N
N
NH
CF3
O
BSc4436
 
To a solution of 4-(imidazo[1,2-a]pyridin-2-yl)aniline (209 mg, 1 mmol, 1.0 eq) in 1 mL 
trifluoroacetic acid (TFA) was added trifluoroacetic anhydride (TFAA) (424 mg, 2.2 mmol, 2.2 
eq) under ice-bath. The resulting solution was stirred at room temperature overnight and the 
reaction mixture was added into ice-water. The residue were collected by filtration, and 
washed with brine (2 x 30 mL). The residue was purified by recrystallization to afford the 
2,2,2-trifluoro-N-(4-(imidazo[1,2-a]pyridin-2-yl)phenyl)acetamide 261 mg.   
Yield: 86 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.32 (s, 1H), 8.52 (dt, J = 7.0 Hz, J = 1.0 
Hz, 1H), 8.38 (s, 1H), 8.00 (d, J = 9.0 Hz, 2H), 7.75 (d, J = 9.0 Hz, 2H), 7.57 (dd, J = 9.0 Hz, 
J = 1.0 Hz, 1H), 7.27-7.22 (m, 1H), 6.89 (td, J = 7.0 Hz, J = 1.5 Hz, 1H) ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 154.5, 154.5, 144.8, 143.6, 135.9, 131.2, 126.8, 126.0, 124.9, 121.1, 
116.5, 112.2, 109.0 ppm. MS (EI, 70 eV): m/z = 305 [M]+. UV/Vis (Ethanol): λmax = 418.0 nm. 
Absorption BSc4436 (EtOH)
0
0.5
1
1.5
200 250 300 350 400
Wavel engt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
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4-(Imidazo[1,2-a]pyridin-2-yl)-N-(2,2,2-trifluoroethyl)aniline (58) 
N
N
NH
CF3
BSc4439
 
A solution of 2,2,2-trifluoro-N-(4-(imidazo[1,2-a]pyridin-2-yl)phenyl)acetamide (305 mg, 1 
mmol, 1.0 eq) in anhydrous THF (0.5 mL) was added dropwise to an ice-cooled suspension 
of LiAlH4 (152 mg, 4 mmol, 4.0 eq) in THF (0.5 mL). The reaction mixture was refluxed 
overnight. After cooled in ice-bath, the mixture was alkalized with 10% NaOH solution and 
extracted with ethyl acetate. The organic layer was washed with brine and dried over Na2SO4. 
After filtration, the solvent was evaporated. The residue was purified by column 
chromatography (SiO2; dichloromethane: methanol = 10:1) to furnish 276 mg of 4-
(imidazo[1,2-a]pyridin-2-yl)-N-(2,2,2-trifluoroethyl)aniline.  
Yield: 95 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.46 (dt, J = 7.0 Hz, J = 1.0 Hz, 1H), 8.17 (s, 
1H), 7.73 (d, J = 9.0 Hz, 2H), 7.50 (dd, J = 9.0 Hz, J = 0.5 Hz, 1H), 7.20-7.15 (m, 1H), 6.83 
(td, J = 7.0 Hz, J = 1.5 Hz, 1H), 6.80 (d, J = 9.0 Hz, 2H), 6.37 (t, J = 7.0 Hz, 1H), 4.00-3.91 
(m, 2H)  ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 147.2, 145.1, 144.5, 126.5, 126.4, 124.1, 
123.0, 116.0, 112.4, 111.7, 107.0, 44.1, 43.8 ppm. MS (EI, 70 eV): m/z = 291 [M]+. UV/Vis 
(Ethanol): λmax = 333.5 nm. 
Absorption BSc4439 (EtOH)
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
200 220 240 260 280 300 320 340 360 380 400
Wa v e l e ngt h [ nm]
 
 
Method A of [8+2] cycloaddition reaction 
Under the protection of inert gas, bromobenzene (15.7 mg, 0.1 mmol, 1.0 eq) was added to a 
mixture of corresponding substrates (0.1 mmol, 1.0 eq), t-BuOK (22.4 mg, 0.2 mmol, 2 eq) in 
2 ml acetonitrile. The reaction was refluxed overnight. The resulting mixture was dissolved in 
ethyl acetate and washed with brine (2 x 30 mL). The solvent was evaporated in vacuo, and 
the residue was purified by flash chromatography (SiO2; ethyl acetate: cyclohexane = 1:2) to 
obtain pure [8+2] cycloaddition products 61 and 62. 
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1-(4-(2,2,2-Trifluoroacetyl)phenyl)benzo[a]imidazo[5,1,2-cd]indolizine (61) 
 
BSc4437
N
N
NH
O
CF3
 
Yield: 45 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.53 (s, 1H), 8.70 (d, J = 8.0 Hz, 1H), 8.62 
(d, J = 8.0 Hz, 1H), 8.47-8.43 (m, 3H), 8.19 (d, J = 8.0 Hz, 1H), 8.12 (dd, J = 8.5 Hz, J = 7.5 
Hz, 1H), 8.03 (d, J = 8.5 Hz, 2H), 7.91 (td, J = 8.5 Hz, J = 1.0 Hz, 1H), 7.75 (td, J = 8.5 Hz, J 
= 1.0 Hz, 1H) ppm. MS (EI, 70 eV): m/z = 379 [M]+. UV/Vis (Ethanol): λmax = 418.0 nm. 
Absorption BSc4437 (EtOH)
-0.4
-0.2
0
0.2
200 250 300 350 400 450 500
Wa v e l e ngt h  [ nm]
 
 
1-(4-(2,2,2-Trifluoroethyl)phenyl)benzo[a]imidazo[5,1,2-cd]indolizine (62) 
BSc4441
N
N
NH
CF3
 
Yield: 41 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.66 (d, J = 8.0 Hz, 1H), 8.51 (d, J = 8.5 Hz, 
1H), 8.37 (d, J = 8.0 Hz, 1H), 8.20 (d, J = 7.5 Hz, 2H), 8.10-8.03 (m, 2H), 7.87 (td, J = 8.0 Hz, 
J = 1.0 Hz, 1H), 7.69 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.04 (d, J = 8.5 Hz, 2H), 6.77 (t, J = 7.0 
Hz, 1H), 4.12-4.01 (m, 2H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 148.6, 146.7, 139.0, 
130.2, 129.2, 129.1, 129.0, 127.7, 126.5, 124.4, 123.7, 122.7, 120.4, 118.5, 112.8, 112.0, 
109.0, 43.9, 43.6 ppm. MS (EI, 70 eV): m/z = 365 [M]+. UV/Vis (Ethanol): λmax = 425.0 nm. 
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Absorption BSc4441 (EtOH)
-0.8
-0.3
0.2
0.7
1.2
200 250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
 
Method B of [8+2] cycloaddition reaction  
Under the protection of inert gas, the benzyne precursor 2-(trimethylsilyl)phenyl 
trifluoromethane sulfonate (59.6 mg, 0.2 mmol, 2.0 eq) was added to a mixture of 
corresponding substrates (0.1 mmol, 1.0 eq), 18-crown-6 (0.11 g, 0.2 mmol, 2.0 eq) and CsF 
(30.4 mg, 0.2 mmol, 2.0 eq) in 2 ml of acetonitrile. The reaction was refluxed overnight. The 
resulting mixture was dissolved in ethyl acetate and washed with brine (2 x 30 mL). The 
solvent was evaporated in vacuo, and the residue was purified by flash chromatography 
(SiO2; ethyl acetate: cyclohexane = 1:2) to obtain the corresponding pure [8+2] cycloaddition 
product. 
1-(4-Aminophenyl)benzo[a]imidazo[5,1,2-cd]indolizine (64) 
BSc4484
N
N
NH2
 
Yield: 42 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.66 (d, J = 8.0 Hz, 1H), 8.51 (d, J = 8.5 Hz, 
1H), 8.36 (dd, J = 6.0 Hz, J = 2.0 Hz, 1H), 8.11 (d, J = 8.5 Hz, 2H), 8.07-8.01 (m, 2H), 7.87 
(td, J = 8.5 Hz, J = 1.0 Hz, 1H), 7.68 (td, J = 8.5 Hz, J = 0.5 Hz, 1H), 6.84 (d, J = 8.5 Hz, 2H), 
5.67 (s, 2H) ppm. MS (EI, 70 eV): m/z = 283 [M]+. 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
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6.3.2. General procedures for synthesis of imidazo[1,2-a]pyrimidines 
derivatives 
2-(4-Nitrophenyl)imidazo[1,2-a]pyrimidine (67) 
N
N N
NO2
 
A mixture of pyrimidin-2-amine (0.95 g, 10.0 mmol, 1.0 eq) and α-bromoketone (2.44 g, 10.0 
mmol, 1.0 eq) was refluxed in ethanol (40 mL) overnight. The solvent was evaporated in 
vacuo. 5 N NaOH was added to adjust pH > 10, Precipitates were filtered off and washed 
with brine and cooled ethyl acetate. The compound was dried under the high vacuum to 
obtain 2-(4-nitrophenyl)imidazo[1,2-a]pyrimidine as yellow solid, which was used in next step 
without further purification. 
 
4-(Imidazo[1,2-a]pyrimidin-2-yl)aniline (68) 
N
N N
NH2
 
To a suspension of 2-(4-nitrophenyl)imidazo[1,2-a]pyrimidine (2.40 g, 10 mmol, 1.0 eq) in 20 
ml ethanol, SnCl2 (9.48 g, 50 mmol, 5.0 eq) was added. The suspension was heated to reflux 
temperature overnight. After cooling down to room temperature, the solvent was evaporated 
in vacuo. 5 N NaOH was to adjusted to pH > 10, the mixture was extracted with ethyl acetate, 
washed with brine (3 x 30 mL) and dried over Na2SO4. After filtration, the solvent was 
evaporated to obtain 2.10 g of 4-(imidazo[1,2-a]pyridin-2-yl)aniline as yellow solid (yield: 
quant.).  
1H-NMR (500 MHz, d6-DMSO): δ = 8.87 (dd, J = 6.5 Hz, J = 2.0 Hz,  1H), 8.42 (dd, J = 4.0 
Hz, J = 2.0 Hz, 1H), 8.09 (s, 1H), 7.68 (d, J = 9.0 Hz, 2H), 6.97 (dd, J = 6.5 Hz, J = 4.0 Hz, 
1H), 6.65 (d, J = 8.5 Hz, 2H), 5.33 (s, 2H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 149.1, 
148.9, 147.8, 146.7, 134.1, 126.7, 120.8, 113.7, 108.2, 104.8 ppm.  
 
A solution of NaNO2 (76 mg, 1.1 mmol, 1.0 eq) in water (1 mL) was added to an ice-cold 
mixture of 4-(imidazo[1,2-a]pyridin-2-yl)aniline (210 mg, 1.0 mmol, 1.0 eq) in 6 N HCl (1mL), 
and the temperature was controlled to stay below 5 °C. The reaction was stirred for 5 min 
and added slowly to a solution of SnCl2·2H2O in HCl (conc., 0.5mL) at -5 °C. The reaction 
mixture was stirred at room temperature for 1 h. 9-Methyl-9H-carbazole-3-carbaldehyde (209 
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mg, 1 mmol, 1.0 eq) was dissolved in 30 ml THF and added to the reaction. The reaction 
mixture was stirred and refluxed for 2 hours. When it was cooled, the mixture was extracted 
with THF twice. The organic phase was dried over Na2SO4, filtered, and concentrated. The 
residue was purified by column chromatography (SiO2; dichloromethane: methanol = 20:1) to 
furnish 162 mg of product as yellow-green solid. 
3-((2-(4-(Imidazo[1,2-a]pyrimidin-2-yl)phenyl)hydrazono)methyl)-9-methyl-9H-carbazole 
(70) 
BSc4456
N
N N
NH
N
N
 
Yield: 41 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.40 (s, 1H), 8.92 (dd, J = 7.5 Hz, J = 2.0 
Hz, 1H), 8.47 (dd, J = 4.0 Hz, J = 2.0 Hz, 1H), 8.40 (d, J = 1.5 Hz, 1H), 8.24(d, J = 8.0 Hz, 
1H), 8.21 (s, 1H), 8.10 (s, 1H), 7.92-7.87 (m, 3H), 7.63 (d, J = 9.0 Hz, 1H), 7.60 (d, J = 8.5 
Hz, 1H), 7.49 (td, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.26-7.19 (m, 3H), 7.01 (dd, J = 7.5 Hz, J = 4.0 
Hz, 1H), 3.90 (s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 149.2, 147.9, 146.2, 145.7, 
140.9, 140.6, 138.6, 134.3, 126.8, 126.8, 125.8, 123.5, 123.3, 122.1, 121.9, 120.4, 118.9, 
118.3, 111.8, 109.4, 109.2, 108.4, 105.5, 29.0 ppm. MS (EI, 70 eV): m/z = 416 [M]+. UV/Vis 
(Ethanol): λmax = 397.0 nm. 
Absorption BSc4456 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
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6.4.  Synthesis of tetrazine derivatives  
Triaminoguanidine monohydrochloride (72) 
H2NHN NHNH2
NNH2HCl
 
To a suspension of guanidine monohydrochloride (9.55 g, 100 mmol, 1.0 eq) in 1,4-dioxane 
(50 mL) was added hydrazine monohydrate (15.5 g, 310 mmol, 3.1 eq) slowly. The reaction 
mixture was heated to reflux for 2 hours during which colorless precipitates formed. When 
the reaction mixture was cooled down to room temperature, the solid was collected by 
suction filtration, washed with 1,4-dioxane and dried under high vacuum overnight to afford 
13.57 g of title compound as a colorless solid (yield: 97 %). 
 
3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,4-dihydro-1,2,4,5-tetrazine (73) 
N
N
H
N
H
NN
N
N
N
 
To slurry of triaminoguanidine monohydrochloride (7.03 g, 50.0 mmol, 1.0 eq) in 50 ml 
distilled water was added acetylacetone (10.00 g, 100.0 mmol, 2.0 eq). The reaction mixture 
was stirred at room temperature for 30 minutes. The solution turned to pale yellow then to a 
clear orange, followed by precipitate formation. The reaction mixture was then heated up to 
70 oC for 4 hours till the orange precipitates formed. The reaction was cooled down to the 
room temperature. The solid was filtered off, washed with water and dried under the high 
vacuum to give 6.04 g of pure product as a yellow solid. 
Yield: 89 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.84 (s, 2H), 8.15 (s, 2H), 2.40 (s, 6H), 2.17 
(s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 149.3, 145.2, 141.6, 109.3, 13.2, 12.8 ppm. 
MS (EI, 70 eV): m/z = 272 [M]+. 
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3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (74) 
N
N
N
NN
N
N
N
BSc4338
 
3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (2.72 g, 10 mmol, 1.0 eq) was 
suspended in the 5 % solution of NaNO2 (40 mL, 2.9 eq) and dichloromethane (4 mL). The 
mixture was placed in the ice bath, and acetic acid (1.5 mL) was added to the mixture. The 
mixture was stirred overnight. The mixture was extracted with dichloromethane, washed with 
base and brine, dried over Na2SO4. After filtration, the solvent was evaporated in vacuo. The 
residue was washed with diethyl ether to give 2.17g of product as a pink solid. 
Yield: 80 %. 1H-NMR (300 MHz, CDCl3): δ = 6.18 (s, 2H), 2.70 (s, 6H), 2.38 (s, 6H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 159.4, 154.6, 143.9, 112.0, 14.8, 14.0 ppm. MS (EI, 70 eV): 
m/z = 270 [M]+. UV/Vis (Ethanol): λmax = 303.5 nm. 
Absorption BSc4338 (EtOH)
0
0.5
1
1.5
2
2.5
250 270 290 310 330 350 370 390 410 430 450
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
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General procedure for nucleophilic substitution 
A mixture of 3,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (270 mg, 1.0 mmol), and 
corresponding aldehyde (2.0 mmol) was refluxed in MeCN (3 mL) for 16 h or under 
microwave condition for 1 h. The solvent was removed in vacuo and the residue was purified 
by recrystallization to obtain corresponding tetrazine compounds 75a-c. 
N1-(6-(3,5-Dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-yl)-N4,N4-dimethylbenzene-1,4-
diamine (75a) 
N
N
N
NN
N
H
N
N
BSc4339
 
Yield: 92 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.66 (s, 1H), 7.52 (d, J = 9.0 Hz, 2H), 6.78 
(d, J = 9.0 Hz, 2H), 6.20 (s, 1H), 2.89 (s, 6H), 2.52 (s, 3H), 2.23 (s, 3H) ppm. 13C-NMR (125 
MHz, d6-DMSO): δ =  160.3, 156.6, 150.1, 147.4, 141.3, 127.2, 121.7, 112.6, 108.5, 40.3, 
13.24, 12.3 ppm. MS (EI, 70 eV): m/z = 310 [M]+. UV/Vis (Ethanol): λmax = 325.5 nm. 
Absorption BSc4339 (EtOH)
0
0.5
1
1.5
2
220 270 320 370 420 470
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
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6-(3,5-Dimethyl-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-1,2,4,5-tetrazin-3-amine (75b) 
N
N
N
NN
N
H
N
O
BSc4340
 
Yield: 96 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.81 (s, 1H), 7.64 (d, J = 9.0 Hz, 2H), 6.99 
(d, J = 9.0 Hz, 2H), 6.21 (s, 1H), 3.76 (s, 3H), 2.44 (s, 3H), 2.24 (s, 3H) ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 160.4, 156.9, 155.7, 150.3, 141.5, 131.0, 121.8, 114.1, 108.8, 53.7, 
13.4, 12.5 ppm. MS (EI, 70 eV): m/z = 397 [M]+. UV/Vis (Ethanol): λmax = 315.5 nm. 
Absorption BSc4340 (EtOH)
0
0.5
1
1.5
2
2.5
3
250 300 350 400 450 500
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
N-(4-(Benzo[d]thiazol-2-yl)phenyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-
amine (75c) 
N
N
N
NN
N
H
N
N
S
BSc4341
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Yield: 34 %. 1H-NMR (500 MHz, d6-DMSO): δ = 10.45 (s, 1H), 8.18-8.11 (m, 3H), 8.04 (d, J 
= 8.0 Hz, 1H), 7.99 (d, J = 8.5 Hz, 2H), 7.54 (td, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.45 (td, J = 8.5 
Hz, J = 1.5 Hz, 1H), 6.26 (s, 1H), 2.50 (s, 3H), 2.26 (s, 3H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 166.9, 160.4, 157.1, 153.7, 150.8, 141.9, 141.3, 134.3, 128.2, 127.5, 126.6, 
125.3, 122.6, 122.3, 119.6, 109.3, 13.4, 12.8 ppm. MS (EI, 70 eV): m/z = 400 [M]+. UV/Vis 
(Ethanol): λmax = 344.5 nm. 
Absorption BSc4341 (EtOH)
0
0.5
1
1.5
2
2.5
3
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
female, 89 years old; CERAD Score: 3; NFTs-level: V. 
 
 
6.5.  Synthesis of bisstyryl derivatives  
6.5.1.  Synthesis of 1,4-bisstyryl-2-methoxybenzene derivatives 
5-(Dimethylamino)thiophene-2-carbaldehyde (82) 
CHOS
N
 
A mixture of 5-bromothiophene-2-carbaldehyde (191 mg, 1.0 mmol, 1.0 eq), 30 % 
dimethylamine solution (750 mg, 5.0 mmol, 5.0 eq) and potassium carbonate (414 mg, 3.0 
mmol, 3.0 eq) was stirred for 1 h at 120 °C under microwave irradiation. Reaction mixture 
was cooled down to room temperature, the residue was purified by column chromatography 
(SiO2; ethyl acetate: cyclohexane = 1:1) to afford 0.96 g of title compound. 
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Yield: 62 %. 1H-NMR (500 MHz, d6-DMSO): δ = 9.41 (s, 1H), 7.67 (d, J = 4.5 Hz, 1H), 6.11 
(d, J = 4.5 Hz, 1H), 3.06 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 179.4, 167.4, 
141.3, 125.3, 103.4, 41.6 ppm. 
 
Tetraethyl (2-methoxy-1,4-phenylene)bis(methylene)diphosphonate  
O
(EtO)2OP
PO(OEt)2
 
To a stirred solution of 2-methoxy-1,4-dimethylbenzene (1.36 g, 10.0 mmol, 1.0 eq) in CCl4 
(30 mL) was added NBS (6.23 g, 35.0 mmol, 3.5 eq) and AIBN (0.23 g, 1.4 mmol, 0.14 eq) at 
room temperature. The reaction mixture was refluxed for 15 h. The cooled reaction mixture 
was then washed with H2O and dried over MgSO4. After removal of the solvent in vacuo, the 
residue was crystallized from cyclohexane to afford the 1,4-bis(bromomethyl)-2-
methoxybenzene, which was used in the next reaction without further purification. 
A mixture of triethyl phosphite (2.49 g, 15.0 mmol, 3.0 eq) and 1,4-bis(bromomethyl)-2-
methoxybenzene (1.47 g, 5.0 mmol, 1.0 eq) was heated to 160 °C for 6 h. The residue was 
purified by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:10) to afford the 
title compound in quantitative yield. 
1H-NMR (500 MHz, d6-DMSO): δ = 7.16 (dd, J = 7.5 Hz, J = 2.0 Hz, 1H), 6.92 (s, 1H), 6.82 
(d, J = 7.5 Hz, 1H), 4.00-3.87 (m, 8H), 3.77 (s, 3H), 3.24-3.09 (m, 4H), 1.20-1.12 (m, 12H) 
ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 156.5, 132.1, 130.5, 121.5, 118.2, 118.2, 112.3, 
61.2 (d, J = 16.5 Hz), 55.3, 32.2 (d, J = 134.8 Hz), 25.4 (d, J = 137.0 Hz), 16.1 (t, J = 3.3 Hz) 
ppm. 
 
General procedure for Wittig-Horner coupling 
The t-BuOK (168 mg, 1.5 mmol, 3.0 eq) was added to a stirred solution of tetraethyl (2-
methoxy-1,4-phenylene)bis(methylene)diphosphonate (198 mg, 0.5 mmol, 1.0 eq) in DMF (4 
mL) at room temperature. The mixture was stirred under argon for 5 min. Then 
corresponding aldehyde (1.0 mmol, 2.0 eq) was added to the mixture, and further reacted at 
room temperature overnight. The reaction was then quenched with H2O (10 mL). Precipitates 
were filtered off and purified by column chromatography (SiO2; ethyl acetate: cyclohexane = 
1:2) to afford the corresponding compound with yields of 47-63 %. 
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1,1'-(4,4'-(1E,1'E)-2,2'-(2-Methoxy-1,4-phenylene)bis(ethene-2,1-diyl)bis(4,1-
phenylene))dipyrrolidine (79a) 
O
N
N
BSc4882
 
Yield: 63 %. 1H-NMR (500 MHz, CDCl3): δ = 7.53 (d, J = 8.5 Hz, 1H), 7.42 (t, J = 8.5 Hz, 
4H), 7.25 (d, J = 16.5 Hz, 1H), 7.09-6.97 (m, 4H), 6.87 (d, J = 16.5 Hz,  1H), 6.59-6.52 (m, 
4H), 3.94 (s, 3H), 3.36-3.28 (m, 8H), 2.05-1.98 (m, 8H) ppm. 13C-NMR (125 MHz, CDCl3): δ 
= 156.7, 147.5, 137.8, 128.8, 128.5, 127.7, 127.7, 126.0, 125.8, 123.7, 118.9, 118.2, 111.8, 
108.2, 55.6, 47.6, 25.5 ppm. MS (EI, 70 eV): m/z = 450 [M]+. UV/Vis (Ethanol): λmax = 
407.0 nm. 
Absorption BSc4482 (EtOH)
0
0.02
0.04
0.06
0.08
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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4,4'-(4,4'-(1E,1'E)-2,2'-(2-Methoxy-1,4-phenylene)bis(ethene-2,1-diyl)bis(4,1-
phenylene))bis(1-methylpiperazine) (79b) 
O
N
N
BSc4883
N
N
 
Yield: 47 %. 1H-NMR (500 MHz, CDCl3): δ= 7.54 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 8.0 Hz, 4H), 
7.32 (d, J = 16 Hz, 1H), 7.10-6.88 (m, 9H), 3.93 (s, 3H), 3.29-3.23 (m, 8H), 2.60 (t, J = 5.0 
Hz, 8H), 2.37 (s, 6H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 156.8, 150.6, 150.4, 137.8, 
129.6, 128.7, 128.4, 128.1, 127.4, 126.1, 126.0, 125.8, 120.3, 119.1, 115.8, 115.7, 108.4, 
55.6, 55.0, 48.7, 48.6, 46.1, 45.8, 8.8 ppm. MS (EI, 70 eV): m/z = 508 [M]+. UV/Vis 
(Ethanol): λmax = 388.0 nm. 
Absorption BSc4483 (EtOH)
0
0.1
0.2
0.3
300 350 400 450 500
W aveleng t h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
5,5'-(1E,1'E)-2,2'-(2-Methoxy-1,4-phenylene)bis(ethene-2,1-diyl)bis(N,N-
dimethylthiophen-2-amine) (83) 
O
S
S
N
N
BSc4979
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Yield: 53 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.45 (d, J = 8.5 Hz, 1H), 7.27 (d, J = 16.0 
Hz, 1H), 7.20 (d, J = 16.0 Hz, 1H), 7.06 (d, J = 1.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.83 (d, 
J = 4.0 Hz, 1H), 6.78 (d, J = 4.0 Hz, 1H), 6.68 (d, J = 16.0 Hz, 1H), 6.45 (d, J = 16.0 Hz, 1H), 
5.82 (d, J = 4.0 Hz, 1H), 5.79 (d, J = 4.0 Hz, 1H), 3.87 (s, 3H), 2.91 (s, 6H), 2.90 (s, 6H) ppm. 
13C-NMR (125 MHz, d6-DMSO): δ = 158.1, 157.8, 155.8, 136.9, 128.3, 127.9, 127.5, 126.6, 
125.0, 124.1, 122.6, 122.5, 121.5, 118.2, 115.8, 107.8, 102.0, 102.0, 55.3, 42.0, 41.9 ppm. 
UV/Vis (Ethanol): λmax = 434.0 nm. 
Absorption BSc4979 (EtOH)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
6.5.2. Synthesis of 1,4-bisstyryl-2-bromobenzene and 1,4-bisstyryl-2,5-
dibromobenzene derivatives 
6.5.2.1. Synthesis of 1,4-bisstyryl-2-bromobenzene derivative 
2,2'-(1E,1'E)-2,2'-(2-Bromo-1,4-phenylene)bis(ethene-2,1-diyl)bis(1-methyl-1H-pyrrole) 
(88) 
Br
N
N
BSc4575
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The t-BuOK (168 mg, 1.5 mmol, 3.0 eq) was added to a stirred solution of tetraethyl (2-
bromo-1,4-phenylene)bis(methylene)diphosphonate (229 mg, 0.5 mmol, 1.0 eq) in DMF (4 
mL) at room temperature. The mixture was stirred for 5 min under argon. Then 1-methyl-1H-
pyrrole-2-carbaldehyde (109 mg, 1.0 mmol, 2.0 eq) was added to the mixture, which was 
further stirred at room temperature overnight. The reaction was then quenched with H2O (10 
mL). Precipitates were filtered off and purified by column chromatography (SiO2; 
dichloromethane: methanol = 10:1) to afford the title compound 96 mg. 
Yield: 52 %. 1H-NMR (500 MHz, CDCl3): δ = 7.66 (d, J = 1.5 Hz, 1H), 7.55 (d, J = 8.0 Hz, 
1H), 7.33 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H), 7.19 (d, J = 16.0 Hz, 1H), 6.93 (t, J = 15.5 Hz, 2H), 
6.76 (d, J = 16.0 Hz, 1H), 6.68-6.64 (m, 2H), 6.56 (dd, J = 4.0 Hz, J = 1.5 Hz, 1H), 6.51 (dd, J 
= 4.0 Hz, J = 1.5 Hz, 1H), 6.19-6.15 (m, 2H), 3.72 (s, 3H), 3.71 (s, 3H) ppm. 13C-NMR (125 
MHz, CDCl3): δ = 138.1, 125.7, 131.9, 131.7, 130.0, 125.8, 125.1, 124.3, 124.1, 124.0, 
123.8, 119.1, 117.8, 108.5, 108.1, 107.3, 34.4, 34.2 ppm. UV/Vis (Ethanol): λmax = 395.0 nm. 
Absorption BSc4575 (EtOH)
0
0.1
0.2
0.3
0.4
300 320 340 360 380 400 420 440 460 480 500
Wa v e le ngt h [ nm]
 
 
6.5.2.2. Synthesis of 1,4-bisstyryl-2,5-dibromobenzene derivatives 
Tetraethyl (2,5-dibromo-1,4-phenylene)bis(methylene)diphosphonate (91) 
Br
Br
(EtO)2OP
PO(OEt)2
 
To a stirred solution of 1,4-dibromo-2,5-dimethylbenzene (2.64 g, 10.0 mmol, 1.0 eq) in 
CHCl3 (30 mL) was added NBS (6.23 g, 35.0 mmol, 3.5 eq) and AIBN (0.23 g, 1.4 mmol, 
0.14 eq) at room temperature. The reaction mixture was refluxed for 15 h. The cooled 
reaction mixture was then washed with H2O and dried over MgSO4. After removal of the 
solvent in vacuo, the residue was crystallized from cyclohexane to afford the 1,4-dibromo-
2,5-bis(bromomethyl)benzene, which was used in the next reaction without further 
purification. 
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A mixture of triethyl phosphite (2.49 g, 15.0 mmol, 3.0 eq) and 1,4-dibromo-2,5-
bis(bromomethyl)benzene (2.11 g, 5.0 mmol, 1.0 eq) was heated to 160 °C for 6 h. The 
residue was purified by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:10) to 
afford 2.11 g of title compound. 
Yield: 79 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.65 (d, J = 2.0 Hz, 2H), 4.01-3.94 (m, 8H), 
3.39 (d, J = 20.5 Hz, 4H), 1.18 (t, J = 7.0 Hz, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 
134.9, 132.7, 122.8, 61.6, 31.7(d, J = 135.8 Hz), 16.0 ppm. MS (EI, 70 eV): m/z = 535 
[M+1]+. 
 
General procedure for Wittig-Horner coupling 
The t-BuOK (168 mg, 1.5 mmol, 3.0 eq) was added to a stirred solution of tetraethyl (2,5-
dibromo-1,4-phenylene)bis(methylene)diphosphonate (268 mg, 0.5 mmol, 1.0 eq) in DMF (4 
mL) at room temperature. The mixture was stirred for 5 min under argon. Then the 
corresponding aldehyde (1.0 mmol, 2.0 eq) was added to the mixture, which was further 
stirred at room temperature overnight. The reaction was then quenched with H2O (10 mL), 
and the precipitates were filtered off, the residue was purified by column chromatography 
(SiO2; dichloromethane: methanol = 10:1) to afford the 92a-c in moderate yields. 
6.5.2.3. Synthesis of 1,4-bisstyryl-2,5-dibromobenzene derivatives 
2,2'-(1E,1'E)-2,2'-(2,5-Dibromo-1,4-phenylene)bis(ethene-2,1-diyl)bis(1-methyl-1H-
pyrrole) (92a) 
Br
BrN
N
BSc4568
 
Yield: 45 %. 1H-NMR (500 MHz, CDCl3): δ = 7.78 (s, 2H), 7.09 (d, J = 16 Hz, 2H), 6.90 (d, J 
= 15.5 Hz, 2H), 6.68 (s, 2H), 6.58 (d, J = 3.0 Hz, 2H), 6.18 (t, J = 3.0 Hz, 2H), 3.74 (s, 6H) 
ppm. 13C-NMR (125 MHz, CDCl3): δ = 137.1, 131.5, 129.4, 124.7, 122.6, 122.5, 120.1, 
108.7, 108.5, 34.4 ppm. UV/Vis (Ethanol): λmax = 401.0 nm. 
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Absorption BSc4568 (EtOH)]
0
0.05
0.1
0.15
0.2
300 320 340 360 380 400 420 440 460 480 500
Wa v e l e ngt h [ nm]
 
 
4,4'-(1E,1'E)-2,2'-(2,5-Dibromo-1,4-phenylene)bis(ethene-2,1-diyl)bis(N,N-diethylaniline) 
(92b) 
N
N
Br
Br
BSc4576
 
Yield: 37 %. 1H-NMR (500 MHz, CDCl3): δ = 7.82 (s, 2H), 7.42 (d, J = 9.0 Hz, 4H), 7.12 (d, J 
= 16.0 Hz, 2H), 6.96 (d, J = 16.0 Hz, 2H), 6.67 (d, J = 9.0 Hz, 4H), 3.43-3.36 (m, 8H), 1.19 (t, 
J = 7.0 Hz, 12H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 147.9, 137.1, 131.8, 129.5, 128.4, 
124.1, 122.5, 120.7, 111.6, 44.4, 12.7 ppm. UV/Vis (Ethanol): λmax = 422.0 nm. 
Absorption BSc4576 (EtOH)
0
0.02
0.04
0.06
0.08
0.1
0.12
300 350 400 450 500 550 600
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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3,3'-(1E,1'E)-2,2'-(2,5-Dibromo-1,4-phenylene)bis(ethene-2,1-diyl)dipyridine (92c) 
N
N
Br
Br
BSc4583
 
Yield: 52 %. 1H-NMR (500 MHz, CDCl3): δ = 8.76 (d, J = 2.0 Hz, 2H), 8.55 (dd, J = 4.5 Hz, J 
= 1.5 Hz, 2H), 7.91-7.87 (m, 4H), 7.43 (d, J = 16.0 Hz, 2H), 7.33 (dd, J = 8.0 Hz, J = 5.0 Hz, 
2H), 7.05 (d, J = 16.0 Hz, 2H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 149.4, 148.9, 137.3, 
133.1, 132.2, 130.6, 128.8, 127.8, 123.7, 123.2 ppm. UV/Vis (Ethanol): λmax = 350.0 nm. 
Absorption BSc4583 (EtOH)
0
0.2
0.4
0.6
0.8
1
280 300 320 340 360 380 400 420
Wa v e l e ngt h [ nm]
 
 
6.5.2.4. Synthesis of amides via palladium-catalyzed amidation of aryl bromides 
N1,N4-Di-tert-butyl-2,5-bis((E)-2-(1-methyl-1H-pyrrol-2-yl)vinyl)terephthalamide (94) 
N
N
HN
O
O
NH
t-Bu
t-Bu
BSc4574
 
To the mixture of 92a (BSc4568) (111.5 mg, 0.25 mmol, 1.0 eq) and PdCl2(PPh3)2 (17.6 mg, 
0.025 mmol, 0.1 eq) in 2.0 ml DMSO was added successively CsF (76 mg, 0.5 mmol, 2.0 eq) 
and H2O (0.1 mL). After stirring for 5 min, 2-isocyano-2-methylpropane (52 mg, 0.625 mmol, 
2.5 eq) was added. The reaction mixture was stirred at 90oC for 16h. The reaction mixture 
was extracted with dichloromethane, and then the combined organic layers were washed 
with brine, dried over Na2SO4. After filtration, the solvent was evaporated in vacuo, the 
residue was purified by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:3) to 
give 33 mg of pure product. 
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Yield: 27 %. 1H-NMR (500 MHz, CDCl3): δ = 7.63 (s, 2H), 7.05 (d, J = 16.0 Hz, 2H), 6.98 (d, 
J = 16.0 Hz, 2H), 6.67-6.64 (m, 2H), 6.49 (dd, J = 4.0 Hz, J = 1.5 Hz, 2H), 6.17-6.14 (m, 2H), 
5.61 (s, 2H), 3.71 (s, 6H), 1.49 (s, 18H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 168.7, 137.6, 
133.5, 131.7, 124.3, 124.2, 121.1, 119.8, 108.6, 107.6, 52.2, 34.4, 28.9 ppm. UV/Vis 
(Ethanol): λmax = 377.5 nm. 
Absorption BSc4574 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
300 350 400 450 500 550
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
6.5.3. Synthesis of 1,4-bisstyryl-2-fluorobenzene and 1,2,4,5-tetrafluoro-3,6-
bisstyrylbenzene derivatives 
6.5.3.1. Synthesis of methyl 5-formyl-2-methoxybenzoate 
Methyl 5-formyl-2-methoxybenzoate (96) 
O
O
O
OHC
 
To a stirred solution of formyl salicylic acid (166 mg, 1.0 mmol, 1.0 eq) in DMF (1 mL) at 
room temperature was added CH3I (568 mg, 4.0 mmol, 4.0 eq). The reaction mixture was 
stirred for 2 days. The reaction mixture was extracted with EtOAc, washed with H2O and 
dried over MgSO4. After filtration, the solvent was evaporated in vacuo, the residue was 
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purified by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:3) to afford 190 mg 
of title compound. 
Yield: 98 %. 1H-NMR (500 MHz, d6-DMSO): δ = 9.92-9.90 (s, 1H), 8.20-8.18 (d, J = 2.0 Hz, 
1H), 8.10-8.06 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 7.38-7.35 (d, J = 9.0 Hz, 1H), 3.95-3.93 (s, 
3H), 3.83-3.81 (s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 190.9, 165.1, 162.5, 134.7, 
132.4, 128.6, 120.3, 113.0, 56.4, 52.1 ppm. MS (EI): m/z = 194 [M]+. 
 
6.5.3.2. Synthesis of 1,4-bisstyryl-2-fluorobenzene derivatives 
Tetraethyl (2-fluoro-1,4-phenylene)bis(methylene)diphosphonate (99) 
F
(EtO)2OP
PO(OEt)2
 
To a stirred solution of 2-fluoro-1,4-dimethylbenzene (1.24 g, 10.0 mmol, 1.0 eq) in CHCl3 
(30 mL) was added NBS (6.23 g, 35.0 mmol, 3.5 eq) and AIBN (0.23 g, 1.4 mmol, 0.14 eq) at 
room temperature. The reaction mixture was refluxed for 15 h. The cooled reaction mixture 
was then washed with H2O and dried over MgSO4. After filtration, the solvent was 
evaporated in vacuo, the residue was crystallized from cyclohexane to afford the 1,4-
bis(bromomethyl)-2-fluorobenzene, which was used in the next reaction without further 
purification. 
A mixture of triethyl phosphite (2.49 g, 15.0 mmol, 3.0 eq) and 1,4-bis(bromomethyl)-2-
fluorobenzene (1.41 g, 5.0 mmol, 1.0 eq) was heated to 160 °C for 6 h. The residue was 
purified by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:10) to afford the 
title compound in quantitative yield. 
1H-NMR (500 MHz, d6-DMSO): δ = 7.29 (td, J = 8.0 Hz, J = 2.5 Hz, 1H), 7.12-7.05 (m, 2H), 
3.99-3.91 (m, 8H), 3.28-3.15 (m, 4H), 1.17 (t, J = 7.0 Hz, 12H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 159.9 (brd, J = 247.5 Hz), 133.4 (brs), 131.6 (d, J = 2.8 Hz), 125.5 (t, J = 3.1 
Hz), 117.4 (brs), 116.3 (brd, J = 19.1 Hz), 61.4 (brs), 32.1, 31.0, 25.7, 24.6, 16.0 (brs) ppm. 
 
General procedure for Wittig-Horner coupling 
The t-BuOK (168 mg, 1.5 mmol, 3.0 eq) was added to a stirred solution of tetraethyl (2-
fluoro-1,4-phenylene)bis(methylene)diphosphonate (198 mg, 0.5 mmol, 1.0 eq) in DMF (4 
mL) at room temperature. The mixture was stirred for 5 min under argon. Then 
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corresponding aldehyde (1.0 mmol, 2.0 eq) was added to the mixture, which was further 
stirred at room temperature overnight. The reaction was then quenched with H2O (10 mL), 
and the precipitates were filtered off, the residue was purified by column chromatography 
(SiO2; dichloromethane: methanol = 10:1) to afford the corresponding compound in moderate 
yields (Table 3.3). 
Dimethyl 5,5'-(1E,1'E)-2,2'-(2-fluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(2-methoxy 
benzoate) (100a) 
F
MeOOC
COOMe
O
O
BSc4740
 
Yield: 57 %. 1H-NMR (500 MHz, CDCl3): δ = 7.97 (dd, J = 4.5 Hz, J = 2.5 Hz, 2H), 7.63 (dd, 
J = 9.0 Hz, J = 2.5 Hz, 1H), 7.60 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 
7.25 (dd, J = 8.0 Hz, J = 1.5 Hz, 1H), 7.20 (dd, J = 7.0 Hz, J = 1.5 Hz, 1H), 7.14 (d, J = 3.5 
Hz, 2H), 7.04-6.96 (m, 4H), 3.93 (s, 6H), 3.93 (s, 6H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 
166.5, 160.8 (brd, J = 247.9 Hz), 158.8, 158.8, 138.3, 138.3, 131.4 (d, J = 10.5 Hz), 129.9, 
129.8, 129.7, 129.3, 129.1, 129.1, 128.2, 127.1 (d, J = 3.8 Hz), 126.4, 124.2 (d, J = 12.9 Hz), 
122.4, 120.4 (d, J = 4.1 Hz), 119.9, 113.0 (d, J = 22.9 Hz), 112.4, 56.2, 52.1. UV/Vis 
(Ethanol): λmax = 366.0 nm. 
Absorption BSc4740 (EtOH)
0
0.2
0.4
0.6
0.8
300 320 340 360 380 400 420 440
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
2,2'-(1E,1'E)-2,2'-(2-Fluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(1-methyl-1H-pyrrole) 
(100b) 
F
BSc4975
N
N
 
Yield: 55 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.72 (t, J = 8.0 Hz, 1H), 7.45 (dd, J = 13.0 
Hz, J = 1.0 Hz, 1H), 7.33 (dd, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.24 (d, J = 5.0 Hz, 1H), 7.20 (d, J 
= 5.0 Hz, 1H), 6.93-6.78 (m, 4H), 6.54-6.48 (m, 2H), 6.07-6.02 (m, 2H), 3.70 (s, 3H), 3.70 (s, 
3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 159.5 (brd, J = 244.5 Hz), 138.2, 131.3, 131.1, 
126.5, 124.3, 124.2, 123.2, 122.9, 122.4, 119.1, 119.1, 118.4, 115.7, 111.8, 111.7, 108.0, 
106.8, 33.6, 33.6 ppm. UV/Vis (Ethanol): λmax = 391.0 nm. 
Absorption BSc4975 (EtOH)
0
0.1
0.2
0.3
0.4
300 320 340 360 380 400 420 440 460 480 500
Wa v e l e ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
5,5'-(1E,1'E)-2,2'-(2-Fluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(N,N-dimethylthiophen-
2-amine) (100c) 
F
BSc4976
S
S
N
N
 
Yield: 39 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.55 (t, J = 8.0 Hz, 1H), 7.32-7.20 (m, 4H), 
6.86 (dd, J = 10.5 Hz, J = 4.0 Hz, 2H), 6.42 (t, J = 16.0 Hz, 2H), 5.85-5.81 (m, 2H), 2.93 (s, 
6H), 2.92 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 158.6, 137.6, 129.3, 129.2, 
126.3, 126.1, 123.9, 121.7, 119.9, 112.5, 111.5, 102.0, 41.9 ppm. UV/Vis (Ethanol): λmax = 
409.5 nm. 
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Absorption BSc4976 (EtOH)
0
0.05
0.1
0.15
300 350 400 450 500 550
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
 
1,1'-(4,4'-(1E,1'E)-2,2'-(2-Fluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(4,1-
phenylene))dipyrrolidine (100d) 
F
BSc4977
N
N
 
Yield: 62 %. 1H-NMR (500 MHz, CDCl3): δ = 7.53 (t, J = 8.0 Hz, 1H), 7.44 (dd, J = 14.5 Hz, J 
= 3.5 Hz, 4H), 7.23-7.00 (m, 5H), 6.89-6.60 (m, 5H), 3.38 (s, 8H), 2.07 (s, 8H) ppm. UV/Vis 
(Ethanol): λmax = 358.5 nm. 
Absorption BSc4977 (EtOH)
0
0.05
0.1
0.15
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
 
3,3'-(1E,1'E)-2,2'-(2-Fluoro-1,4-phenylene)bis(ethene-2,1-diyl)dipyridine (100e) 
F
BSc4978
N N
 
Yield: 66 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.81-8.76 (m, 2H), 8.50-8.45 (m, 2H), 8.07 
(d, J = 8.0 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 8.0 Hz, 1H), 7.55-7.35 (m, 8H) ppm. 
13C-NMR (125 MHz, d6-DMSO): δ = 160.0 (brd, J = 246.9 Hz), 148.7, 148.6, 148.4, 148.3, 
138.5, 136.5, 132.7, 132.4, 132.3, 128.7, 127.8, 127.7, 127.6, 127.5, 126.6, 123.7, 123.1, 
122.0, 113.4 (d, J = 22.6 Hz) ppm. UV/Vis (Ethanol): λmax = 349.5 nm. 
Absorption BSc4978 (EtOH)
0
0.05
0.1
0.15
300 320 340 360 380 400 420 440
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
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6.5.3.3. Synthesis of 1,2,4,5-tetrafluoro-3,6-bisstyrylbenzene derivatives 
1,4-Bis(bromomethyl)-2,3,5,6-tetrafluorobenzene (102) 
FF
F F
Br
Br
 
To a stirred solution of 2,3,5,6-tetrafluoro-p-xylene (1.78 g, 10.0 mmol, 1.0 eq) in CHCl3 (30 
mL) was added NBS (6.23 g, 35.0 mmol, 3.5 eq) and AIBN (0.23 g, 1.4 mmol, 0.14 eq) at 
room temperature. The reaction mixture was refluxed for 15 h. The cooled reaction mixture 
was then washed with H2O and dried over MgSO4. After filtration, the solvent was 
evaporated in vacuo, the residue was crystallized from cyclohexane to afford 2.37 g of target 
compound.  
Yield: 71 %. 1H-NMR (500 MHz, d6-DMSO): δ = 4.73 (s, 4H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 143.8 (brd, J = 249.3), 117.7, 17.7 ppm. MS (EI, 70 eV): m/z = 336 [M]+. 
 
1,2,4,5-Tetrafluoro-3,6-bis(diethylphosphonylmethyl)benzene (103) 
FF
F F
(EtO)2OP
PO(OEt)2
 
A mixture of triethyl phosphite (2.49 g, 15.0 mmol, 3 eq) and 1,4-bis(bromomethyl)-2,3,5,6-
tetrafluorobenzene (1.68 g, 5.0 mmol, 1.0 eq) was heated to 160 °C for 6 h. The residue was 
crystallized from diethyl ether to afford the colorless solid, which was used in the next 
reaction without further purification.  
1H-NMR (500 MHz, d6-DMSO): δ = 4.05-3.97 (m, 8H), 3.36 (d, J = 20 Hz, 4H), 1.18 (t, J = 
7.0 Hz, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 144.2 (brd, J = 225.0 Hz), 110.8 
(brs), 61.9 (t, J = 7.0 Hz), 20.9 (d, J = 138.9 Hz), 15.9 ppm. MS (EI, 70 eV): m/z = 450 [M]+. 
 
General procedure for Wittig-Horner coupling 
The t-BuOK (336 mg, 3.0 mmol, 3.0 eq) was added to a stirred solution of 1,2,4,5-tetrafluoro-
3,6-bis(diethylphosphonylmethyl)benzene (450 mg, 1.0 mmol, 1.0 eq) in DMF (4 mL) at room 
temperature. The mixture was stirred for 5 min under argon. Then corresponding aldehyde 
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(2.0 mmol, 2.0 eq) was added to the mixture, which was further stirred at room temperature 
overnight. The reaction was then quenched with H2O (15 mL), and the precipitates were 
filtered off, the residue was purified by column chromatography (SiO2; dichloromethane: 
methanol = 10:1) to afford the corresponding compound in moderate yields (Table 3.4). 
2,2'-(1E,1'E)-2,2'-(Perfluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(1-methyl-1H-pyrrole) 
(104a) 
FF
F FN
N
BSc4566
 
Yield: 69 %. 1H-NMR (500 MHz, CDCl3): δ = 7.36 (d, J = 16.5 Hz, 2H), 6.82 (d, J = 16.5 Hz, 
2H), 6.70 (t, J = 2.0 Hz, 2H), 6.63 (dd, J = 4.0 Hz, J = 1.0 Hz, 2H), 6.20-6.18 (m, 2H), 3.70 (s, 
6H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 144.4 (brd, J = 238.6 Hz), 131.8, 124.9, 124.3, 
114.6 (brs), 110.5, 109.0, 106.1, 34.0 ppm. MS (EI): m/z = 360 [M]+. UV/Vis (Ethanol): λmax = 
406.5 nm. 
Absorption BSc4566 (EtOH)
0
0.2
0.4
0.6
0.8
1
300 350 400 450 500
W aveleng t h [ nm]
 
 
4,4'-(1E,1'E)-2,2'-(Perfluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(N,N-dimethylaniline) 
(104b) 
FF
F F
N
N
BSc4567
 
Yield: 65 %. 1H-NMR (500 MHz, CDCl3): δ = 7.47-7.39 (m, 6H), 6.88 (d, J = 16.5 Hz, 2H), 
6.73 (d, J = 7.5 Hz, 4H), 3.02 (s, 12H) ppm. UV/Vis (Ethanol): λmax = 412.5 nm. 
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Absorption BSc4567 (EtOH)
0
0.02
0.04
0.06
0.08
0.1
300 350 400 450 500 550 600
W aveleng t h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
5,5'-(1E,1'E)-2,2'-(Perfluoro-1,4-phenylene)bis(ethene-2,1-diyl)di-2,2'-bithiophene (104c) 
BSc4569
F
FS
S
S
S
F
F
 
Yield: 66 %. 1H-NMR (500 MHz, CDCl3): δ = 7.56 (d, J = 16.5 Hz, 2H), 7.27-7.22 (m, 4H), 
7.11 (d, J = 3.5 Hz, 2H), 7.07 (d, J = 3.5 Hz, 2H), 7.04 (dd, J = 5.0 Hz, J = 3.5 Hz, 2H), 6.85 
(d, J = 16.5 Hz, 2H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 141.2, 138.3, 137.1, 129.3, 128.0, 
125.1, 124.3, 124.3, 124.2, 113.2 ppm. UV/Vis (Ethanol): λmax = 428.0 nm. 
Absorption BSc4569 (EtOH)
0
0.05
0.1
0.15
300 350 400 450 500 550 600
W avelengt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
3,3'-(1E,1'E)-2,2'-(Perfluoro-1,4-phenylene)bis(ethene-2,1-diyl)dipyridine (104d) 
BSc4570
F
F F
F
N
N
 
Yield: 62 %. 1H-NMR (500 MHz, CDCl3): δ = 8.76 (d, J = 2.0 Hz, 2H), 8.57 (dd, J = 4.5 Hz, J 
= 1.5 Hz, 2H), 7.90 (dt, J = 8.0 Hz, J = 2.0 Hz, 2H), 7.51 (d, J = 16.5 Hz, 2H), 7.34 (dd, J = 
8.0 Hz, J = 4.5 Hz, 2H), 7.15 (d, J = 17.0 Hz, 2H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 
149.8, 149.0, 144.8(brd, J = 252.8 Hz ), 133.6, 132.9, 132.4, 123.7, 116.0, 115.0 (brs) ppm. 
UV/Vis (Ethanol): λmax = 342.5 nm. 
Absorption BSc4570 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
250 270 290 310 330 350 370 390
W aveleng t h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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(4,4'-(1E,1'E)-2,2'-(Perfluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(4,1-
phenylene))bis(methylsulfane) (104e) 
BSc4571
F
F F
F
S
S
 
Yield: 59 %. 1H-NMR (500 MHz, CDCl3): δ = 7.50-7.43 (m, 6H), 7.26 (d, J = 7.5 Hz, 4H), 
7.05 (d, J = 16.5 Hz, 2H), 2.52 (s, 6H) ppm. UV/Vis (Ethanol): λmax = 373.5 nm. 
Absorption BSc4571 (EtOH)
0
0.05
0.1
0.15
0.2
250 300 350 400 450 500
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4,4'-(1E,1'E)-2,2'-(Perfluoro-1,4-phenylene)bis(ethene-2,1-diyl)dibenzonitrile (104f) 
BSc4572
F
F F
F
NC
CN
 
Yield: 53 %. 1H-NMR (500 MHz, CDCl3): δ = 7.69 (d, J = 8.0 Hz, 4H), 7.64 (d, J = 8.5 Hz, 
4H), 7.53 (d, J = 17 Hz, 2H), 7.20 (d, J = 16.5 Hz, 2H) ppm. UV/Vis (Ethanol): λmax = 
357.5 nm. 
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Absorption BSc4572 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
280 330 380 430 480
Wa v e le ngt h [ nm]
 
 
4,4'-(1E,1'E)-2,2'-(Perfluoro-1,4-phenylene)bis(ethene-2,1-diyl)bis(N,N-diethylaniline) 
(104g) 
BSc4573
FF
F F
N
N
 
Yield: 59 %. 1H-NMR (500 MHz, CDCl3): δ = 7.44-7.38 (m, 6H), 6.85 (d, J = 16.5 Hz, 2H), 
6.67 (d, J = 9.0 Hz, 4H), 3.43-3.37 (m, 8H), 1.20 (t, J = 7.0 Hz, 12H) ppm. 13C-NMR (125 
MHz, CDCl3): δ = 148.1, 144.5 (brd, J = 243.8 Hz ), 136.4, 128.4, 124.3, 114.6 (brs), 111.6, 
109.0, 44.4, 12.6 ppm. UV/Vis (Ethanol): λmax = 422.0 nm. 
Absorption BSc4573 (EtOH)
0
0.02
0.04
0.06
0.08
0.1
280 330 380 430 480 530 580
Wa v e le ngt h [ nm]
 
 
6.5.4.  Synthesis of 1,4-bisstyryl-2-bromo-5-cyanobenzene derivatives 
4-Bromo-2,5-dimethylbenzonitrile (105) 
Br
NC
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A mixture of 1,4-dibromo-2,5-dimethylbenzene (1.32 g, 5.0 mmol, 1.0 eq) and CuCN (0.448 
g, 5.0 mmol, 1.0 eq) in DMF (10 mL) at 80 °C for 1 h. The reaction was then quenched with 
H2O (15 mL) and extracted with EtOAc. The organic phase was dried over Na2SO4. After 
filtration, the solvent was evaporated in vacuo, the residue was purified by column 
chromatography (SiO2; ethyl acetate: cyclohexane = 1:10) to afford 0.73 g of title compound. 
Yield: 70 %. 1H-NMR (500 MHz, CDCl3): δ = 7.49 (s, 1H), 7.41 (s, 1H), 2.46 (s, 3H), 2.36 (s, 
3H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 140.5, 136.4, 134.0, 133.7, 130.0, 117.4, 111.7, 
22.1, 19.6 ppm. 
 
4-Bromo-2,5-bis(bromomethyl)benzonitrile (106) 
Br
NC
Br
Br
 
To a stirred solution of 4-bromo-2,5-dimethylbenzonitrile (2.10 g, 10.0 mmol, 1.0 eq) in CHCl3 
(30 mL) was added NBS (6.23 g, 35.0 mmol, 3.5 eq) and AIBN (0.23 g, 1.4 mmol, 0.14 eq) at 
room temperature. The reaction mixture was refluxed for 15 h. The cooled reaction mixture 
was then washed with H2O and dried over MgSO4. After filtration, the solvent was 
evaporated in vacuo, the residue was crystallized from cyclohexane to afford 2.89 g of target 
compound.  
Yield: 79 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.20 (s, 1H), 8.12 (s, 1H), 4.77 (s, 2H), 4.73 
(s, 2H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 142.9, 138.8, 135.9, 135.1, 129.6, 115.8, 
111.6, 32.2, 29.2 ppm. MS (EI, 70 eV): m/z = 368 [M]+. 
 
Tetraethyl (2-bromo-5-cyano-1,4-phenylene)bis(methylene)diphosphonate (107) 
Br
NC
(EtO)2OP
PO(OEt)2
 
A mixture of triethyl phosphite (2.49 g, 15.0 mmol, 3.0 eq) and 4-bromo-2,5-
bis(bromomethyl)benzonitrile (1.84 g, 5.0 mmol, 1.0 eq) was heated to 160 °C for 6 h. The 
residue was crystallized from cyclohexane to afford the colorless solid, which was used in 
the next reaction without further purification. 
 Page 172 
1H-NMR (500 MHz, d6-DMSO): δ = 7.81 (s, 1H), 7.80 (s, 1H), 4.03-3.95 (m, 8H), 3.46 (d, J = 
6.0 Hz, 2H), 3.42 (d, J = 6.0 Hz, 2H), 1.20-1.15 (m, 12H) ppm. 
 
General procedure for Wittig-Horner coupling 
The t-BuOK (336 mg, 3 mmol, 3.0 eq) was added to a stirred solution of tetraethyl (2-bromo-
5-cyano-1,4-phenylene)bis(methylene)diphosphonate (482 mg, 1 mmol, 1.0 eq) in DMF (4 
mL) at room temperature. The mixture was stirred for 5 min under argon. Then 
corresponding aldehyde (2.0 mmol, 2.0 eq) was added to the mixture, which was further 
stirred at room temperature overnight. The reaction was then quenched with H2O (15 mL), 
and the precipitates were filtered off, the residue was purified by column chromatography 
(SiO2; dichloromethane: methanol = 10:1) to afford the corresponding compound in moderate 
yields (Table 3.5). 
4-Bromo-2,5-bis(4-(diethylamino)styryl)benzonitrile (108a) 
N
N
Br
NC
BSc4577
 
Yield: 77 %. 1H-NMR (500 MHz, CDCl3): δ = 7.94 (s, 1H), 7.83 (s, 1H), 7.44 (t, J = 9.0 Hz, 
4H), 7.19-7.07 (m, 3H), 6.99 (d, J = 16.0 Hz, 1H), 6.67 (dd, J = 9.0 Hz, J = 3.5 Hz, 4H), 3.44-
3.36 (m, 8H), 1.20 (td, J = 7.0 Hz, J = 1.5 Hz, 12H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 
148.3, 148.1, 139.9, 136.3, 133.6, 132.7, 129.7, 128.8, 128.7, 128.5, 123.8, 123.2, 120.0, 
118.0, 117.2, 111.6, 111.5, 109.6, 44.4, 12.6 ppm. MS (EI, 70 eV): m/z = 527 [M]+. UV/Vis 
(Ethanol): λmax = 442.0 nm. 
Absorption BSc4577 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
300 350 400 450 500 550
Wa v e l e ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4-Bromo-2,5-bis((E)-2-(1-methyl-1H-pyrrol-2-yl)vinyl)benzonitrile (108b) 
BSc4578
Br
NCN
N
 
Yield: 73 %. 1H-NMR (500 MHz, CDCl3): δ = 7.87 (s, 1H), 7.80 (s, 1H), 7.19-6.91 (m, 4H), 
6.74-6.68 (m, 2H), 6.65 (dd, J = 4.0 Hz, J = 1.0 Hz, 1H), 6.61 (dd, J = 4.0 Hz, J = 1.0 Hz, 
1H), 6.22-6.17 (m, 2H), 3.76 (s, 3H), 3.75 (s, 3H) ppm. MS (EI, 70 eV): m/z = 393 [M+2]+. 
UV/Vis (Ethanol): λmax = 417.5 nm. 
Absorption BSc4578 (EtOH)
0
0.05
0.1
0.15
300 350 400 450 500 550 600
Wa v e le ngt h [ nm]
 
 
4-Bromo-2,5-bis((E)-2-(pyridin-3-yl)vinyl)benzonitrile (108c) 
N
N
BSc4580
Br
NC
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Yield: 82 %. 1H-NMR (500 MHz, CDCl3): δ = 7.78 (dd, J = 6.5 Hz, J = 2.0 Hz,  2H), 8.58 (td, 
J = 5.0 Hz, J = 1.0 Hz,  2H), 8.06 (s, 1H), 7.97-7.93 (m, 2H), 7.90 (dt, J = 8.0 Hz, J = 2.0 Hz, 
1H), 7.49-7.39 (m, 2H), 7.38-7.33 (m, 2H), 7.28 (d, J = 16.0 Hz, 1H), 7.10 (d, J = 16.0 Hz, 
1H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 150.0, 149.7, 149.3, 148.9, 139.6, 136.8, 133.3, 
133.1, 131.9, 131.5, 130.8 130.7, 130.2, 129.9, 129.2, 127.1, 124.5, 123.8, 123.7, 117.0, 
111.0 ppm. UV/Vis (Ethanol): λmax = 341.5 nm. 
Absorption BSc4580 (EtOH)
0
0.05
0.1
0.15
0.2
280 300 320 340 360 380 400 420
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
Dimethyl 5,5'-(1E,1'E)-2,2'-(2-bromo-5-cyano-1,4-phenylene)bis(ethene-2,1-diyl)bis (2-
methoxybenzoate) (108d) 
Br
NC
H3COOC
COOCH3
OCH3
H3CO
BSc4581
 
Yield: 66 %. 1H-NMR (500 MHz, CDCl3): δ = 8.01-7.96 (m, 3H), 7.87 (s, 1H), 7.71 (dd, J = 
9.0 Hz, J = 2.5 Hz, 1H), 7.66 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 7.27 (d, J = 16.5 Hz, 1H), 7.22 
(s, 2H), 7.06-6.99 (m, 3H), 3.96-3.91 (m, 12H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 166.3, 
166.1, 159.7, 159.4, 139.7, 136.6, 132.7, 131.9, 131.8, 131.8, 130.9, 130.4, 130.4, 129.7, 
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128.9, 128.6, 128.2, 124.1, 121.4, 120.5, 120.5, 117.4, 112.5, 112.4, 110.4, 56.2, 52.2, 52.2 
ppm. UV/Vis (Ethanol): λmax = 371.5 nm. 
Absorption BSc4581 (EtOH)
0
0.02
0.04
0.06
0.08
0.1
280 300 320 340 360 380 400 420 440 460 480
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4-Bromo-2,5-bis(4-methoxystyryl)benzonitrile (108e) 
Br
NC
O
O
BSc4582
 
Yield: 69 %. 1H-NMR (500 MHz, CDCl3): δ = 7.98 (s, 1H), 7.87 (s, 1H), 7.54-7.49 (m, 4H), 
7.24 (d, J = 16.5 Hz, 1H), 7.21 (s, 2H), 7.04 (d, J = 16.0 Hz, 1H), 6.95-6.91 (m, 4H), 3.85 (s, 
3H), 3.85 (s, 3H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 160.5, 160.2, 139.8, 136.6, 133.5, 
132.6, 130.2, 129.4, 129.1, 128.8, 128.7, 128.4, 123.0, 120.3, 117.6, 114.4, 114.3, 110.3, 
55.4 ppm. UV/Vis (Ethanol): λmax = 379.0 nm. 
Absorption BSc4582 (EtOH)
0
0.05
0.1
0.15
0.2
300 350 400 450 500
W aveleng t h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
Dimethyl 5,5'-(1E,1'E)-2,2'-(2-bromo-5-cyano-1,4-phenylene)bis(ethene-2,1-diyl)bis (2-
hydroxybenzoate) (108f) 
Br
NC
H3COOC
COOCH3
OH
HO
BSc4642
 
A 1.0 N solution of boron tribromide in dichloromethane (5.0 mL, 5.0 mmol, 5.0 eq) was 
added dropwise over 10 min to a stirred suspension of 108d (561 mg, 1.0 mmol, 1.0 eq) in 
anhydrous dichloromethane (10 mL) at -20 °C. The reaction mixture was stirred for 12 h at 
room temperature. The reaction mixture was then quenched with 20 mL of water to afford 
108f as precipitates, which was filtered off and washed with water and ethyl acetate. 
Yield: 97 %. MS (EI, 70 eV): m/z = 535 [M+2]+. UV/Vis (Ethanol): λmax = 372.5 nm. 
Absorption BSc4642 (EtOH)
0
0.05
0.1
0.15
220 270 320 370 420 470 520
Wa v e le ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
5,5'-(1E,1'E)-2,2'-(2-Bromo-5-cyano-1,4-phenylene)bis(ethene-2,1-diyl)bis(2-
hydroxybenzoic acid) (108g) 
To 108f (106 mg, 0.2 mmol, 1.0 eq) was added 1.0 N NaOH (5.0 mL, 5.0 mmol, 25 eq), and 
the solution was stirred at 90 °C overnight. After cooling down to room temperature, the 
solution was quenched with 5 mL water and 1 mL 6.0 M HCl solution. Precipitates were 
filtered off and washed with water and ethyl acetate to afford 108g without further purification. 
Br
NC
HOOC
COOH
OH
HO
BSc4702
 
Yield: 84 %. 1H-NMR (500 MHz, CDCl3): δ = 8.31 (s, 2H), 8.04 (d, J = 2.0 Hz, 1H), 8.00 (d, J 
= 2.5 Hz, 1H), 7.86-7.80 (m, 2H), 7.66 (d, J = 16.0 Hz, 1H), 7.50 (d, J = 16.5 Hz, 1H), 7.20 
(d, J = 16.0 Hz, 1H), 7.14 (d, J = 16.0 Hz, 1H), 7.06-7.00 (m, 2H) ppm. UV/Vis (Ethanol): 
λmax = 384.0 nm. 
Absorption BSc4702 (EtOH)
0
0.02
0.04
0.06
0.08
0.1
280 300 320 340 360 380 400 420 440 460 480
Wa v e l e ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
6.5.5.  Synthesis of bis(arylvinyl)pyrimidine derivatives 
6.5.5.1. Synthesis of aldehydes based on microwave irradiation  
4-(Dimethylamino)-3-fluorobenzaldehyde (110) 
CHO
N
F
 
A mixture of 3,4-difluorobenzaldehyde (1.42 g, 10.0 mmol, 1.0 eq), 30 % dimethylamine  
solution (1.8 g, 12.0 mmol, 1.2 eq) and potassium carbonate (4.14 g, 30.0 mmol, 3.0 eq) in 
DMSO (5 mL) was stirred for 12 h at 60 °C under microwave irradiation. Reaction mixture 
was cooled down to room temperature, diluted with EtOAc (20 mL) and washed with water (2 
x 10 mL). Organic layer was dried over Na2SO4. After filtration, the solvent was evaporated in 
vacuo, the residue was purified by column chromatography (SiO2; ethyl acetate: cyclohexane 
= 1:1) to afford 1.47 g of title compound as yellow oil. 
Yield: 88 %. 1H-NMR (500 MHz, CDCl3): δ = 9.74 (d, J = 2.0 Hz, 1H), 7.53-7.45 (m, 2H), 
6.81 (t, J = 8.5 Hz, 1H), 3.04 (d, J = 2.0 Hz, 6H) ppm. 13C-NMR (125 MHz, CDCl3): δ = 189.5, 
154.8 (d, J = 977.5 Hz), 145.2 (d, J = 32.0 Hz), 128.1, 127.7 (d, J = 23.5 Hz), 116.2 (d, J = 
87.0 Hz), 115.9 (d, J = 16.5 Hz), 42.1 (d, J = 24.5 Hz) ppm. 
 
4-(2-Hydroxyethylamino)benzaldehyde (113) 
O
H
HN
HO
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A mixture of 4-bromobenzaldehyde (1.01 g, 5.0 mmol, 1.0 eq), 2-aminoethanol (458 mg, 7.5 
mmol, 1.5 eq), K3PO4 (2.12 g, 10.0 mmol, 2.0 eq), CuI (95 mg, 0.5 mmol, 0.1 eq), and proline 
(115 mg, 1.0 mmol, 0.2 eq) in 3 mL of DMSO was heated at 80 oC under microwave 
irradiation. Water was added to the reaction mixture. The mixture was then extracted with 
EtOAc twice. The combined organic layers were washed with brine, dried over Na2SO4. After 
filtration, the solvent was evaporated in vacuo. The residue was purified by column 
chromatography (SiO2; ethyl acetate: cyclohexane = 1:1) to afford 0.84 g of title compound. 
Yield: 93 %. 1H-NMR (500 MHz, CDCl3): δ = 9.62 (s, 1H), 7.62 (d, J = 9.0 Hz, 2H), 6.58 (t, J 
= 8.5 Hz, 2H), 5.03 (s, 1H), 3.84 (t, J = 5.0 Hz, 2H), 3.34 (t, J = 5.0 Hz, 2H), 3.05 (s, 1H) 
ppm. 13C-NMR (125 MHz, CDCl3): δ = 190.6, 153.6, 132.4, 126.1, 111.9, 60.7, 45.1 ppm 
 
6.5.5.2. General procedures for synthesis of bis(arylvinyl)pyrimidine derivatives  
A mixture of 4,6-dimethylpyrimidine (108 mg, 1.0 mmol, 1.0 eq), corresponding aldehyde (2 
mmol, 2.0 eq), Aliquat 336 (60.6 mg, 0.15 mmol, 0.15 eq) and 5 N NaOH solution (5 mL) was 
stirred at 80 oC for 16 h. The reaction was then quenched with H2O (10 mL). The precipitates 
were filtered off and washed with water, the residue was purified by column chromatography 
(SiO2; ethyl acetate: cyclohexane = 1:2) to afford the corresponding compound in moderate 
yields (Table 3.6). 
2,2'-(4,4'-(1E,1'E)-2,2'-(Pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(4,1-
phenylene))bis(azanediyl)diethanol (115a) 
N N
N
H
N
H
HO OH
BSc4919
 
Yield: 82 %. 1H-NMR (300 MHz, d6-DMSO): δ = 8.85 (d, J = 0.9 Hz, 1H), 7.78 (d, J = 15.9 
Hz, 2H), 7.49-7.41 (m, 5H), 6.88 (d, J = 15.9 Hz, 2H), 6.63 (d, J = 8.7 Hz, 4H), 6.15 (s, 2H), 
4.70 (s, 2H), 3.57 (t, J = 6.0 Hz, 4H), 3.16 (t, J = 6.0 Hz, 4H) ppm. 13C-NMR (75 MHz, d6-
DMSO): δ = 162.4, 157.6, 150.3, 137.2, 129.3, 122.8, 119.6, 114.5, 111.9, 59.4, 45.1 ppm. 
UV/Vis (Ethanol): λmax = 432.0 nm. 
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Absorption BSc4919 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
300 350 400 450 500 550 600
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
4,4'-(1E,1'E)-2,2'-(Pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(2-fluoro-N,N-
dimethylaniline) (115b) 
BSc4921
N N
N N
FF
 
Yield: 77 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.97 (s, 1H), 7.82 (d, J = 16.0 Hz, 2H), 7.55-
7.49 (m, 3H), 7.40 (dd, J = 8.5 Hz, J = 2.0 Hz, 2H), 7.12 (d, J = 16.0 Hz, 2H), 6.94 (t, J = 9.0 
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Hz, 2H) , 2.87 (s, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 162.2, 158.1, 153.4 (d, J = 
933.0 Hz), 140.9 (d, J = 33.5 Hz), 135.2, 127.6 (d, J = 29.5 Hz), 124.9, 123.8, 117.6 (d, J = 
14.0 Hz), 115.8, 114.4 (d, J = 36.5 Hz), 41.9 (d, J = 18.0 Hz)  ppm. UV/Vis (Ethanol): λmax = 
403.5 nm. 
Absorption BSc4921 (EtOH)
0
0.5
1
1.5
300 350 400 450 500 550
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4,6-Bis((E)-2-(5-bromothiophen-2-yl)vinyl)pyrimidine (115c) 
BSc4959
N N
S S
BrBr
 
Yield: 62 %. 1H-NMR (500 MHz, d6-DMSO): δ = 9.00 (s, 1H), 8.01 (d, J = 16.0 Hz, 2H), 7.61 
(s, 1H), 7.31 (d, J = 3.5 Hz, 2H), 7.27 (d, J = 4.0 Hz, 2H), 6.89 (d, J = 15.5 Hz, 2H) ppm. 13C-
NMR (125 MHz, d6-DMSO): δ = 161.62, 158.2, 142.4, 131.7, 130.8, 128.6, 125.4, 116.4, 
113.5 ppm. 
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5,5'-(1E,1'E)-2,2'-(Pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N-dimethylthiophen-2-
amine) (115d) 
BSc4960
N N
S S
NN
 
Yield: 96 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.75 (d, J = 1.0 Hz, 1H), 7.87 (d, J = 15.0 
Hz, 2H), 7.24 (d, J = 1.0 Hz, 1H), 7.10 (d, J = 4.0 Hz, 2H), 6.30 (d, J = 15.0 Hz, 2H), 5.91 (d, 
J = 4.0 Hz, 2H) , 2.98 (s, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 161.9, 160.7, 133.3, 
130.3, 124.2, 117.4, 114.0, 102.4, 41.8 ppm. UV/Vis (Ethanol): λmax = 490.0 nm. 
Absorption BSc4960 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
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6.6.  Synthesis of spiropyran derivatives  
6.6.1. General procedures for synthesis of 5-substitute-2,3,3-
trimethylindolenine  
A mixture of substituted phenylhydrazine hydrochloride (10.0 mmol, 1.0 eq) and 3-methyl-2-
butanone (1.03 g, 12.0 mmol, 1.2 eq) was dissolved in glacial acetic acid (20 mL) and then 
heated under reflux temperature for 12 h under argon. When it was cooled down to room 
temperature, the solvent was evaporated in vacuo and the residue was dissolved in 
dichloromethane (30 mL), washed with 10% aqueous Na2CO3 (2 × 30 mL), dried over 
Na2SO4. After filtration, the solvent was evaporated in vacuo. The crude product was purified 
by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:2) to afford the pure 
product as yellow liquid (yield: 73-88 %). 
2,3,3-Trimethyl-3H-indole (118a) 
N
 
Yield: 81 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.42 (d, J = 7.5 Hz, 1H), 7.39 (d, J = 7.0 Hz, 
1H), 7.26 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.16 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 2.19 (s, 3H), 
1.22 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 187.5, 153.5, 145.8, 127.2, 124.6, 
121.4, 119.1, 53.0, 22.4, 14.9 ppm. MS (EI, 70 eV): m/z = 159 [M]+. 
 
5-Fluoro-2,3,3-trimethyl-3H-indole (118b) 
N
F
 
Yield: 73 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.49-7.44 (m, 1H), 7.01-6.95 (m, 2H), 2.28 
(s, 3H), 1.30 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 187.9 (d, J = 3.3 Hz), 161.3 (d, 
J = 242.4 Hz), 148.9, 147.4 (d, J = 8.4 Hz), 120.4 (d, J = 8.9 Hz),  114.2 (d, J = 22.3 Hz), 
109.1 (d, J = 24.4 Hz),  54.2, 23.0, 15.3 ppm. 
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5-Bromo-2,3,3-trimethyl-3H-indole (118c) 
N
Br
 
Yield: 86 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.66 (d, J = 2.0 Hz, 1H), 7.44 (dd, J = 8.5 
Hz, J = 2.0 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 2.19 (s, 3H), 1.24 (s, 6H) ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 188.6, 152.6, 148.4, 130.1, 124.9, 120.9, 117.7, 53.7, 22.1, 14.9 ppm. 
 
5-Methoxy-2,3,3-trimethyl-3H-indole (118d) 
N
O
 
Yield: 88 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7. 44 (d, J = 8.0 Hz, 1H), 6.85-6.80 (m, 2H), 
3.82 (s, 3H), 2.26 (s, 3H), 1.29 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 186.0, 
158.0, 147.1, 120.0, 112.1, 108.2, 55.7, 53.7, 23.2, 15.2 ppm. 
 
6.6.2. General procedures for synthesis of 1-alkyl/PEG-2,3,3-tetramethyl-3H-
indolium 
5-Substitute-1-alkyl -2,3,3-tetramethyl-3H-indolium 
5-Substituted-2,3,3-trimethylindolenine (5 mmol, 1.0 eq) and methyl iodide (1.42 g, 10.0 
mmol, 2.0 eq) were dissolved in anhydrous acetonitrile (15.0 mL). The reaction mixture was 
refluxed overnight. When it was cooled down to room temperature, the solvent was 
evaporated in vacuo and the residue was treated with ethyl acetate (30.0 mL). The final 
product was collected by filtration and washed with ethyl acetate. The colorless solid was 
used in the next reaction without further purification. 
1,2,3,3-Tetramethyl-3H-indolium iodide (119a) 
N I-
 
1H-NMR (500 MHz, d6-DMSO): δ = 7.93-7.89 (m, 1H), 7.84-7.81 (m, 1H), 7.65-7.59 (m, 2H), 
3.97 (s, 3H), 2.77 (s, 3H), 1.53 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 195.9, 
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142.0, 141.5, 129.2, 128.7, 123.1, 115.0, 53.8, 34.6, 21.6, 14.0 ppm. MS (EI, 70 eV): m/z = 
173 [M-H]+ . mp: 258–259 °C (MeCN). 
 
5-Fluoro-1,2,3,3-tetramethyl-3H-indolium iodide (119c) 
N I-
F
 
1H-NMR (500 MHz, d6-DMSO): δ = 7.96 (dd, J = 9.0 Hz, J = 4.5 Hz, 1H), 7.83 (dd, J = 8.0 Hz, 
J = 2.5 Hz, 1H), 7.50 (td, J = 9.0 Hz, J = 2.5 Hz, 1H), 3.96 (s, 3H), 2.75 (s, 3H), 1.54 (s, 6H) 
ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 195.9, 162.5 (d, J = 245.4 Hz), 144.8 (d, J = 
9.9Hz), 138.2, 116.9 (d, J = 9.6 Hz), 115.7 (d, J = 24.8 Hz), 111.2 (d, J = 25.9 Hz), 54.0, 34.8, 
21.4, 14.1 ppm. 
 
5-Bromo-1,2,3,3-tetramethyl-3H-indolium iodide (119d) 
N I-
Br
 
1H-NMR (500 MHz, d6-DMSO): δ = 8.16 (d, J = 1.5 Hz, 1H), 7.89-7.82 (m, 2H), 3.95 (s, 3H), 
2.75 (s, 3H), 1.53 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 196.4, 143.7, 141.3, 
131.6, 126.6, 122.5, 117.0, 54.1, 34.8, 21.4, 14.1 ppm. 
 
5-Methoxy-1,2,3,3-tetramethyl-3H-indolium iodide (119e) 
N I-
O
 
1H-NMR (500 MHz, d6-DMSO): δ = 7.80 (d, J = 9.0 Hz, 1H), 7.46 (d, J = 2.5 Hz, 1H), 7.14 
(dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 3.93 (s, 3H), 3.86 (s, 3H), 2.70 (s, 3H), 1.50 (s, 6H) ppm. 
13C-NMR (125 MHz, d6-DMSO): δ = 193.1, 160.6, 143.6, 135.3, 116.0, 114.1, 109.2, 56.1, 
53.7, 34.6, 21.8, 13.7 ppm. 
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1-Butyl-2,3,3-trimethyl-3H-indolium iodide (119b) 
N I-
 
2,3,3-Trimethyl-3H-indole (318 mg, 2.0 mmol, 1.0 eq) and 1-iodobutane (552 mg, 3.0 mmol, 
1.5 eq) were refluxed overnight in ethylmethylketone (10 mL). When it was cooled down to 
room temperature, the solvent was evaporated in vacuo and the residue was purified by 
column chromatography (SiO2; dichloromethane: methanol = 20:1) to afford 502 mg of 
product as pale yellow solid.  
Yield: 73 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.99-7.94 (m, 1H), 7.96-7.82 (m, 1H), 7.66-
7.60 (m, 2H), 4.45 (t, J = 7.5 Hz, 2H), 2.84 (s, 3H), 1.86-1.77(m, 2H), 1.54 (s, 6H), 1.47-1.38 
(m, 2H), 0.94 (t, J = 7.5 Hz, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 196.3, 141.8, 
141.0, 129.3, 128.9, 123.4, 115.4, 54.1, 47.3, 29.2, 21.9, 19.2, 13.9, 13.5 ppm. MS (EI, 70 
eV): m/z = 215 [M-H]+ . mp: 135-136 °C. 
 
1-(2-Methoxyethyl)-2,3,3-trimethyl-3H-indolium chloride (119g) 
N Cl-
O
 
2-Methoxyethanol (0.76 g, 10.0 mmol, 1.0 eq) with THF (3 mL) was added dropwise to a 
solution of NaOH (0.52 g, 13.0 mmol, 1.3 eq) in 1.0 mL water at 0 °C. The solution of p-
toluenesulfonyl chloride (2.1 g, 11.0 mmol, 1.1 eq) was then added to the mixture. After 12 
hours of stirring at room temperature, the reaction was quenched by 2.5 mL water and 
extracted with dichloromethane (20 mL). The combined organic phases were washed 
successively with 2 N HCl (15 mL) and saturated NaCl solution (15 mL), dried over MgSO4. 
After filtration, the solvent was evaporated in vacuo. 
2,3,3-Trimethyl-indolenine (0.80 g, 5.0 mmol, 1.0 eq) and 2-methoxyethyl 4-
methylbenzenesulfonate (2.3 g, 10.0 mmol, 2.0 eq) were dissolved in anhydrous acetonitrile 
(10.0 mL). The reaction mixture was refluxed for 4 days. The color of reaction mixture turned 
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to purple, and then it was cooled down to room temperature. The crude product was purified 
by column chromatography (SiO2; dichloromethane: methanol: triethylamine= 10:1:0.1) to 
afford the purple liquid (yield: 23 %). 
 
6.6.3.  General procedures for synthesis of spiropyran derivatives 
A mixture of corresponding substituted salicylaldehyde (1.1 mmol, 1.1 eq) and indolium 
derivatives (1.0 mmol, 1.0 eq) in EtOH (5 mL) was refluxed overnight. The solvent was 
evaporated in vacuo and the residue was purified by column chromatography (SiO2; 
dichloromethane: methanol = 10:1) to furnish the corresponding compound in moderate 
yields (yield: 35-77 %).  
N,N-Diethyl-1',3',3'-trimethylspiro[chromene-2,2'-indolin]-7-amine (120a) 
N O
N
BSc4452
 
Yield: 77 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.11-7.04 (m, 2H), 6.90 (d, J = 8.5 Hz, 1H), 
6.83 (d, J = 10.0 Hz, 1H), 6.74 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.53 (d, J = 7.5 Hz, 1H), 6.13 
(dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 5.88 (d, J = 2.5 Hz, 1H), 5.38 (d, J = 10.0 Hz, 1H), 3.27-3.20 
(m, 4H), 2.65 (s, 3H), 1.21 (s, 3H), 1.06 (s, 3H), 1.01 (t, J = 7.0 Hz, 6H) ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 155.5, 148.6, 148.0, 136.5, 129.15, 127.14, 127.2, 121.3, 118.5, 112.8, 
107.0, 106.5, 104.0, 103.5, 96.3, 50.9, 43.5, 28.4, 25.7, 19.7, 12.4 ppm. MS (EI, 70 eV): m/z 
= 348 [M]+. UV/Vis (Ethanol): λmax = 549.0 nm. 
Absorption BSc4452 (EtOH)
0
0.05
0.1
0.15
0.2
0.25
280 330 380 430 480 530 580
Wa v e l e ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
8-Methoxy-1',3',3'-trimethylspiro[chromene-2,2'-indoline] (120b) 
N O
O
BSc4453
 
Yield: 46 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.10 (td, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.07 
(dd, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.97 (d, J = 10.0 Hz, 1H), 6.84 (t, J = 5.0 Hz, 1H), 6.79-6.74 
(m, 3H), 6.55 (d, J = 7.5 Hz, 1H), 5.74 (d, J = 10.5 Hz, 1H), 3.62 (s, 3H), 2.66 (s, 3H), 1.07-
1.04 (s, 3H), 1.20 (s, 3H), 1.08 (s, 3H)  ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 147.7, 
146.4, 142.8, 136.2, 129.1, 127.3, 121.4, 119.7, 119.5, 119.1, 118.9, 118.6, 113.1, 106.5, 
103.6, 55.4, 51.3, 28.3, 25.7, 19.7 ppm. MS (EI, 70 eV): m/z = 307 [M]+. UV/Vis (Ethanol): 
λmax = 226.0 nm. 
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Absorption BSc4453 (EtOH)
0
0.5
1
1.5
200 220 240 260 280 300 320 340 360 380 400
Wa v e le ngt h [ nm]
 
 
1',3',3'-Trimethylspiro[chromene-2,2'-indolin]-6-ol (120c) 
N O OH
BSc4454
 
Yield: 45 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.88 (s, 1H), 7.11-7.04 (m, 2H), 6.91 (d, J = 
10.0 Hz, 1H), 6.74 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.57 (d, J = 3.0 Hz,  1H), 6.54-6.48 (m, 
3H), 5.72 (d, J = 10.0 Hz, 1H), 2.62 (s, 3H), 1.20 (s, 3H), 1.07 (s, 3H)  ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 150.5, 147.8, 146.6, 136.3, 129.3, 127.2, 121.3, 119.6, 118.8, 118.6, 
116.1, 114.6, 112.7, 106.5, 103.0, 51.0, 28.5, 25.6, 19.9 ppm. MS (EI, 70 eV): m/z = 293 
[M]+. UV/Vis (Ethanol): λmax = 231.5 nm. 
Absorption BSc4454 (EtOH)
0
0.5
1
1.5
2
200 250 300 350 400
W aveleng t h [ nm]
 
 
1',3',3'-Trimethyl-6-nitrospiro[chromene-2,2'-indoline] (120d) 
BSc4455
N O NO2
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1H-NMR (500 MHz, d6-DMSO): δ = 8.20 (d, J = 3.0 Hz, 1H), 8.00 (dd, J = 9.0 Hz, J = 2.5 Hz, 
1H), 7.20 (d, J = 10.5 Hz, 1H), 7.15-7.09 (m, 2H), 6.87 (d, J = 9.0 Hz,  1H), 6.80 (td, J = 7.5 
Hz, J = 1.0 Hz, 1H), 6.60 (d, J = 7.5 Hz, 1H), 5.97 (d, J = 10.5 Hz, 1H), 2.66 (s, 3H), 1.20 (s, 
3H), 1.10 (s, 3H)  ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 159.4, 147.4, 140.5, 135.9, 
128.3, 127.7, 125.8, 122.8, 121.6, 121.5, 119.5, 118.9, 115.4, 107.0, 106.2, 51.9, 28.5, 25.7, 
19.7 ppm. MS (EI, 70 eV): m/z = 322 [M]+. 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
6-Fluoro-1',3',3'-trimethylspiro[chromene-2,2'-indoline] (120e) 
BSc4487
N O F
 
Yield: 47 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.14-7.03 (m, 3H), 7.00 (d, J = 10.0 Hz, 1H), 
6.91 (td, J = 9.0 Hz, J = 3.0 Hz 1H), 6.77 (t, J = 7.5 Hz, 1H), 6.68 (dd, J = 9.0 Hz, J = 4.0 Hz, 
1H), 6.55 (d, J = 7.5 Hz, 1H), 5.84 (d, J = 10.0 Hz, 1H), 2.64 (s, 3H), 1.21 (s, 3H), 1.08 (s, 3H) 
ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 155.9 (d, J = 233.6 Hz), 150.0, 147.6, 136.1, 128.5, 
127.3, 121.3, 120.7, 119.4 (d, J = 8.6 Hz), 118.9, 115.7 (d, J = 23.1 Hz), 115.3 (d, J = 8.0 Hz), 
112.7 (d, J = 23.6 Hz), 106.7, 103.8, 51.3, 28.4, 25.5, 19.8 ppm. MS (EI, 70 eV): m/z = 295 
[M]+. UV/Vis (Ethanol): λmax = 215.0 nm. 
Absorption BSc4487 (EtOH)
0
0.5
1
1.5
2
2.5
200 250 300 350 400
W avelengt h [ nm]
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1',3',3'-Trimethylspiro[chromene-2,2'-indoline] (120f)  
BSc4488
N O
 
Yield: 53 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.16 (dd, J = 7.5 Hz, J = 1.5 Hz, 1H), 7.12-
7.06 (m, 3H), 7.00 (d, J = 10.0 Hz, 1H), 6.82 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.76 (td, J = 7.5 
Hz, J = 1.0 Hz, 1H), 6.65 (d, J = 8.5 Hz, 1H), 6.55 (d, J = 8.0 Hz, 1H), 5.74 (d, J = 10.5 Hz, 
1H), 2.64 (s, 3H), 1.21 (s, 3H), 1.09 (s, 3H)  ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 153.9, 
147.8, 136.2, 129.7, 129.2, 127.4, 126.8, 121.4, 120.1, 119.1, 118.8, 118.6, 114.2, 106.7, 
103.8, 51.3, 28.5, 25.6, 19.8 ppm. MS (EI, 70 eV): m/z = 277 [M]+. UV/Vis (Ethanol): λmax = 
217.5 nm. 
Absorption BSc4488 (EtOH)
0
0.5
1
1.5
2
2.5
200 250 300 350
W avelengt h [ nm]
 
 
1',3',3',6-Tetramethylspiro[chromene-2,2'-indoline] (120g)  
BSc4489
N O
 
Yield: 64 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.11-7.04 (m, 2H), 6.97-6.92 (m, 3H), 6.88 
(dd, J = 8.0 Hz, J = 2.0 Hz, 1H), 6.75 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.65-6.51 (m, 2H), 5.72 
(d, J = 10.5 Hz, 1H), 2.62 (s, 3H), 2.18 (s, 3H), 1.19 (s, 3H), 1.07 (s, 3H)  ppm. 13C-NMR 
(125 MHz, d6-DMSO): δ = 151.8, 147.9, 136.4, 130.2, 129.4, 128.8, 127.4, 127.2, 121.4, 
119.3, 118.9, 118.4, 114.1, 106.7, 103.7, 51.3, 28.6, 25.7, 20.0, 19.9 ppm. MS (EI, 70 eV): 
m/z = 291 [M]+. UV/Vis (Ethanol): λmax = 208.0 nm. 
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Absorption BSc4489 (EtOH)
0
0.5
1
200 250 300 350 400
W aveleng t h [ nm]
 
 
1'-Butyl-N,N-diethyl-3',3'-dimethylspiro[chromene-2,2'-indolin]-7-amine (120h) 
BSc4744
N O
N
 
Yield: 61 %. 1H-NMR (500 MHz, CDCl3): δ = 7.17 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.09 (dd, J 
= 7.0 Hz, J = 1.0 Hz, 1H), 6.88 (d, J = 8.5 Hz, 1H), 6.82 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.74 
(d, J = 10.0 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 6.16 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.07 (d, J 
= 2.5 Hz, 1H), 5.41 (d, J = 10.5 Hz, 1H), 3.33-3.07 (m, 6H), 1.70-1.52 (m, 2H), 1.44-1.25 (m, 
5H), 1.18 (s, 3H), 1.13 (t, J = 7.0 Hz, 6H), 0.93 (t, J = 7.0 Hz, 3H) ppm. 13C-NMR (125 MHz, 
CDCl3): δ = 156.0, 149.3, 148.1, 137.1, 129.1, 127.4, 121.6, 118.3, 114.1, 107.7, 106.2, 
105.0, 103.4, 97.7, 51.7, 44.4, 43.6, 31.4, 26.2, 20.6, 20.1, 14.1, 12.7 ppm. UV/Vis 
(Ethanol): λmax = 550.0 nm. 
Absorption BSc4744 (EtOH)
0
0.2
0.4
0.6
0.8
1
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
N,N-Diethyl-5'-fluoro-1',3',3'-trimethylspiro[chromene-2,2'-indolin]-7-amine (120i) 
BSc4807
N O
N
F
 
Yield: 41 %. 1H-NMR (500 MHz, d6-DMSO): δ = 6.96 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.91-
6.83 (m, 2H), 6.81 (d, J = 10.0 Hz, 1H), 6.47 (dd, J = 8.5 Hz, J = 4.0 Hz, 1H), 6.12 (dd, J = 
8.5 Hz, J = 2.5 Hz, 1H), 5.88 (d, J = 2.5 Hz, 1H), 5.35 (d, J = 10.0 Hz, 1H), 3.25-3.17 (m, 4H), 
2.62 (s, 3H), 1.21 (s, 3H), 1.07 (s, 3H), 1.00 (t, J = 7.0 Hz, 6H)  ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 156.5 (d, J = 231.6 Hz), 155.4, 148.9, 144.4, 138.7 (d, J = 7.4 Hz), 129.2, 127.5, 
112.7, 112.5, 109.4 (d, J = 24.1 Hz),  106.9, 106.7 (d, J = 8.0 Hz), 104.3, 103.5, 96.3, 51.0, 
43.5, 28.7, 25.3, 19.4, 12.3 ppm. UV/Vis (Ethanol): λmax = 549.0 nm. 
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Absorption BSc4807 (EtOH)
0
0.5
1
1.5
350 400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
 
5'-Bromo-N,N-diethyl-1',3',3'-trimethylspiro[chromene-2,2'-indolin]-7-amine (120j) 
BSc4808
N O
N
Br
 
Yield: 53 %. 1H-NMR (500 MHz, CDCl3): δ = 7.25 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H), 7.15 (d, J 
= 2.0 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 10.0 Hz, 1H), 6.39 (d, J = 8.5 Hz, 1H), 
6.16 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.05 (d, J = 2.5 Hz, 1H), 5.34 (d, J = 10.0 Hz, 1H), 
3.31-3.25 (m, 4H), 2.72 (s, 3H), 1.30 (s, 3H), 1.15 (s, 3H), 1.12 (t, J = 7.0 Hz, 6H)  ppm. 13C-
NMR (125 MHz, CDCl3): δ = 155.8, 149.4, 147.6, 139.7, 130.1, 129.6, 127.5, 124.8, 112.7, 
110.5, 108.1, 107.5, 104.5, 103.6, 97.3, 51.4, 44.3, 28.9, 25.8, 19.9, 12.7 ppm. UV/Vis 
(Ethanol): λmax = 554.0 nm. 
Absorption BSc4808 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
380 430 480 530 580 630
Wa v e le ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
  
 
N,N-Diethyl-5'-methoxy-1',3',3'-trimethylspiro[chromene-2,2'-indolin]-7-amine (120k) 
BSc4809
N O
N
O
 
Yield: 55 %. 1H-NMR (500 MHz, CDCl3): δ = 6.86 (d, J = 8.5 Hz, 1H), 6.76-6.69 (m, 3H), 
6.44 (d, J = 8.0 Hz, 1H), 6.15 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.07 (d, J = 2.0 Hz, 1H), 5.32 
(d, J = 10.0 Hz, 1H), 3.80 (s, 3H), 3.31-3.24 (m, 4H), 2.71 (s, 3H), 1.32 (s, 3H), 1.16 (s, 3H), 
1.11 (t, J = 7.0 Hz, 6H)  ppm. 13C-NMR (125 MHz, CDCl3): δ = 156.2, 153.6, 149.3, 142.9, 
139.0, 129.2, 127.4, 113.5, 111.1, 109.7, 107.8, 106.8, 104.9, 103.5, 97.5, 55.9, 51.6, 44.3, 
39.4, 25.9, 20.1, 12.7 ppm. 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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N,N-Diethyl-1'-(2-methoxyethyl)-3',3'-dimethylspiro[chromene-2,2'-indolin]-7-amine 
(120l) 
BSc4903
N O
N
O
 
Yield: 35 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.09-7.03 (m, 2H), 6.89 (d, J = 8.5 Hz, 1H), 
6.80 (d, J = 10.0 Hz, 1H), 6.72 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.57 (d, J = 7.5 Hz, 1H), 6.13 
(dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 5.87 (d, J = 2.0 Hz, 1H), 5.39 (d, J = 10.0 Hz, 1H), 3.51-3.13 
(m, 11H), 1.21 (s, 3H), 1.04 (s, 3H), 1.01 (t, J = 7.0 Hz, 6H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 155.2, 148.8, 147.2, 136.1, 129.0, 127.5, 127.1, 121.4, 118.2, 113.2, 106.8, 
106.0, 104.2, 103.5, 96.5, 70.5, 58.1, 51.2, 43.5, 42.6, 25.9, 19.6, 12.4 ppm. UV/Vis 
(Ethanol): λmax = 551.0 nm. 
Absorption BSc4903 (EtOH)
0
0.2
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1
1.2
350 400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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6.7.  Synthesis of merocyanine derivatives  
6.7.1.  Synthesis of 3-ethyl-1,2,3-trimethyl-3H-indolium iodide 
3-Ethyl-2,3-dimethyl-3H-indole (123) 
N
 
A mixture of phenylhydrazine hydrochloride (1.44 g, 10.0 mmol, 1.0 eq) and 3-methylpentan-
2-one (1.2 g, 12.0 mmol, 1.2 eq) was dissolved in glacial acetic acid (20 mL) and then 
heated under reflux temperature for 12 h under argon. When it was cooled down to room 
temperature, the solvent was evaporated in vacuo and the residue was dissolved in 
dichloromethane (30 mL), washed with 10% aqueous Na2CO3 (2 × 30 mL), dried over 
Na2SO4. After filtration, the solvent was evaporated in vacuo. The crude product was purified 
by column chromatography (SiO2; ethyl acetate: cyclohexane = 1:2) to afford 1.68 g of 
product as red liquid.  
Yield: 96 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.54 (d, J = 7.5 Hz, 1H), 7.31 (td, J = 7.5 Hz, 
J = 2.5 Hz, 1H), 7.25-7.18 (m, 2H), 2.26 (s, 3H), 1.96-1.75 (m, 2H), 1.30 (s, 3H), 0.40 (t, J = 
7.5 Hz, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 187.4, 153.9, 143.3, 127.6, 125.2, 
121.6, 119.6, 58.4, 30.1, 22.3, 15.6, 8.5 ppm. 
 
3-Ethyl-1,2,3-trimethyl-3H-indolium iodide (124) 
N I-
 
3-Ethyl-2,3-dimethyl-3H-indole (0.88 g, 5.0 mmol, 1.0 eq) and methyl iodide (1.42 g, 10.0 
mmol, 2.0 eq) were dissolved in anhydrous acetonitrile (15.0 mL). The reaction mixture was 
refluxed overnight. When the reaction mixture was cooled down to room temperature, the 
solvent was evaporated in vacuo and the residue was treated with ethyl acetate (30.0 mL). 
The final product was collected by filtration and washed with ethyl acetate. The colorless 
solid was used in the next reaction without further purification. 
1H-NMR (500 MHz, d6-DMSO): δ = 7.93-7.89 (m, 1H), 7.79-7.75 (m, 1H), 7.67-7.61 (m, 2H), 
4.00 (s, 3H), 2.77 (s, 3H), 2.25-2.03 (m, 2H), 1.51 (s, 3H), 0.39 (t, J = 7.5 Hz, 3H) ppm. 13C-
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NMR (125 MHz, d6-DMSO): δ = 196.2, 142.8, 139.7, 129.5, 129.0, 123.6, 115.1, 58.9, 34.7, 
29.7, 20.6, 14.0, 8.3 ppm. 
 
6.7.2.  Synthesis of 3-substitute-2-methylbenzo[d]oxazol-3-ium iodide 
2,3-Dimethylbenzo[d]oxazol-3-ium iodide (127) 
N
O
I-
 
2-Methylbenzo[d]oxazole (0.67 g, 5.0 mmol, 1.0 eq) and methyl iodide (1.42 g, 10.0 mmol, 
2.0 eq) were dissolved in anhydrous acetonitrile (15.0 mL). The reaction mixture was 
refluxed overnight. When the reaction mixture was cooled down to room temperature, the 
solvent was evaporated in vacuo and the residue was treated with ethyl acetate (30.0 mL). 
The final product was collected by filtration and washed with ethyl acetate. The colorless 
solid was used in the next reaction without further purification. 
3-Butyl-2-methylbenzo[d]oxazol-3-ium iodide (130) 
N
O
I-
 
The mixture of 2-methylbenzo[d]oxazole (0.67 g, 5.0 mmol, 1.0 eq) and butyl iodide (1.84 g, 
10.0 mmol, 2.0 eq) was stirred at 120 °C overnight. When the reaction mixture was cooled 
down to room temperature, the residue was treated with ethyl acetate (30.0 mL). The final 
product was collected by filtration and washed with ethyl acetate. The colorless solid was 
used in the next reaction without further purification. 
 
6.7.3.  Synthesis of merocyanine derivatives 
A mixture of corresponding substituted aldehyde (1.1 mmol, 1.1 eq) and indolium derivatives 
(1.0 mmol, 1.0 eq) in EtOH (5 mL) was refluxed overnight. The solvent was evaporated in 
vacuo and the residue was purified by column chromatography (SiO2; dichloromethane: 
methanol = 10:1) to furnish the corresponding compound with yields of 77-96 %. 
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(E)-1-Butyl-2-(4-(diethylamino)styryl)-3,3-dimethyl-3H-indolium iodide (121a) 
N N
I-
BSc4743
 
Yield: 96 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.32 (d, J = 16.5 Hz, 1H), 8.06 (d, J = 8.5 
Hz, 2H), 7.77 (d, J = 7.5 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.54 (td, J = 7.5 Hz, J = 1.5 Hz, 
1H), 7.46 (td, J = 7.5 Hz, J = 0.5 Hz, 1H), 7.21 (d, J = 16.0 Hz, 1H), 6.86 (d, J = 8.0 Hz, 2H), 
4.50 (t, J = 7.5 Hz, 2H), 3.60-3.52 (m, 4H), 1.81-1.71 (m, 8H), 1.47-1.38 (m, 2H), 1.18 (t, J = 
7.5 Hz, 6H), 0.93 (t, J = 7.5 Hz, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 179.0, 154.2, 
152.6, 142.5, 141.0, 134.6 (brs), 128.7, 127.3, 122.7, 121.9, 113.4, 112.0, 104.0, 50.7, 44.7, 
44.4, 29.8, 26.5, 19.2, 13.6, 12.5 ppm. IR (KBr): ṽ = 3428, 2970, 1742, 1613, 1564, 1523, 
1466, 1418, 1351, 1318, 1289, 1267, 1190, 1154, 1072, 838, 751, 715, 507 cm−1. MS (EI, 70 
eV): m/z = 376 [M+H]+ . Anal. calcd for C26H35IN2: C 62.15, H 7.02, N 5.58, found: C 62.28, 
H 7.00, N 5.66. UV/Vis (Ethanol): λmax = 558.0 nm. 
Absorption BSc4743 (EtOH)
0
0.1
0.2
0.3
0.4
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
(E)-2-(4-(Dimethylamino)styryl)-1,3,3-trimethyl-3H-indolium iodide (121b) 
N N
I-
BSc4745
 
Yield: 93 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.30 (d, J = 16.5 Hz, 1H), 8.07 (d, J = 9.0 
Hz, 2H), 7.77 (d, J = 7.5 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.55 (td, J = 7.5 Hz, J = 1.0 Hz, 
1H), 7.48 (td, J = 7.5 Hz, J = 0.5 Hz, 1H), 7.25 (d, J = 16.5 Hz, 1H), 6.88 (d, J = 9.0 Hz, 2H), 
3.96 (s, 3H), 3.16 (s, 6H), 1.75 (s, 6H). 13C-NMR (125 MHz, d6-DMSO): δ = 179.5, 154.3, 
154.0, 142.4, 142.0, 133.8 (brs), 128.6, 127.4, 122.5, 122.2, 113.5, 112.1, 105.1, 50.8, 33.0, 
26.1 ppm. IR (KBr): ṽ = 3420, 2921, 1574, 1527, 1477, 1375, 1290, 1193, 1170, 1113, 832, 
786, 728, 509 cm−1. MS (EI, 70 eV): m/z = 304 [M-H]+ . Anal. calcd for C21H25IN2: C 58.34, H 
5.83, N 6.48, found: C 58.59, H 5.82, N 6.41. UV/Vis (Ethanol): λmax = 547.5 nm.  
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Absorption BSc4745 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
(E)-2-(4-Methoxystyryl)-1,3,3-trimethyl-3H-indolium iodide (121c) 
N O
I-
BSc4746
 
Yield: 77 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.40 (d, J = 16.0 Hz, 1H), 8.21 (d, J = 8.5 
Hz, 2H), 7.87-7.83 (m, 2H), 7.64-7.57 (m, 2H), 7.54 (d, J = 16.0 Hz, 1H), 7.16 (d, J = 9.0 Hz, 
2H), 4.11 (s, 3H), 3.90 (s, 3H), 1.78 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 181.5, 
 Page 202 
163.7, 153.1, 143.2, 141.7, 133.0, 128.9, 128.8, 127.3, 122.7, 114.9, 114.7, 110.3, 55.8, 51.8, 
34.1, 25.5 ppm. IR (KBr): ṽ = 3435, 2927, 1585, 1564, 1526, 1478, 1298, 1271, 1256, 1171, 
1126, 1035, 828, 761, 517 cm−1. MS (EI, 70 eV): m/z = 291 [M-H]+. Anal. calcd for 
C20H20INO: C 57.29, H 5.29, N 3.34, found: C 57.01, H 5.24, N 3.25. UV/Vis (Ethanol): λmax = 
426.0 nm.  
Absorption BSc4746 (EtOH)
0
0.05
0.1
0.15
300 350 400 450 500 550
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
(E)-2-(4-(Diethylamino)styryl)-1,3,3-trimethyl-3H-indolium iodide (121d) 
N N
I-
BSc4747
 
Yield: 92 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.26 (d, J = 15.5 Hz, 1H), 8.02 (d, J = 8.5 
Hz, 2H), 7.74 (d, J = 7.5 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.53 (td, J = 7.5 Hz, J = 1.0 Hz, 
1H), 7.46 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.19 (d, J = 15.5 Hz, 1H), 6.86 (d, J = 9.0 Hz, 2H),  
3.93 (s, 3H), 3.57-3.51 (m, 4H), 1.73 (s, 6H), 1.17 (t, J = 7.0 Hz, 6H). 13C-NMR (125 MHz, d6-
DMSO): δ = 179.4, 153.9, 152.6, 142.4, 142.1, 134.6 (brs), 128.7, 127.4, 122.6, 121.9, 113.4, 
112.0, 104.6, 50.8, 44.5, 32.9, 26.3, 12.6 ppm. IR (KBr): ṽ = 3420, 1924, 1574, 1526, 1479, 
1404, 1353, 1270, 1191, 1112, 1073, 928, 783, 714, 506 cm−1. MS (EI, 70 eV): m/z = 334 
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[M+H]+ . HRMS: m/z [M]+ calcd for C23H29N2: 333.2331, found: 333.2336. UV/Vis (Ethanol): 
λmax = 548.0 nm. 
Absorption BSc4747 (EtOH)
0
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0.1
0.15
0.2
0.25
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
(E)-2-(4-Hydroxystyryl)-1,3,3-trimethyl-3H-indolium iodide (121e) 
N OH
I-
BSc4748
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Yield: 83 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.33 (d, J = 16.0 Hz, 1H), 8.10 (d, J = 8.5 
Hz, 2H), 7.81 (m, 2H), 7.60 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.55 (td, J = 7.5 Hz, J = 1.0 Hz,  
1H), 7.41 (d, J = 16.5 Hz, 1H), 6.82 (d, J = 8.5 Hz, 2H),  4.06 (s, 3H), 1.76 (s, 6H) ppm. 13C-
NMR (125 MHz, d6-DMSO): δ = 180.8, 164.1, 153.3, 142.9, 141.8, 133.6, 128.7, 128.4, 
125.6, 122.6, 116.7, 114.3, 108.5, 51.5, 33.7, 25.6 ppm. IR (KBr): ṽ = 3442, 3046, 1760, 
1592, 1574, 1538, 1368, 1311, 1273, 1219, 1166, 1108, 940, 818, 766, 666, 483 cm−1. MS 
(EI, 70 eV): m/z = 277 [M-H]+. Anal. calcd for C19H20INO: C 56.31, H 4.97, N 3.46, found: C 
56.63, H 5.09, N 3.43. UV/Vis (Ethanol): λmax = 546.0 nm. 
Absorption BSc4748 (EtOH)
0
0.1
0.2
0.3
0.4
400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
(E)-1,3,3-Trimethyl-2-(4-(4-methylpiperazin-1-yl)styryl)-3H-indolium iodide (121f) 
N N
I-
BSc4749
N
 
Yield: 91 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.30 (d, J = 16.0 Hz, 1H), 8.07 (d, J = 9.0 
Hz, 2H), 7.79 (d, J = 7.5 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H),  7.56 (td, J = 7.5 Hz, J = 1.5 Hz, 
1H), 7.51 (td, J = 7.5 Hz, J = 1.0 Hz,  1H), 7.32 (d, J = 16.0 Hz, 1H), 7.10 (d, J = 9.5 Hz, 2H),  
4.00 (s, 3H), 3.53 (t, J = 5.0 Hz, 4H), 2.46 (t, J = 4.5 Hz, 4H), 2.25 (s, 3H), 1.75 (s, 6H) ppm. 
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13C-NMR (125 MHz, d6-DMSO): δ = 180.1, 154.2, 153.6, 142.7, 141.9, 133.7, 128.7, 127.8, 
123.5, 122.6, 113.8, 113.5, 106.5, 54.1, 51.0, 46.0, 45.4, 33.3, 26.0 ppm. IR (KBr): ṽ = 3434, 
2919, 2802, 1568, 1520, 1479, 1439, 1375, 1291, 1242, 1190, 1172, 1114, 998, 918, 826, 
786, 750, 640, 492 cm−1. MS (EI, 70 eV): m/z = 361.37 [M+H]+. HRMS: m/z [M]+ calcd for 
C24H30N3: 360.2440, found: 360.2399. UV/Vis (Ethanol): λmax = 530.5 nm. 
Absorption BSc4749 (EtOH)
0
0.05
0.1
0.15
0.2
400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
(E)-1,3,3-Trimethyl-2-(4-(pyrrolidin-1-yl)styryl)-3H-indolium iodide (121g) 
N N
I-
BSc4750
 
Yield: 96 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.30 (d, J = 15.5 Hz, 1H), 8.07 (d, J = 8.5 
Hz, 2H), 7.76 (d, J = 7.5 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H),  7.54 (td, J = 7.5 Hz, J = 1.0 Hz, 
1H), 7.46 (td, J = 7.5 Hz, J = 1.0 Hz,  1H), 7.22 (d, J = 15.5 Hz, 1H), 6.75 (d, J = 9.0 Hz, 2H),  
3.95 (s, 3H), 3.48 (t, J = 7.5 Hz, 4H), 2.04-1.98 (m, 4H), 1.74 (s, 6H) ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 179.1, 154.0, 151.9, 142.3, 142.0, 134.2 (brs), 128.5, 127.2, 122.5, 
122.1, 113.3, 112.6, 104.5, 50.6, 47.8, 32.8, 26.2, 24.7 ppm. IR (KBr): ṽ = 3429, 2925, 1614, 
1576, 1529, 1477, 1396, 1293, 1188, 1114, 930, 817, 774, 706 cm−1. MS (EI, 70 eV): m/z = 
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332 [M+H]+. Anal. calcd for C23H27IN2: C 60.27, H 5.94, N 6.11, found: C 60.22, H 5.92, N 
5.96. UV/Vis (Ethanol): λmax = 555.5 nm. 
Absorption BSc4750 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
(E)-2-(2-(1H-Indol-5-yl)vinyl)-1,3,3-trimethyl-3H-indolium iodide (121h) 
N NH
I-
BSc4751
 
Yield: 87 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.67 (s, 1H), 8.56 (d, J = 16.5 Hz, 1H), 
8.51 (s, 1H), 8.02 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.86-7.81 (m, 2H),  7.64-7.55 (m, 4H), 
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7.52 (t, J = 8.0 Hz,  1H), 6.65-6.62 (m, 1H), 4.11 (s, 3H), 1.81 (s, 6H)  ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 181.2, 156.1, 143.0, 141.8, 139.07, 128.7, 1287.5, 128.1, 127.8, 126.5, 
126.0, 123.0, 122.6, 114.4, 112.5, 109.1, 103.0, 51.6, 33.8, 25.6  ppm. UV/Vis (Ethanol): 
λmax = 457.5 nm. 
Absorption BSc4751 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
350 370 390 410 430 450 470 490 510 530 550
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
(E)-2-(4-(Diethylamino)styryl)-5-fluoro-1,3,3-trimethyl-3H-indolium iodide (121i) 
N N
I-
BSc4815
F
 
Yield: 81 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.27 (d, J = 15.5 Hz, 1H),8.04 (d, J = 8.5 Hz, 
2H), 7.77 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 7.71 (dd, J = 9.0 Hz, J = 4.5 Hz, 1H), 7.40 (td, J = 
8.5 Hz, J = 2.5 Hz, 1H), 7.18 (d, J = 15.5 Hz, 1H), 6.87 (d, J = 9.5 Hz, 2H), 3.93 (s, 3H), 3.59-
3.51 (m, 4H), 1.75 (s, 6H), 1.17 (t, J = 7.0 Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 
179.3, 161.4 (J = 243.1 Hz), 153.7, 152.4, 144.7 (J = 9.3 Hz), 138.3, 134.4 (brs), 121.8, 
115.4 (J = 24.3 Hz), 114.8 (J = 9.1 Hz), 111.8, 110.6 (J = 13.3 Hz), 104.6, 50.9, 44.3, 33.1, 
26.0, 12.4 ppm. UV/Vis (Ethanol): λmax = 554.0 nm. 
 Page 208 
Absorption BSc4815 (EtOH)
0
0.2
0.4
0.6
0.8
1
350 400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
(E)-2-(4-(Diethylamino)styryl)-5-methoxy-1,3,3-trimethyl-3H-indolium iodide (121j) 
N N
I-
BSc4816
O
 
Yield: 89 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.20 (d, J = 16.0 Hz, 1H),8.00 (d, J = 9.0 Hz, 
2H), 7.62 (d, J = 9.0 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.17 (d, J = 15.5 Hz, 1H), 7.09 (dd, J = 
8.5 Hz, J = 2.5 Hz,  1H), 6.85 (d, J = 9.5 Hz, 2H), 3.94 (s, 3H), 3.86 (s, 3H), 3.56-3.49 (m, 
4H), 1.74 (s, 6H), 1.17 (t, J = 7.0 Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 177.9, 
159.5, 152.1, 151.9, 144.4, 135.3, 133.7 (brs), 121.7, 114.4, 114.0, 111.6, 108.6, 104.9, 55.9, 
50.8, 44.2, 33.0, 26.0, 12.4 ppm. UV/Vis (Ethanol): λmax = 553.0 nm. 
Absorption BSc4816 (EtOH)
0
0.2
0.4
0.6
0.8
350 400 450 500 550 600 650
Wa v e le ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
(E)-5-Bromo-2-(4-(diethylamino)styryl)-1,3,3-trimethyl-3H-indolium iodide (121k) 
N N
I-
BSc4817
Br
 
Yield: 92 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.30 (d, J = 15.5 Hz, 1H),8.10-8.02 (m, 3H), 
7.73 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.17 (d, J = 15.5 Hz, 1H), 6.89 
(d, J = 9.0 Hz, 2H), 3.91 (s, 3H), 3.60-3.53 (m, 4H), 1.75 (s, 6H), 1.18 (t, J = 7.0 Hz, 6H) 
ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 178.9, 154.2, 152.7, 144.5, 141.4, 134.5 (brs), 
131.3, 125.8, 122.0, 119.8, 115.0, 112.0, 104.2, 50.7, 44.4, 32.9, 26.0, 12.5 ppm. UV/Vis 
(Ethanol): λmax = 564.0 nm. 
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Absorption BSc4817 (EtOH)
0
0.5
1
1.5
350 400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
(E)-2-(4-(Diethylamino)styryl)-3-ethyl-1,3-dimethyl-3H-indolium iodide (123a) 
N N
I-
BSc4813
 
Yield: 93 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.26 (d, J = 15.5 Hz, 1H),8.03 (d, J = 8.5 Hz, 
2H), 7.71-7.65 (m, 2H), 7.55 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.47 (td, J = 7.5 Hz, J = 1.0 Hz, 
1H), 7.23 (d, J = 15.0 Hz, 1H), 6.86 (d, J = 9.0 Hz, 2H), 3.95 (s, 3H), 3.57-3.51 (m, 4H), 2.47-
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2.25 (m, 2H), 1.73 (s, 3H), 1.17 (t, J = 7.0 Hz, 6H), 0.33 (t, J = 7.5 Hz, 3H) ppm. 13C-NMR 
(125 MHz, d6-DMSO): δ = 178.3, 153.4, 152.7, 142.9, 140.3, 134.7 (brs), 238.9, 127.45, 
122.7, 121.9, 113.2, 112.1, 104.8, 55.9, 44.5, 33.6, 32.9, 25.8, 12.6, 8.5 ppm. UV/Vis 
(Ethanol): λmax = 556.5 nm. 
Absorption BSc4813 (EtOH)
0
0.2
0.4
0.6
0.8
350 400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
(E)-2-(4-(Dimethylamino)styryl)-3-ethyl-1,3-dimethyl-3H-indolium iodide (123b) 
N N
I-
BSc4814
 
Yield: 90 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.31 (d, J = 16.0 Hz, 1H),8.07 (d, J = 8.5 Hz, 
2H), 7.71 (t, J = 8.0 Hz, 2H), 7.56 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.49 (td, J = 7.5 Hz, J = 1.0 
Hz, 1H), 7.29 (d, J = 15.5 Hz, 1H), 6.89 (d, J = 9.0 Hz, 2H), 4.00 (s, 3H), 3.17 (s, 6H), 2.46-
2.28 (m, 2H), 1.74 (s, 3H), 0.34 (t, J = 7.5 Hz, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 
178.5, 154.4, 153.5, 142.8, 140.3, 133.9 (brs), 128.7, 127.4, 122.6, 122.1, 113.3, 112.1, 
105.2, 55.9, 33.4, 32.9, 25.6, 8.4 ppm. UV/Vis (Ethanol): λmax = 549.5 nm. 
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Absorption BSc4814 (EtOH)
0
0.2
0.4
0.6
0.8
350 400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
(E)-2-(2-(1H-Indol-5-yl)vinyl)-3-ethyl-1,3-dimethyl-3H-indolium iodide (123c) 
N NH
I-
BSc4865
 
Yield: 80 %. 1H-NMR (500 MHz, d6-DMSO): δ = 11.68 (s, 1H), 8.57 (d, J = 16.0 Hz, 1H),8.51 
(s, 1H), 8.02 (d, J = 9.0 Hz, 1H), 7.85 (d, J = 7.5 Hz, 1H), 7.81 (d, J = 7.5 Hz, 1H), 7.66-7.55 
(m, 4H), 7.53 (t, J = 2.5 Hz, 1H), 6.64 (s, 1H), 4.15 (s, 3H), 3.58-2.37 (m, 2H), 1.81 (s, 3H), 
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0.37 (t, J = 7.0 Hz, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 180.56, 155.86, 142.56, 
140.97, 139.17, 128.90, 128.59, 128.16, 127.87, 126.69, 125.97, 122.99, 122.79, 114.33, 
112.51, 109.24, 103.07, 56.79, 33.81, 33.32, 25.07, 8.34 ppm. UV/Vis (Ethanol): λmax = 
458.5 nm. 
Absorption BSc4865 (EtOH)
0
0.1
0.2
0.3
0.4
320 370 420 470 520 570
Wa v e l e ngt h [ nm]
 
 
(E)-3-Ethyl-1,3-dimethyl-2-(4-(pyrrolidin-1-yl)styryl)-3H-indolium iodide (123d) 
N N
I-
BSc4866
 
Yield: 94 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.29 (d, J = 15.5 Hz, 1H), 8.07 (d, J = 8.0 
Hz, 2H), 7.74-7.67 (m, 2H), 7.56 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.26 (d, J = 15.5 
Hz, 1H), 6.75 (d, J = 8.5 Hz, 2H), 3.97 (s, 3H), 3.49 (t, J = 6.0 Hz, 4H), 2.47-2.27 (m, 2H), 
2.01 (t, J = 6.0 Hz, 4H), 1.74 (s, 3H), 0.35 (t, J = 7.5 Hz, 3H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 178.1, 153.6, 152.0, 142.8, 140.2, 134.2, 128.7, 127.2, 122.6, 122.1, 113.1, 
112.7, 104.7, 55.7, 47.8, 33.5, 32.8, 25.7, 24.7, 8.4 ppm. UV/Vis (Ethanol): λmax = 557.5 nm. 
Absorption BSc4866 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
350 400 450 500 550 600 650
Wa v e le ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
(E)-3-Methyl-2-(4-(pyrrolidin-1-yl)styryl)benzo[d]oxazol-3-ium iodide (129) 
N
O
N
I-
BSc4905
 
Yield: 79 %. 1H-NMR (300 MHz, d6-DMSO): δ = 8.22 (d, J = 15.9 Hz, 1H), 7.98-7.87 (m, 4H), 
7.69-7.63 (m, 2H), 7.30 (d, J = 15.9 Hz, 1H), 6.72 (d, J = 9.0 Hz, 2H), 4.06 (s, 3H), 3.47-3.39 
(m, 4H), 2.04-1.97 (m, 4H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 163.0, 151.2, 151.1, 
146.7, 133.2, 131.4, 127.4, 126.8, 120.7, 113.2, 112.3, 111.7, 95.6, 47.5, 31.5, 24.7 ppm. 
UV/Vis (Ethanol): λmax = 504.0 nm. 
Absorption BSc4905 (EtOH)
0
0.5
1
1.5
2
2.5
3
350 400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
 
(E)-3-Butyl-2-(4-(pyrrolidin-1-yl)styryl)benzo[d]oxazol-3-ium iodide (131) 
N
O
N
I-
BSc4906
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Yield: 83 %. 1H-NMR (300 MHz, d6-DMSO): δ = 8.24 (d, J = 15.0 Hz, 1H), 8.01-7.88 (m, 4H), 
7.69-7.61 (m, 2H), 7.31 (d, J = 15.3 Hz, 1H), 6.71 (d, J = 8.7 Hz, 2H), 4.57 (t, J = 7.2 Hz, 2H), 
3.47-3.40 (m, 4H), 2.04-1.97 (m, 4H), 1.91-1.78 (m, 2H), 1.53-1.38 (m, 2H), 0.94 (t, J = 7.2 
Hz, 3H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 162.7, 151.6, 151.3, 146.9, 133.3, 130.6, 
127.4, 126.8, 120.7, 113.3, 112.3, 111.8, 95.3, 47.6, 44.7, 30.1, 24.7, 19.1, 13.5 ppm. 
UV/Vis (Ethanol): λmax = 509.0 nm. 
Absorption BSc4906 (EtOH)
0
0.2
0.4
0.6
350 400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
 
6.8.  Synthesis of trimethine cyanine derivatives  
6.8.1.  Synthesis of 1-alkyl/PEG-2,3,3-tetramethyl-3H-indolium 
1,2,3,3-Tetramethyl-5-nitro-3H-indolium iodide (134a) 
I-
N
O2N
 
A mixture of (4-nitrophenyl)hydrazine hydrochloride (1.89 g, 10.0 mmol, 1.0 eq) and 3-
methyl-2-butanone (1.03 g, 12.0 mmol, 1.2 eq) was dissolved in glacial acetic acid (20 mL) 
and then heated under reflux temperature for 12 h under argon. When the reaction mixture 
was cooled down to room temperature, the solvent was evaporated under reduced pressure 
and the residue was dissolved in dichloromethane (30 mL), washed with 10% aqueous 
Na2CO3 (2 × 30 mL), dried over Na2SO4. After filtration, the solvent was evaporated in vacuo. 
The crude product was purified by column chromatography (SiO2; ethyl acetate: cyclohexane 
= 1:2) to afford the product as brown liquid. 
2,3,3-Trimethyl-5-nitro-3H-indole (1.02 g, 5 mmol, 1.0 eq) and methyl iodide (1.42 g, 10.0 
mmol, 2.0 eq) were dissolved in anhydrous acetonitrile (15.0 mL). The reaction mixture was 
refluxed overnight. When the reaction mixture was cooled down to room temperature, the 
solvent was evaporated in vacuo and the residue was treated with ethyl acetate (30.0 mL). 
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The final product was collected by filtration and washed with ethyl acetate. The colorless 
solid was used in the next reaction without further purification. 
 
1-Decyl-2,3,3-trimethyl-3H-indolium bromide (134b) 
N
Br-
 
A solution of 2,3,3-trimethylindolenine (0.96 g, 6.0 mmol, 1.0 eq) and 1-bromodecane (4.2 g, 
19 mmol, 3.1 eq) in 15 mL MeCN was heated under reflux temperature and argon overnight. 
When the reaction mixture was cooled down to room temperature, the solvent was 
evaporated under reduced pressure. The final product purified by column chromatography 
(SiO2; dichloromethane: methanol = 10:1) to afford 1.12 g of 1-decyl-2,3,3-trimethyl-3H-
indolium bromide as red waxy solid (yield: 49 %). 
 
1-PEG-2,3,3-tetramethyl-3H-indolium (134c-e) 
N
Cl- PEG
 
Polyethylene glycol (10.0 mmol, 1.0 eq) with THF (3 mL) was added dropwise to a solution of 
NaOH (0.52 g, 13.0 mmol, 1.3 eq) in 1.0 mL water in 0 °C. The solution of p-toluenesulfonyl 
chloride (2.1 g, 11.0 mmol, 1.1 eq) was then added to the mixture. After 12 hours of stirring 
at room temperature, the reaction was quenched with 2.5 mL water and extracted with 
dichloromethane (20 mL). The combined organic phases were washed successively with 2 N 
HCl (15 mL) and brine (15 mL), the organic phase was dried over MgSO4 After filtration, the 
solvent was evaporated in vacuo. 
 Page 217 
2,3,3-Trimethyl-indolenine (5.0 mmol, 1.0 eq) and polyethylene glycol 4-
methylbenzenesulfonate (10.0 mmol, 2.0 eq) were dissolved in anhydrous acetonitrile (10.0 
mL). The reaction mixture was refluxed for 4 days. The color of the reaction mixture turned to 
purple, then it was cooled down to room temperature. The crude product was purified by 
column chromatography (SiO2; dichloromethane: methanol = 10:1, 2 % triethylamine) to 
afford the purple liquid (Yield < 20 %). 
 
6.8.2.  Synthesis of 3-substitute-2-methylbenzo[d]thiazol-3-ium 
2,3-Dimethylbenzo[d]thiazol-3-ium iodide (137a) 
N
S
I-
 
2-Methylbenzo[d]thiazole (0.75 g, 5.0 mmol, 1.0 eq) and methyl iodide (1.42 g, 10.0 mmol, 
2.0 eq) were dissolved in anhydrous acetonitrile (15.0 mL). The reaction mixture was 
refluxed overnight. When the reaction mixture was cooled down to room temperature, the 
solvent was evaporated under reduced pressure and the residue was treated with ethyl 
acetate (30.0 mL). The final product was collected by filtration and washed with ethyl 
acetate. The colorless solid was used in the next reaction without further purification. 
 
3-PEG-2-methylbenzo[d]thiazol-3-ium (137b-c) 
N
S
TsO- PEG
 
2-Methylbenzo[d]thiazole (5.0 mmol, 1.0 eq) and polyethylene glycol 4-
methylbenzenesulfonate (10.0 mmol, 2.0 eq) were stirred at 130 °C for 2 days. The color of 
the reaction mixture turned to purple, then it was cooled to room temperature. The crude 
product was purified by column chromatography (SiO2; dichloromethane: methanol = 10:1) to 
afford the waxy solid (Yield < 20 %). 
 
6.8.3.  General procedures for synthesis of trimethine cyanine  
A solution of corresponding indolium / 3-substitute-2-methylbenzo[d]thiazol-3-ium / 3- 
substitute -2-methylbenzo[d]oxazol-3-ium (1.0 mmol, 1.0 eq) and triethyl orthoformate (296 
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mg, 2.0 mmol, 4.0 eq) in 1 mL of dry pyridine was refluxed for 16 h under argon. When the 
reaction mixture was cooled down to room temperature, the residue was purified by column 
chromatography (SiO2; dichloromethane: methanol = 10:1) to afford the final product in 
moderate yields (yield: 29-83 %). 
1,3,3-Trimethyl-2-((1E,3E)-3-(1,3,3-trimethylindolin-2-ylidene)prop-1-enyl)-3H-indolium 
iodide (135a) 
BSc4704
N
I-
N
 
Yield: 83 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.34 (t, J = 13.5 Hz, 1H), 7.62 (d, J = 7.0 
Hz, 2H), 7.46-7.42 (m, 4H), 7.32-7.27 (m, 2H), 6.44 (d, J = 13.5 Hz, 2H), 3.64 (s, 6H), 1.68 
(s, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 174.4, 149.6, 142.7, 140.6, 128.7, 125.3, 
122.5, 111.5, 102.7, 48.9, 31.4, 27.4 ppm. UV/Vis (Ethanol): λmax = 547.0 nm. 
Absorption BSc4704 (EtOH)
0
0.1
0.2
0.3
400 420 440 460 480 500 520 540 560 580 600
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
1,3,3-Trimethyl-5-nitro-2-((1E,3E)-3-(1,3,3-trimethyl-5-nitroindolin-2-ylidene)prop-1-
enyl)-3H-indolium iodide (135b) 
N
I-
N
O2N NO2
BSc4705
 
Yield: 53 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.60 (d, J = 2.5 Hz, 2H), 8.44 (t, J = 13.5 
Hz, 1H), 8.38 (dd, J = 9.0 Hz, J = 2.5 Hz, 2H), 7.70 (d, J = 9.0 Hz, 2H), 6.74 (d, J = 13.5 Hz, 
2H), 3.74 (s, 6H), 1.76 (s, 12H)  ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 178.5, 151.5, 
147.8, 144.5, 141.9, 125.4, 118.2, 112.1, 105.7, 54.8, 49.0, 32.2, 26.8 ppm. MS (EI, 70 eV): 
m/z = 446 [M-1]+. UV/Vis (Ethanol): λmax = 567.0 nm. 
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Absorption JG268 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
 
1-Decyl-2-((1E,3E)-3-(1-decyl-3,3-dimethylindolin-2-ylidene)prop-1-enyl)-3,3-dimethyl-
3H-indolium bromide (135c) 
N
Br-
N
BSc4737
 
Yield: 68 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.35 (t, J = 13.5 Hz, 1H), 7.65 (d, J = 7.5 
Hz, 2H), 7.47 (d, J = 7.5 Hz, 2H), 7.43 (td, J = 8.0 Hz, J = 1.0 Hz, 2H), 7.29 (td, J = 8.0 Hz, J 
= 1.0 Hz, 2H), 6.65 (d, J = 13.5 Hz, 2H), 4.15 (t, J = 7.5 Hz, 4H), 1.76-1.68 (m, 4H), 1.69 (s, 
12H), 1.44-1.35 (m, 4H), 1.35-1.26 (m, 4H), 1.26-1.14 (m, 20H), 0.81 (t, J = 7.0 Hz, 6H) ppm. 
13C-NMR (125 MHz, d6-DMSO): δ = 173.6, 149.7, 141.7, 140.5, 128.5, 125.1, 122.4, 111.5, 
102.7, 48.7, 43.7, 31.1, 28.8, 28.7, 28.7, 28.5, 27.3, 26.9, 25.9, 21.9, 13.8 ppm. UV/Vis 
(Ethanol): λmax = 551.0 nm. 
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Absorption BSc4737 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
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1-(2-(2-(2-Methoxyethoxy)ethoxy)ethyl)-2-((1E,3E)-3-(1-(2-(2-(2-
methoxyethoxy)ethoxy)ethyl)-3,3-dimethylindolin-2-ylidene)prop-1-enyl)-3,3-dimethyl-
3H-indolium chloride (135d) 
N
Cl-
N
O
O
O
O
O
O
BSc4738
 
Yield: 38 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.38 (t, J = 13.0 Hz, 1H), 7.63 (d, J = 7.0 
Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.42 (td, J = 8.0 Hz, J = 1.0 Hz, 2H), 7.29 (td, J = 8.0 Hz, J 
= 1.0 Hz, 2H), 6.55 (d, J = 13.5 Hz, 2H), 4.34 (t, J = 5.0 Hz, 4H), 3.82 (t, J = 5.0 Hz, 4H), 
3.55-3.50 (m, 4H), 3.44-3.40 (m, 4H), 3.39-3.36 (m, 4H), 3.31-3.27 (m, 4H), 3.16 (s, 6H), 
1.70 (s, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 174.5, 149.7, 142.1, 140.3, 128.3, 
125.0, 122.2, 111.9, 103.1, 71.1, 70.2, 69.7, 69.5, 67.1, 57.9, 48.8, 44.1, 27.4 ppm. MS (EI): 
m/z = 622 [M+1]+. UV/Vis (Ethanol): λmax = 551.5 nm. 
Absorption BSc4738 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
1-Butyl-2-((1E,3E)-3-(1-butyl-3,3-dimethylindolin-2-ylidene)prop-1-enyl)-3,3-dimethyl-
3H-indolium iodide (135e) 
N
I-
N
BSc4739
 
Yield: 61 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.36 (t, J = 13.5 Hz, 1H), 7.64 (d, J = 7.0 
Hz, 2H), 7.49-7.41 (m, 4H), 7.30 (td, J = 7.5 Hz, J = 1.5 Hz, 2H), 6.58 (d, J = 13.5 Hz, 2H), 
4.14 (t, J = 7.5 Hz, 4H), 1.77-1.71 (m, 4H), 1.70 (s, 12H), 1.48-1.40 (m, 4H), 0.94 (t, J = 7.5 
Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 173.7, 149.8, 141.8, 140.5, 128.5, 125.1, 
122.4, 111.5, 102.5, 48.8, 43.6, 29.1, 17.4, 19.5, 13.7 ppm. UV/Vis (Ethanol): λmax = 
550.5 nm. 
Absorption BSc4739 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
400 450 500 550 600 650
Wa v e le ngt h [ nm]
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In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
1-(2-Methoxyethyl)-2-((1E,3E)-3-(1-(2-methoxyethyl)-3,3-dimethylindolin-2-
ylidene)prop-1-enyl)-3,3-dimethyl-3H-indolium chloride (135f) 
N
Cl-
N
O O
BSc4741
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Yield: 29 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.39 (t, J = 13.0 Hz, 1H), 7.63 (d, J = 7.0 
Hz, 2H), 7.48-7.40 (m, 4H), 7.29 (td, J = 8.0 Hz, J = 1.5 Hz, 2H), 6.53 (d, J = 13.5 Hz, 2H), 
4.34 (t, J = 5.5 Hz, 4H), 3.26 (s, 6H), 1.70 (s, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 
174.5, 149.9, 142.2, 140.3, 128.4, 125.0, 122.3, 111.8, 103.0, 68.8, 58.6, 48.8, 44.1, 27.4 
ppm. UV/Vis (Ethanol): λmax = 550.0 nm. 
Absorption BSc4741 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
0.6
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
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5-Bromo-2-((1E,3E)-3-(5-bromo-1,3,3-trimethylindolin-2-ylidene)prop-1-enyl)-1,3,3-
trimethyl-3H-indolium iodide (135g) 
BSc4742
N
I-
N
Br Br
 
Yield: 58 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.30 (t, J = 13.5 Hz, 1H), 7.93 (d, J = 2.0 
Hz, 2H), 7.64 (dd, J = 8.5 Hz, J = 2.0 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 6.45 (d, J = 13.5 Hz, 
2H), 3.63 (s, 6H), 1.68 (s, 12H)  ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 174.1, 149.6, 
142.7, 141.9, 131.2, 125.5, 117.4, 113.2, 103.1, 48.9, 31.5, 26.9, 26.2 ppm. UV/Vis 
(Ethanol): λmax = 556.0 nm. 
Absorption BSc4742 (EtOH)
0
0.2
0.4
0.6
0.8
1
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
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In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
 
 
5-Fluoro-2-((1E,3E)-3-(5-fluoro-1,3,3-trimethylindolin-2-ylidene)prop-1-enyl)-1,3,3-
trimethyl-3H-indolium iodide (135h) 
BSc4806
N
I-
N
F F
 
Yield: 43 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.28 (t, J = 13.5 Hz, 1H), 7.64 (dd, J = 8.0 
Hz, J = 2.5 Hz, 2H), 7.48 (dd, J = 9.0 Hz, J = 4.0 Hz, 2H), 7.30 (td, J = 9.0 Hz, J = 2.5 Hz, 
2H), 6.40 (d, J = 13.5 Hz, 2H), 3.63 (s, 6H), 1.69 (s, 12H) ppm. 13C-NMR (125 MHz, d6-
DMSO): δ = 174.3, 160.2 (d, J = 240.4 Hz), 149.1, 142.5 (d, J = 8.6 Hz), 138.9, 115.0 (d, J = 
24.3 Hz),  112.5 (d, J = 8.8 Hz), 110.5 (d, J = 25.5 Hz), 102.6, 49.0, 31.5, 27.0 ppm. UV/Vis 
(Ethanol): λmax = 547.0 nm. 
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Absorption BSc4806 (EtOH)
0
0.2
0.4
0.6
0.8
380 430 480 530 580 630
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
5-Methoxy-2-((1E,3E)-3-(5-methoxy-1,3,3-trimethylindolin-2-ylidene)prop-1-enyl)-1,3,3-
trimethyl-3H-indolium iodide (135i) 
BSc4810
N
I-
N
O O
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Yield: 51 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.23 (t, J = 13.5 Hz, 1H), 7.35 (d, J = 8.5 Hz, 
2H), 7.29 (d, J = 2.5 Hz, 2H), 6.99 (dd, J = 8.5 Hz, J = 2.5 Hz, 2H), 6.32 (d, J = 13.5 Hz, 2H), 
3.82 (s, 6H), 3.60 (s, 6H), 1.67 (s, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 172.9, 
157.7, 147.6, 142.0, 136.1, 113.3, 111.9, 109.1, 101.8, 55.8, 48.8, 31.3, 27.2 ppm. UV/Vis 
(Ethanol): λmax = 574.0 nm. 
Absorption BSc4810 (EtOH)
0
0.5
1
1.5
2
400 450 500 550 600 650 700
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
 
 
 
 Page 230 
3-Ethyl-2-((1E,3E)-3-(3-ethyl-1,3-dimethylindolin-2-ylidene)prop-1-enyl)-1,3-dimethyl-
3H-indolium iodide (135j) 
BSc4811
N
I-
N
 
Yield: 67 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.29 (t, J = 13.5 Hz, 1H), 7.57 (d, J = 7.5 Hz, 
2H), 7.48-7.42 (m, 4H), 7.33-7.28 (m, 2H), 6.48 (d, J = 13.5 Hz, 2H), 3.65 (s, 6H), 2.37-2.04 
(m, 4H), 1.66 (s, 3H), 1.65 (s, 3H), 0.42-0.36 (m, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ 
= 172.9, 148.5, 143.5, 138.3, 128.7, 125.2, 122.4, 111.2, 103.0, 54.0, 34.1, 31.3, 26.9, 26.8, 
8.6, 8.5 ppm. UV/Vis (Ethanol): λmax = 548.5 nm. 
Absorption BSc4811 (EtOH)
0
0.5
1
1.5
2
2.5
350 400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
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1-(2-(2-Methoxyethoxy)ethyl)-2-((1E,3E)-3-(1-(2-(2-methoxyethoxy)ethyl)-3,3-
dimethylindolin-2-ylidene)prop-1-enyl)-3,3-dimethyl-3H-indolium 4-methylbenzene 
sulfonate (135k) 
N N
O
O
O
O
BSc4818
-O
S
O
O
 
Yield: 34 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.38 (t, J = 13.5 Hz, 1H), 7.63 (d, J = 7.5 
Hz, 2H), 7.51-7.39 (m, 6H), 7.29 (t, J = 7.5 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 6.54 (d, J = 13.0 
Hz, 2H), 4.34 (t, J = 5.5 Hz, 4H), 3.81 (t, J = 5.5 Hz, 4H), 3.55-3.50 (m, 4H), 3.36-3.32 (m, 
4H), 3.11 (s, 6H), 2.28 (s, 3H), 1.70 (s, 12H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 174.5, 
149.7, 145.7, 142.1, 140.3, 137.4, 128.3, 127.9, 125.4, 125.0, 122.2, 111.9, 103.1, 71.1, 
70.0, 67.1, 58.0, 48.8, 44.1, 27.4, 20.7 ppm. UV/Vis (Ethanol): λmax = 550.5 nm. 
Absorption BSc4818 (EtOH)
0
0.5
1
1.5
2
2.5
350 400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
 
1-(3-Methoxypropyl)-2-((1E,3E)-3-(1-(3-methoxypropyl)-3,3-dimethylindolin-2-
ylidene)prop-1-enyl)-3,3-dimethyl-3H-indolium chloride (135l) 
N
Cl-
N
O O
BSc4920
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Yield: 35 %. 1H-NMR (300 MHz, d6-DMSO): δ = 8.38 (t, J = 13.5 Hz, 1H), 7.64 (d, J = 7.2 
Hz, 2H), 7.50-7.40 (m, 4H), 7.35-7.24 (m, 2H), 6.48 (d, J = 13.5 Hz, 2H), 4.20 (t, J = 6.9 Hz, 
4H), 3.39 (t, J = 5.7 Hz, 4H), 3.21 (s, 6H), 3.12-3.00 (m, 4H), 1.70 (s, 12H) ppm. 13C-NMR 
(75 MHz, d6-DMSO): δ = 174.0, 153.8, 149.7, 147.0, 141.5, 128.5, 125.1, 122.4, 111.3, 
102.4, 68.5, 57.8, 48.9, 27.3, 26.9 ppm. UV/Vis (Ethanol): λmax = 550.0 nm. 
Absorption BSc4920 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
400 450 500 550 600 650
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
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3-Methyl-2-((1E,3E)-3-(3-methylbenzo[d]thiazol-2(3H)-ylidene)prop-1-
enyl)benzo[d]thiazol-3-ium iodide (138a) 
BSc4706
N
S
I- N
S
 
Yield: 72 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.96 (d, J = 8.0 Hz, 2H), 7.74-7.66 (m, 3H), 
7.53 (t, J = 8.0 Hz, 2H), 7.37 (t, J = 8.0 Hz, 2H), 6.52 (d, J = 13.0 Hz, 2H), 3.80 (s, 6H)  ppm. 
13C-NMR (125 MHz, d6-DMSO): δ = 164.8, 145.9, 141.7, 127.9, 125.0, 124.71, 122.8, 113.4, 
98.8, 33.4 ppm. UV/Vis (Ethanol): λmax = 558.0 nm. 
Absorption BSc4706 (EtOH)
0
0.05
0.1
0.15
0.2
400 420 440 460 480 500 520 540 560 580 600
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
      
 
3-(2-Methoxyethyl)-2-((1E,3E)-3-(3-(2-methoxyethyl)benzo[d]thiazol-2(3H)-ylidene)prop-
1-enyl)benzo[d]thiazol-3-ium 4-methylbenzenesulfonate (138b) 
BSc4867
N
S
N
S
O O
-O
S
O
O
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Yield: 37 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.85 (d, J = 8.0 Hz, 2H), 7.61 (t, J = 12.5 
Hz, 1H), 7.53 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.17 (t, J 
= 7.5 Hz, 2H), 7.15-7.08 (m, 4H), 4.48-4.40 (m, 4H), 3.83-3.76 (m, 4H), 3.20 (s, 6H), 2.30 (s, 
3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 164.4, 146.9, 144.3, 142.2, 138.8, 128.4, 
127.5, 126.0, 124.9, 124.7, 121.9, 113.8, 101.1, 70.2, 59.0, 47.4, 21.2 ppm. UV/Vis 
(Ethanol): λmax = 547.0 nm. 
Absorption BSc4867 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
 
3-(2-(2-(2-Methoxyethoxy)ethoxy)ethyl)-2-((1E,3E)-3-(3-(2-(2-(2-methoxyethoxy)ethoxy) 
ethyl)benzo[d]thiazol-2(3H)-ylidene)prop-1-enyl)benzo[d]thiazol-3-ium 4-methyl 
benzenesulfonate (138c) 
BSc4868
N
S
N
S
O
O
O
O -O
S
O
O
O O
 
Yield: 34 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.82 (d, J = 8.0 Hz, 2H), 7.63 (t, J = 13.0 
Hz, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.19 (t, J 
= 7.5 Hz, 2H), 7.16-7.09 (m, 4H), 4.50-4.40 (m, 4H), 3.90-3.85 (m, 4H), 3.52-3.34 (m, 16H), 
3.28 (s, 6H), 2.29 (s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 164.5, 147.0, 144.1, 
142.3, 138.8, 128.4, 127.4, 126.0, 124.8, 124.7, 141.8, 114.1, 101.2, 71.7, 70.6, 70.2, 70.2, 
68.6, 58.8, 47.4, 21.2 ppm. UV/Vis (Ethanol): λmax = 563.5 nm. 
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Absorption BSc4868 (EtOH)
0
0.5
1
1.5
2
400 450 500 550 600 650
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 71 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
3-Methyl-2-((1E,3E)-3-(3-methylbenzo[d]oxazol-2(3H)-ylidene)prop-1-
enyl)benzo[d]oxazol-3-ium iodide (138d) 
N
O
N
O
I-
BSc4904
 
Yield: 70 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.28 (t, J = 13.5 Hz, 1H), 7.75 (d, J = 8.0 
Hz, 2H), 7.70 (d, J = 7.5 Hz, 2H), 7.46 (td, J = 7.5 Hz, J = 1.0 Hz, 2H), 7.39 (td, J = 7.5 Hz, J 
= 1.0 Hz, 2H), 6.01 (d, J = 13.5 Hz, 2H), 3.73 (s, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ 
 Page 236 
= 162.0, 146.2, 145.7, 131.8, 125.7, 124.8, 111.1, 110.6, 84.8, 30.2 ppm. UV/Vis (Ethanol): 
λmax = 484.0 nm. 
Absorption BSc4904 (EtOH)
0
0.5
1
1.5
2
2.5
300 350 400 450 500 550 600
Wa v e l e ngt h [ nm]
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
 
 
3-Butyl-2-((1E,3E)-3-(3-butylbenzo[d]oxazol-2(3H)-ylidene)prop-1-enyl)benzo[d]oxazol-
3-ium iodide (138e) 
BSc4907
N
O
N
O
I-
 
Yield: 68 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.32 (t, J = 13.5 Hz, 1H), 7.76 (d, J = 7.5 
Hz, 2H), 7.70 (d, J = 7.5 Hz, 2H), 7.47 (td, J = 8.0 Hz, J = 1.0 Hz, 2H), 7.41 (td, J = 8.0 Hz, J 
= 1.0 Hz, 2H), 6.11 (d, J = 13.5 Hz, 2H), 4.21 (t, J = 7.5 Hz, 4H), 1.81-1.72 (m, 4H), 1.45-
1.36 (m, 4H), 0.94 (t, J = 7.0 Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 161.6, 146.3, 
131.2, 125.8, 124.9, 111.3, 110.8, 85.0, 43.6, 29.4, 19.3, 13.5 ppm. UV/Vis (Ethanol): λmax = 
486.5 nm. 
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Absorption BSc4907 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
350 370 390 410 430 450 470 490 510 530 550
Wa v e l e ngt h [ nm]
 
 
6.9. Synthesis of N-2-aryl-1,2,3-triazole derivatives  
6.9.1.  General procedures for azo coupling 
To a mixture of 4-substituted-2-nitroanilinein (2.0 mmol, 1.0 eq), water (5 mL) and 
concentrated hydrochloric acid (HCl, 12 mol/L, 0.5 mL) at 0 oC, a solution of sodium nitrite 
(152 mg, 2.2 mmol, 1.1 eq) in water (5 mL) was added dropwise while the temperature was 
maintained below 5 oC. After stirring for 20 min, a solution of benzenediazonium chloride was 
prepared. Subsequently, the solution was added gradually to a mixture of aromatic 
compounds (2.2 mmol, 1.1 eq), sodium hydroxide (80 mg, 2 mmol, 1.0 eq), ethanol (5 mL) 
and water (20 mL) at 0-5 oC. After the addition of the above diazonium solution, the mixture 
was further stirred for 6 h until a lot of precipitates were produced. The reaction residue was 
extracted with EtOAc and washed with water. The crude product was purified by column 
chromatography (SiO2; ethyl acetate: cyclohexane = 1:10) to furnish the corresponding 
compound. 
 (E)-4-((4-(Dimethylamino)phenyl)diazenyl)-3-nitrobenzonitrile (141a) 
N
NO2NC
N
N
 
Yield: 21 %. 1H-NMR (300 MHz, d6-DMSO): δ = 8.60 (d, J = 1.8 Hz, 1H), 8.16 (dd, J = 8.4 
Hz, J = 1.8 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 9.3 Hz, 2H), 6.88 (d, J = 9.3 Hz, 
2H), 3.13 (s, 6H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 154.3, 146.8, 146.5, 143.0, 136.6, 
128.1, 126.7, 119.4, 117.2, 111.9, 110.6, 39.9 ppm. 
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(E)-N,N-Dimethyl-4-((2-nitrophenyl)diazenyl)aniline (141b) 
N
NO2
N
N
 
Yield: 32 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.98 (dd, J = 8.0 Hz, J = 1.0 Hz, 1H), 7.77-
7.69 (m, 4H), 7.62-7.57 (m, 1H), 6.84 (d, J = 9.0 Hz, 2H), 3.08 (s, 6H) ppm. 13C-NMR (125 
MHz, d6-DMSO): δ = 153.3, 146.8, 144.4, 142.5, 132.9, 129.3, 125.6, 123.6, 118.2, 111.5, 
39.7 ppm. 
 
(E)-N,N-Diethyl-4-((2-nitrophenyl)diazenyl)aniline (141c) 
N
NO2
N
N
 
Yield: 28 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.96 (dd, J = 8.5 Hz, J = 1.0 Hz, 1H), 7.75-
7.67 (m, 4H), 7.59-7.54 (m, 1H), 6.78 (d, J = 9.0 Hz, 2H), 3.47-3.37 (m, 4H), 1.12 (t, J = 7.0 
Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 151.0. 146.8. 144.5. 142.2. 132.8. 129.1. 
126.0. 123.6. 118.2. 111.0. 44.1. 12.3 ppm. 
 
(E)-N,N-Dimethyl-4-((4-methyl-2-nitrophenyl)diazenyl)aniline (141d) 
N
NO2
N
N
 
Yield: 41%. 1H-NMR (500 MHz, d6-DMSO): δ = 7.81 (d, J = 0.5 Hz, 1H), 7.72 (d, J = 9.5 Hz, 
2H), 7.64 (d, J = 8.5 Hz, 1H), 7.58-7.54 (m, 1H), 6.84 (d, J = 9.0 Hz, 2H), 3.08 (s, 6H), 2.44 
(s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 153.1, 147.0, 142.5, 142.1, 140.1, 133.4, 
125.3, 123.5, 117.8, 111.5, 39.7, 20.4 ppm. 
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(E)-N,N-Diethyl-4-((4-methyl-2-nitrophenyl)diazenyl)aniline (141e) 
N
NO2
N
N
 
Yield: 34 %. 1H-NMR (500 MHz, d6-DMSO): δ = 7.78 (d, J = 1.0 Hz, 1H), 7.70 (d, J = 9.0 Hz, 
2H), 7.62 (d, J = 8.5 Hz, 1H), 7.55-7.51 (m, 1H), 6.80 (d, J = 9.5 Hz, 2H), 3.49-3.42 (m, 4H), 
3.42 (s, 3H), 1.14 (t, J = 7.5 Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 150.8, 146.9, 
142.2, 142.1, 139.8, 133.3, 125.7, 123.5, 117.8, 111.0, 44.1, 20.4, 12.3 ppm. 
 
(E)-4-((4-Methoxy-2-nitrophenyl)diazenyl)-N,N-dimethylaniline (141f) 
N
NO2O
N
N
 
Yield: 31 %. 1H-NMR (300 MHz, d6-DMSO): δ = 7.75 (d, J = 9.0 Hz, 1H), 7.69 (d, J = 9.3, 
2H), 7.57 (d, J = 2.7 Hz, 1H), 7.30 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 6.83 (d, J = 9.3 Hz, 2H), 
3.90 (s, 3H), 3.07 (s, 6H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 159.8, 152.8, 148.6, 142.4, 
137.5, 125.0, 119.0, 118.8, 111.5, 107.9, 56.3, 39.7 ppm. 
 
(E)-N,N-Diethyl-4-((4-methoxy-2-nitrophenyl)diazenyl)aniline (141g) 
N
NO2O
N
N
 
Yield: 37 %. 1H-NMR (300 MHz, d6-DMSO): δ = 7.74 (d, J = 9.0 Hz, 1H), 7.67 (d, J = 9.3, 
2H), 7.56 (d, J = 2.7 Hz, 1H), 7.29 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 6.80 (d, J = 9.3 Hz, 2H), 
3.90 (s, 3H), 3.51-.341 (m, 4H), 1.15 (t, , J = 7.2 Hz, 6H) ppm. 13C-NMR (75 MHz, d6-DMSO): 
δ = 159.6, 150.5, 148.4, 142.0, 137.6, 125.4, 119.0, 118.8, 111.0, 107.8, 56.2, 44.0, 12.4 
ppm. 
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6.9.2.  General procedures for synthesis of N-2-aryl-1,2,3-triazole 
2-Nitroazobenzene derivatives (1.0 mmol, 1.0 eq) and of sodium azide (325 mg, 5.0 mmol, 
5.0 eq) were stirred for 2 days at 125° C in 2 mL DMSO. When the conversion had taken 
place, the mixture was cooled down and water was added to the mixture. The reaction 
residue was extracted with EtOAc and washed with water. The crude product was purified by 
column chromatography (SiO2; ethyl acetate: cyclohexane = 1:10) to furnish the 
corresponding final compound in poor yields. 
2-(4-(Dimethylamino)phenyl)-2H-benzo[d][1,2,3]triazole-5-carbonitrile (142a) 
N
N
N
N
NC
BSc 4954
 
Yield: 21 %. 1H-NMR (500 MHz, CDCl3): δ = 8.33 (m, 1H), 8.27 (d, J = 9.0 Hz, 2H), 8.00 (dd, 
J = 9.0 Hz, J = 1.0 Hz,  1H), 7.54 (dd, J = 8.0 Hz, J = 1.5 Hz, 1H), 6.99 (d, J = 9.0 Hz, 2H), 
3.11 (s, 6H) ppm. UV/Vis (Ethanol): λmax = 390.5 nm. 
Absorption BSc4954 (EtOH)
0
0.02
0.04
0.06
0.08
0.1
0.12
300 350 400 450 500
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
 
 
 
 Page 241 
4-(2H-benzo[d][1,2,3]triazol-2-yl)-N,N-dimethylaniline (142b) 
N
N
N
N
BSc 4955
 
Yield: 29 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.12 (d, J = 9.5 Hz, 2H), 7.97 (dd, J = 6.5 
Hz, J = 3.0 Hz,  2H), 7.46 (dd, J = 6.5 Hz, J = 3.0 Hz,  2H), 6.90 (d, J = 9.5 Hz, 2H), 3.02 (s, 
6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 150.7. 144.0. 129.0. 126.6. 121.1. 117.6. 
112.0. 39.9 ppm. UV/Vis (Ethanol): λmax = 361.0 nm. 
Absorption BSc4955 (EtOH)
0
0.2
0.4
0.6
0.8
300 350 400 450
Wavelength [nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of PD brain sections: Tissues: midbrain; Patient: male, 
76 years old. 
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4-(2H-Benzo[d][1,2,3]triazol-2-yl)-N,N-diethylaniline (142c) 
N
N
N
N
BSc 4956
 
Yield: 25 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.09 (d, J = 9.5 Hz, 2H), 7.96 (dd, J = 6.5 
Hz, J = 3.0 Hz,  2H), 7.45 (dd, J = 6.5 Hz, J = 3.0 Hz,  2H), 6.84 (d, J = 9.5 Hz, 2H), 3.45-
3.39 (m, 4H), 1.14 (t, J = 7.0 Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 148.0, 143.9, 
128.1, 126.5, 121.5, 117.5, 111.2, 43.8, 12.3 ppm. UV/Vis (Ethanol): λmax = 368.5 nm. 
Absorption BSc4956 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
300 350 400 450 500
W aveleng t h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
In vitro neuropathological staining of AD olfactory epithelium sections: Tissues: 
olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD Score: 3. 
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N,N-Dimethyl-4-(5-methyl-2H-benzo[d][1,2,3]triazol-2-yl)aniline (142d) 
N
N
N
N
BSc 4957
 
Yield: 17 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.09 (d, J = 9.0 Hz, 2H), 7.85 (d, J = 8.5 Hz, 
1H), 7.71 (d, J = 1.0 Hz,  1H), 7.29 (dd, J = 8.5 Hz, J = 1.5 Hz,  1H), 6.88 (d, J = 9.5 Hz, 2H), 
3.00 (s, 6H), 2.45 (s, 3H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 150.5, 144.5, 142.7, 
136.3, 129.3, 129.1, 120.9, 117.1, 115.7, 112.0, 39.8, 21.5 ppm. UV/Vis (Ethanol): λmax = 
359.5 nm. 
Absorption BSc4957 (EtOH)
0
0.1
0.2
0.3
0.4
0.5
300 320 340 360 380 400 420 440
Wa v e le ngt h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
 
N,N-Diethyl-4-(5-methyl-2H-benzo[d][1,2,3]triazol-2-yl)aniline (142e) 
N
N
N
N
BSc 4958
 
Yield: 23 %. 1H-NMR (500 MHz, d6-DMSO): δ = 8.05 (d, J = 9.5 Hz, 2H), 7.84 (d, J = 8.5 Hz, 
1H), 7.71-7.69 (m, 1H), 7.28 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H), 6.82 (d, J = 9.0 Hz, 2H), 3.44-
3.34 (m, 4H), 2.46 (s, 3H), 1.13 (t, J = 7.5 Hz, 6H) ppm. 13C-NMR (125 MHz, d6-DMSO): δ = 
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147.8, 144.4, 142.6, 136.2, 129.1, 128.2, 121.3, 117.0, 115.7, 111.2, 43.7, 21.5, 12.3 ppm. 
UV/Vis (Ethanol): λmax = 362.0 nm. 
Absorption BSc4558 (EtOH)
0
0.1
0.2
0.3
0.4
300 350 400 450 500
W aveleng t h [ nm]
 
In vitro neuropathological staining of AD brain sections: Tissues: hippocampus; Patient: 
male, 72 years old; CERAD Score: 3; NFTs-level: V. 
 
 
4-(5-Methoxy-2H-benzo[d][1,2,3]triazol-2-yl)-N,N-dimethylaniline (142f) 
N
N
N
N
O
BSc5043
 
Yield: 14 %. 1H-NMR (300 MHz, d6-DMSO): δ = 8.05 (d, J = 9.3 Hz, 2H), 7.84 (dd, J = 9.3 
Hz, J = 0.6 Hz, 1H), 7.29 (d, J = 2.1 Hz, 1H), 7.11 (dd, J = 9.3 Hz, J = 2.4 Hz, 1H), 6.89 (d, J 
= 9.3 Hz, 2H), 3.87 (s, 3H), 3.00 (s, 6H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 158.4, 
150.4, 145.0, 140.0, 129.2, 121.0, 120.7, 118.5, 112.1, 95.0, 55.5, 39.9 ppm. UV/Vis 
(Ethanol): λmax = 368.5 nm. 
Absorption BSc5043 (EtOH)
0
0.2
0.4
0.6
0.8
1
1.2
300 320 340 360 380 400 420 440
Wa v e l e ngt h [ nm]
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N,N-Diethyl-4-(5-methoxy-2H-benzo[d][1,2,3]triazol-2-yl)aniline (142g) 
N
N
N
N
O
BSc5044
 
Yield: 17 %. 1H-NMR (300 MHz, d6-DMSO): δ = 8.01 (d, J = 9.3 Hz, 2H), 7.84 (d, J = 9.0 Hz, 
1H), 7.28 (d, J = 2.7, 1H), 7.09 (dd, J = 9.3 Hz, J = 2.4 Hz, 1H), 6.81 (d, J = 9.3 Hz, 2H), 3.86 
(s, 3H), 3.46-3.35 (m, 4H), 1.12 (t, J = 6.9 Hz, 6H) ppm. 13C-NMR (75 MHz, d6-DMSO): δ = 
158.3, 147.6, 145.0, 140.0, 128.4, 121.0, 120.8, 118.4, 111.3, 95.0, 55.5, 43.8, 12.3 ppm. 
 
6.10.  In vitro neuropathological staining of brain sections  
Four micrometers thick serial sections of paraffin-embedded brain sections or olfactory 
epithelium sections of AD patients were used in this study. The brain sections were 
deparaffinized and hydrated in distilled water. The tissue sections were treated with acid 
hemalum solution and wansed with running water. Then the sections immersed in 1 mM 
solution of the probe in DMSO for 10 minutes and then washed with methanol. The sections 
were differentiated in 1 % acetic acid for 20 min, afterwards washed with running water for 5 
min. Finally, the sections were treated with Roti®-Mount FluorCare (from Sigma-Aldrich) and 
covered with a coverslip.  
Table 6.1 Procedures for in vitro neuropathological staining of AD brain sections. 
Steps Procedures Time Notes 
1 Acid Hemalum solution 10 min Nuclear stain in histology 
2 Washed with running water 5 min  
3 Stained the tissues 10 min Keep in dark 
4 
Washed with methanol 
and/or DMSO 
 2-5 mL solvent 
5 1 % acetic acid solution 20 min Differentiate 
6 Washed with running water 5 min  
7 Finalize  
Treat with Roti®-Mount FluorCare 
protected with coverslip 
8 
Visualized by fluorescence 
microscopy 
5 min 
Detection by the DAPI- or FITC-
filters 
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The sections were analyzed by fluorescence microscopy using a Axioskop microsocope with 
a HBO100 fluorescence illuminator (Carl Zeiss, Oberkochem, Germany) with the bandpass 
filter set 09 BP450-490, FT510, LP515, the filter set 02 G365, FT395, LP420 and the filter 
set 15 BP546, FT580, LP590 (all Carl Zeiss, Oberkochem, Germany). 
 
6.11.  In vitro binding affinity determined by Thiazine Red R displacement 
assay  
Recombinant human microtubule associated tau protein purified from E.coli was aggregated 
at a concentration of 5 µM with arachidonic acid (100 µM) in 10 mM Tris, pH = 8, for 24 h at 
37 °C. Synthetic Aβ40 was aggregated at a concentration of 50 µM with arachidonic acid (100 
µM) in 10 mM Tris, pH = 8, for three days at 37 °C, under shaking at 150 rpm. Thiazine Red 
R was added at the concentration corresponding to the Kd of the respective aggregated 
protein binding site to induce a fluorescent signal that could be inhibited by the addition of a 
displacer compound (Kd for aggregated tau = 18 nM, Kd for aggregated Aβ = 49 nM).  
To determine the affinity of a displacer compound to the Thiazine Red R binding sites of the 
aggregated proteins, the compound was added at different concentrations to the assay 
ranging from 0.1 nM to 10000 nM. For the inhibition curve, the compound was measured 
together with the aggregated proteins and Thiazine Red R. The fluorescence of some dyes 
overlapped with the fluorescence of Thiazine Red R when measured at 595 nm. Therefore, 
compounds were also measured together with the aggregated proteins, but without Thiazine 
Red R (autofluorescence curve). Net-fluorescence was calculated by subtracting the 
fluorescence of the wells without Thiazine Red R from the fluorescence of wells containing 
Thiazine Red R (inhibition curve). As negative control Thiazine Red R and aggregated 
protein was used. As positive control, Thiazine Red R, reference compound with known 
activity and aggregated protein was used.  
The assay was performed in Perkin Elmer OptiPlate 384, black, 45 mL assay volume. As 
assay buffer DPBS (no CaCl2 no MgCl2) (GIBCO N. 14020) was used. The tested 
compounds were diluted in DMSO and 2 µL of the solution was added to the assay (5% 
DMSO final). The assay was started by the addition of the aggregated protein (competitive 
condition). The plates were shortly shaken (1 min with Sterico variomag teleshake) and 
incubated at room temperature for 30 min. Measurements were performed with En: Vision 
(Perkin Elmer), at Excitation 531 nm / Emission 595 nm. Corresponding IC50 values 
(inhibitory concentration for 50% decrease) were calculated using the Levenburg Marquardt 
algorithm: y = A + ((B-A)/(1+((C/x)^D))) 
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Table 6.2 Descriptions of the equation.  
Item Description 
A The bottom plateau of the curve corresponds to the final minimum y value. 
B The top of the plateau of the curve corresponds to the final maximum y value. 
C 
The IC50 value represents the x value at which the half maximum y value is 
attained. 
D 
The slope factor. In this model a positive value is returned when y increases 
with increasing x and a negative value when y increases as x is decreasing. 
x Concentration of the tested compound (nM) 
y Net fluorescence in % of controls. 
The obtained values are the average values of replicate experiments. The statistical 
presentation follows the guidelines laid out by G. Cumming.234  
Determination of IC50 values for different compounds on aggregated proteins using the 
Thiazine Red R assay. Data represent average of technical replicates.  
Table 6.3 IC50 values for different reference compounds. 
Compounds Aggr. tau  -  IC50 (nM) Aggr. Aβ40  -  IC50 (nM) 
Evans Blue 1.0 89 
Congo Red 5.4 14 
Hondson 1d117 8.8 13 
BSB 18 78 
MeXO4 246 140 
Crystal Violet 1545 1280 
FDDNP 1635 1467 
IMPY 2707 5671 
PIB 3255 5190 
AZD2184 9802 >10000 
FENE >10000 >10000 
BF-158 >10000 >10000 
 Page 248 
6.12. In vivo zebrafish embryo assay for cytotoxicity 
The zebrafish were bred and maintained according to the methods described by Christiane 
Nuesslein-Volhard and Ralf Dahm.157 In brief, the wild-type zebrafish were raised on  
14-h light-10-h dark cycles at 26.0 ± 0.5°C. The embryos were obtained via natural mating 
and cultured in water. All experiments in this study were carried out according to the ethical 
and welfare principles in legislation on animal research in Germany. The embryos were 
collected and placed into 24-well plates, ten embryos per well. When the embryos were older 
than 6 hpf (> 50% epiboly) were treated with solutions containing 1, 5, 10 µM of the 
corresponding imaging probes in E2 solution. The phenotypes were examined using the Axio 
Scope. A1 microscope system from Carl Zeiss at 24 hpf and 72 hpf. 
 
6.13.  In vitro cell proliferation assay (HepG2) 
Liver hepatocellular carcinoma cells HepG2 were maintained in DMEM/F12 1+1 
supplemented with 10% fetal bovine serum. Cells were cultivated under sterile conditions in 
a humidified incubator (37 °C, 5 % CO2, 95 % humidity) without antibiotics. Mycoplasma 
contamination could be excluded via routinely examinations (PCR). To determine the 
number of viable cells after probes incubation, the CellTiter 96®AQueous non-radioactive cell 
proliferation assay (Promega, Madison, USA) was used. The HepG2 cells were seeded in 
96-well plates at a density of 12000 cells per cm2. 24 hours later, the cells were incubated 
with 0.1 µM, 1 µM, 10 µM and 50 µM of potential compounds for 24 hours. Afterwards, cells 
were washed three times with PBS and CellTiter 96®AQueous non-radioactive cell 
proliferation assay reagent was added to the samples. The colorimetric assay is based on 
the reduction of a tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4sulfophenyl)-2H-tetrazolium, inner salt (MTS) into a formazan product by intrinsic 
dehydrogenases of living cells. The amount of formazan product correlates directly to the 
number of metabolically active cells, and it was calculated after photometric analysis at 
λ=492 nm using a microplate reader (Tecan, Crailsheim, Germany). To quantify cell viability, 
absorbances of treated samples were normalized to untreated controls (percent of 
nontreated controls), which resulted in cell vitality. Thereby cell vitality values between 70 % 
and 120 % represent neither cytotoxic nor proliferative effects on HepG2 and loss of cell 
vitality over 30 % characterizes a substance as cytotoxic, according to the DIN ISO 10993-
5:2009. Finally EC50 was calculated via the best-fitted trendline of cell vitality as a function of 
dye concentration. EC50 declares the dye concentration in which 50 % of the cells died after 
incubation with the probe. 
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